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1  INTRODUCTION 
 
 
 
 
 
Sulfonamido group, the open-chain analog and the historical “ancestor” of sultams, is a very 
common organic functional group; in fact it is well known for its wide range of biological 
activities, holding the prestigious position of being the first synthetic compounds to have had 
utility in human therapy. Sulfonamide drugs in fact were the first antimicrobial drugs, and 
paved the way for the antibiotic revolution in medicine.  
 
The first sulfonamide synthesized was trade named Prontosil and was discovered by a team 
under the general direction of Farben executive Heinrich Hoerlein, synthesized by Bayer 
chemist Josef Klarer and tested under the direction of physician/researcher Gerhard Domagk, 
who subsequently would have received the 1939 Nobel Prize in Medicine.1 The first official 
communication about the breakthrough discovery was not published until 1935,2 more than two 
years after the drug was patented by Klarer and his research partner Fritz Mietzsch. 
Experiments with Prontosil began in 1932 in the laboratories of Bayer AG, at that time a 
component of the huge German chemical trust IG Farben and showed that Prontosil was the 
first medicine ever discovered that could effectively treat a range of bacterial infections inside 
the body.3,4 It had a strong protective action against infections caused by streptococci, including 
blood infections, childbed fever, and erysipelas, and a lesser effect on infections caused by other 
cocci.  
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Few people today would deny that 1936 was the turning point in the history of puerperal 
infection, one of the most common cause of death during childbirth, and that the arrival of 
Prontosil brought about the change: obviously when penicillin became available in 1945 the 
situation became better still, because that antibiotic is an even more potent antistreptoccal agent 
than the sulfonamides, but it is evident that even if penicillin had not arrived when it did, the 
story of streptococcal puerperal fever would not have been very different. 
 
Graphic 2-1: Decline in puerperal sepsis mortality in England and Wales, 1928–1948. The average figure for the 
years 1928–30 istaken as 100 and the total for each subsequent year is expressed in terms of that. 
 
In 1935 Tréfouël and his colleagues at the Pasteur Institute observed that Prontosil had no effect 
at all in the test tube, exerting its antibacterial action only in live animals; they soon surprised 
the scientific world by the suggestion that the red dye was probably a prodrug and that was 
metabolized into two pieces inside the body, to a much simpler compound, p-aminobenzene 
sulfonamide. The discovery helped establish the concept of "bioactivation" and dashed the 
German corporation's dreams of enormous profit; the active sulfanilamide had been known for 
many years being synthesized in 1906 and was widely used in the dye-making industry; its 
patent had since expired and the drug was available to anyone. These findings naturally led to a 
change-over in human therapy from red prontosil to the simpler and cheaper compound which 
we soon came to know by the name Sulfanilide, the first of the ‘‘sulfa drugs’’. 
Synthesis of polyfluorobenzo[d]sultams 
 
7 
 
S
N N
NH2
NH2
O O
H2N
S
NH2
O O
H2N
NH2
O
HO
PABA
Metabolization
Structural
analogy
 
Figure 2-1 
The important role of sulfonamide is due to its structural analogy to p-Aminobenzoic acid 
(PABA) which is needed in bacteria organisms for the synthesis of folic acid; they interfere with 
folate metabolism in the bacterial cell by competitively blocking the biosynthesis of 
tetrahydrofolate, which acts as a carrier of one-carbon fragments and is necessary for the 
ultimate synthesis of nucleic bases (most notably thymine, but also purine bases) but also for 
the synthesis of DNA, RNA and bacterial cell wall proteins. Unlike mammals, bacteria and 
protozoan parasites usually lack a transport system to take up preformed folic acid from their 
environment. Most of these organisms must synthesize folates, although some are capable of 
using exogenous thymidine, circumventing the need for folate metabolism.  
Thus folate deficiency hinders DNA synthesis and cell division, affecting RNA transcription, 
and subsequent protein synthesis. Sulfonamides are capable to interfere with the metabolic 
processes in bacteria that require PABA in particular, having a greater affinity than p-
aminobenzoic acid, they compete as a substrate of the enzyme dihydropteroate synthetase in 
the conversion of dihydropteroate diphosphate in dihydropteroic acid. 
The result of this discovery was a sulfa craze. For several years in the late 1930s hundreds of 
manufacturers produced tens of thousands of tons of myriad forms of sulfa. This and 
nonexistent testing requirements lead to the ELIXIR SULFANILAMIDE DISASTER in the fall of 
1937; in the same year S. E. Massengill Co., a pharmaceutical manufacturer, created a 
preparation of sulfanilamide using diethylene glycol as a solvent, and called the preparation 
"Elixir Sulfanilamide". Diethylene glycol is poisonous to humans, but the company's chief 
pharmacist and chemist, was not aware of this, although it was known at the time. At least 100 
people were poisoned with diethylene glycol and died and this led to the passage of the Federal 
Food, Drug, and Cosmetic Act in 1938 but, as the first and only effective antibiotic available in 
the years before Penicillin, sulfa drugs continued to thrive through the early years of World 
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War II and they are credited with saving the lives of tens of thousands of patients. Sulfa had a 
central role in preventing wound infections during the war: in fact american soldiers were 
issued a first aid kit containing sulfa powder and were told to sprinkle it on any open wound. 
 
 
Figure 2-2 
Many thousands of molecules containing the sulfanilamide structure have been created since its 
discovery (by one account, over 5400 permutations by 1945), yielding improved formulations 
with greater effectiveness and less toxicity. 
Sulfonamides, however, are not only used as competitive inhibitors of the enzyme 
dihydropteroate synthetase but they have been in clinical use for over 50 years, because of their  
antibacterial and antimycotic activity, for example in the treatment of many diseases like: 
• pneumonia caused by Pneumocystis Carinii,  
• drug-resistant Malaria and Toxoplasmosis,  
• some sexually transmitted infections (Trachoma, Clamydia, Chancroid), 
• in inflammatory bowel disease,  
• for respiratory infections for special problems (e.g. infection with Nocardia), 
• for acute urinary tract infection 
• for infected burns. 
Moreover these molecules are still widely used for conditions such as acne and urinary tract 
infections, and are receiving renewed interest for the treatment of infections caused by bacteria 
resistant to other antibiotics. 
Unsaturated sulfonamides were also identified as potent, and irreversible inhibitors of cysteine 
proteases5, which are essential to the life cycles of many pathogenic protozoa; preliminary 
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biological evaluation of some of this molecules has shown a promising pharmacological 
activity; this kind of structures have been studied even in relation with their ability to inhibit a 
series of matrix metalloproteinases, particularly gelatinase A, collagenase-3, and stromelysin-1 
and for the treatment of multiple sclerosis, artherosclerotic plaque rupture, aortic aneurysm, 
heart failure, left ventricular dilation, restenosis, periodontal disease, or other autoimmune or 
inflammatory disorders dependent upon tissue invasion.6  
For example ACETAZOLAMIDE (trade name Diamox) is a carbonic anhydrase inhibitor that 
blocks the formation of H+ and H2CO3 from CO2 and H2O with the end result that bicarbonate is 
excreted in the urine. For glaucoma sufferers, the drug decreases fluid formation in the eye 
resulting in lower intraocular pressure. In epilepsy, its main use is in absence seizures, with 
some benefit in other seizure syndromes. It is also used to decrease generation of cerebrospinal 
fluid in benign intracranial hypertension and has shown efficacy in autosomal dominant 
hyperkalemic periodic paralysis. It's been demonstrated in drug trials to relieve symptoms 
associated with dural ectasia in indivduals with Marfan Syndrome. Off-label uses include 
Acetazolamide as a conjunction drug to merely assist patients with sleep apnea by lowering 
blood pH and encourage respiration. 
FUROSEMIDE (most common trade name Lasix marketed by Sanofi-Aventis) is a loop diuretic 
used in the treatment of congestive heart failure and edema associated with heart failure, 
hepatic cirrhosis, renal impairment, nephrotic syndromeedema, hypertension, adjunct in 
cerebral/pulmonary edema where rapid diuresis is required (IV injection). 
It is also sometimes used in the management of severe hypercalcemia in combination with 
adequate rehydration. Moreover it has been used to prevent thoroughbred and standardbred 
race horses from bleeding through the nose during races. 
Along with some other diuretics, furosemide is also included on the World Anti-Doping 
Agency's banned drug list due to its alleged use as a masking agent for other drugs.  
BUMETANIDE too (trade name Bumex, marketed by Hoffmann-La Roche) is a loop diuretic of 
the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of 
Furosemide are ineffective with the main advantage consisting in Bumetanide higher 
bioavailability.  
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CELECOXIB (trade name Celebrex, marketed by Pfizer) is non-steroidal anti-inflammatory drug 
(NSAID) being a highly selective COX-2 inhibitor and primarily inhibits this isoform of 
cyclooxygenase (inhibition of prostaglandin production), whereas traditional NSAIDs inhibit 
both COX-1 and COX-2 ; it is used in the treatment of osteoarthritis, rheumatoid arthritis, acute 
pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and 
rectum polyps in patients with familial adenomatous polyposis. 
DORZOLAMIDE (trade name Trusopt) is a carbonic anhydrase inhibitor used to lower increased 
intraocular pressure in open-angle glaucoma and ocular hypertension. It is an anti-glaucoma 
agent and topically applied in the form of eye drops(dorzolamide hydrochloride ophthalmic 
solution). This drug has the particularity to be the first drug in human therapy (market 
introduction 1995) which resulted from structure-based drug design developed by University of 
Florida researchers. 
HYDROCHLOROTHIAZIDE (trade names: Apo-Hydro, Aquazide H, Dichlotride, Hydrodiuril, 
HydroSaluric, Microzide, Oretic) belongs to the thiazide class of diuretics, like Furosemide and 
Bumetanide and acts on the kidneys to reduce sodium reabsorption in the distal convoluted 
tubule. This increases the osmolarity in the lumen, causing less water to be reabsorbed by the 
collecting ducts  leading to increased urinary output. 
It is effective for nephrogenic diabetes insipidus (paradoxical effect, which decreases urine 
formation) and is also sometimes used for hypercalciuria and Dent's Disease. 
Thiazides are also used in the treatment of osteoporosis decreasing mineral bone loss by 
promoting calcium retention in the kidney, and by directly stimulating osteoblast 
differentiation and bone mineral formation.  
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Figure 2-4 
SULFAMETHOXAZOLE (trade names Bactrim, Septrin, or Septra) is a sulfonamide bacteriostatic 
antibiotic most often used as part of a synergistic combination with trimethoprim in a 5:1 ratio 
in co-trimoxazole. Its primary activity is against susceptible forms of Streptococcus, Escherichia 
coli, Haemophilus influenzae, and oral anaerobes. 
SULTIAME is a sulfonamide and inhibitor of the enzyme carbonic anhydrase. It is used as an 
anticonvulsant with specific effects in benign focal epilepsies of childhood as well in West 
syndrome and other refractory epilepsies. 
Among the huge number of therapeuthic sulfonamides we must name CHLORTALIDONE, 
XIPAMIDE, CLOPAMIDE, INDAPAMIDE, MEFRUSIDE, METOLAZONE, all thiazide-like diuretics, 
DICLOFENAMIDE and ETHOXYZOLAMIDE a sulfonamide medications that function as a carbonic 
anhydrase inhibitors. They are used in the treatment of glaucoma, duodenal ulcers, MAFENIDE 
(Sulfamylon) is a sulfonamide often used to treat severe burns, PROBENECID is used to combat 
influenza increasing antibiotic concentrations in serious infections while SUMATRIPTAN is a 
triptan drug for the treatment of migraine headaches. 
Finally, one of the last applications concerns the use of a series of polyhalobenzene 
sulfonamides as chemotherapic drug7, showing the ability to inhibit the growth of a variety of 
human tumour cell lines, like cervical adenocarcinoma or human breast tumour. 
 
 
 
 
 
Synthesis of polyfluorobenzo[d]sultams 
 
12 
 
 
  
Synthesis of polyfluorobenzo[d]sultams 
 
13 
 
2    SULTAMS 
 
 
 
 
Sultams, containing a functional group very similar to sulfonamidic, have been incorporated 
into a wide range of known biologically active compounds, either as a substituent group or as a 
replacement of another ring. Moreover, since the introduction of Oppolzer’s camphorsultam, 
sultams have been used as an instrument to control the stereochemical course of many reactions 
and they rank today among the most practical chiral auxiliaries available for organic chemistry.  
 
2.1 Sultams in medicinal chemistry 
 
One of the first example in which a sultam ring is employed as pharmacological active 
compound was reported in 1971 by Lombardino8: in his work he investigated the anti-
inflammatory activity of a series of 3-carboxamides of 2-alkyl-4-hydroxy-2H-1,2-benzothiazine 
1,l-dioxide. Inspired by a work by Abe and coworkers9, the first to apply the principle of the 
Gabriel-Colman rearrangement of phthalimide to the rearrangement of N-phenacylsaccharin, 
Lombardino studied a powerful procedure for isomerizing saccharin-2-acetic ester and 
acetamides to 4-hydroxy-2H-l,2-benzothiazine-3—esters/amides 1,1-dioxide in DMSO (Scheme 
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2-1) and compared their anti-inflammatory activity to that of the clinically useful drugs 
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Scheme 2-1 
indomethacin and phenylbutazone. The good results obtained showed that most compounds 
were inhibitors of carrageenin-induced rat foot edema and some exceeded phenylbutazone in 
potency. Sunkel et coworkers10 in 1988 reported a series of l,4-dihydropyridines bound to 1,2-
benzisothiazol-3-one (Scheme 2-2). They synthesized and evaluated them for their ability to 
inhibit platelet aggregation induced by collagen in human platelet-rich plasma (PRP) and to 
protect mice against experimental thrombosis.  
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Scheme 2-2 
The results showed that the compounds were in vitro inhibitors of collagen-induced platelet 
aggregation and that most of them were also effective in reducing mortality in antithrombotic 
assay conducted in mouses.  
In 1995 Nagasawa et Al11. described for the first time the synthesis of N-hydroxysaccharin, 
(Scheme 2-3) a nitroxyl prodrug, starting from o-sulfobenzoic anhydride the oxygenated 
saccharine analogue; 
Synthesis of polyfluorobenzo[d]sultams 
 
15 
 
O
S
O
O O
N
S
O
O O
OR
EtOH, NH3
SOCl2, DMF
RONH2 HCl/NaOH
170°C, neat
S
O
O O
Cl
OEt
 
Scheme 2-3 
this molecule, when treated with aqueous NaOH, liberates nitroxyl, a known inhibitor of 
aldehyde dehydrogenase (AlDH). The author makes a paragon between his new compound 
and Piloty’s acid (benzenesulfohydroxamic acid) another well known prodrug of nitroxyl by 
releasing it either by the cytochrome P-450-catalyzed dealkylation of the O-alkyl group or by 
esterase-mediated deacylation of the O-acyl moiety (Scheme 2-4). 
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Scheme 2-4 
Results indicated that hydroxysultam was a much more stable molecule and this was reflected 
in the differential inhibition of yeast AlDH by Piloty’s acid and N-hydroxysaccharin 
respectively. 
Always talking about saccharine-derived compounds, we must mention the 3-aryl pyrrolidine 
derivative showed in Figure 2-1: the development of selective and potent ligands for serotonin 
N
S
O
O O
N
Ar
 
Figure 2-1 
receptors has attracted a considerable interest, since they are promising drug candidates for 
treatment of mood and anxiety disorders. This molecule, synthesized in 1999 by Ahn et Al.12, 
showed good affinity and selectivity toward serotonin 1A receptor (5-HTIA): is noteworthy 
notice that all the examples showed until now use as starting material the natural occurring 
sultam saccharine. 
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Much more interesting is the example reported by Miller, Humphrey and Lieberman13 in which 
the synthesis of a naphthosultam based side chain of a novel anti-MRSA carbapenem, is carried 
out in a seven step protocol (Scheme 2-5) with an overall yield of 27%. 
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Scheme 2-5 
The synthesis has been reproducibly demonstrated on the multikilogram scale in high purity 
and has allowed the production of side chain essential for the large-scale synthesis of the novel 
β-lactam antibiotic. In the same year Matsumoto and coworkers14 described the synthesis of 
novel γ-sultam derivatives containing the di-tert-butylphenol antioxidant moiety. 
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Scheme 2-6 
Along with this employment of sultams, bicyclic β-lactam ring systems, that are isomeric to 
those of the penicillin, penem, and clavulanic acid families of antibiotics, have been studied as 
an alternative to the well known antibiotics: 
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 in particular penem-monobactam hybrid (Scheme 2-7)  
N S
O
O O
Ph
IHH
X
N S
O
Ph
IHH
X
Cl
X
O
Ar
N
Ph
N Ar
O
HHX
Ph
N SMe
O
HHX
Ph
Et3N
1) CAN
2) BuLi, -78°C
3) MeSSO2Me
I2 mCPBA
82%
87%
X = OMe 89%
X = N-phtalimidyl 92%
64%
83%
72%
84%
 
Scheme 2-7 
and clavulanic acid-monobactam hybrid (Scheme 2-8) have been synthesized and studied.15  
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Scheme 2-8 
Among the several compounds synthesized, γ-sultam shoved in Scheme 2-6 displays multiple 
inhibition of cyclooxygenase (COX)-2 and 5-lipoxygenase (5-LO), as well as inflammatory 
cytokines interleukin (IL)-1 production (similar to tenidap) and also good selective COX-2 
inhibition like celecoxib. The molecule, designated as an agent having both NSAID and 
cytokine modulating properties and exerteding excellent anti-inflammatory activity without 
any ulcerogenic effects, is now under clinical trials. 
In 2001 Bihovsky and coworkers discovered a novel class of benzothiazine peptide mimetics16 
that potently and selectively inhibit calpain I. Calpains, nonlysosomal calcium-activated 
cysteine proteases present in most mammalian cells including neurons, have been implicated in 
neurodegeneration following cerebral ischemia, traumatic brain injury, spinal cord trauma, 
Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, motor neuron damage, and 
muscular dystrophy. Calpain I inhibitors appear to prevent some 
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Scheme 2-9 
of the damage caused by overactivated calpain under pathophysiological conditions and are 
therefore being investigated as possible treatments for neurodegeneration resulting from 
cerebral ischemia, traumatic brain injury, or spinal cord trauma.17 The sultams synthesized 
(Scheme 2-9) inhibit calpain I with a strong efficiency and ranks among the best reversible and 
selective inhibitors evaluated. 
Some years later, the group of Zhuang prepared and studied the inhibition properties of a 
sultam-naphthyridine18 (Scheme 2-10) of the strand transfer of the integration process catalyzed 
by Human immunodeficiency virus-type 1 integrase: results indicate 
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Scheme 2-10 
very low values of IC50 with an inhibition of 95% of the spread of HIV-1 infection in cell 
culture. It does not exhibit cytotoxicity in cell culture showing a good pharmacokinetic profile 
when dosed orally to rats; moreover the antiviral activity of the sultam-naphthyridine and its 
effect on integration were confirmed using viruses with specific integrase mutations. 
In 2003 Hanessian19 prepared a series of bicyclic sultams as constrained proline analogues; the 
synthesis, performed from the known 4-cis-(2-propenyl)-N-Boc-L-proline benzyl ester, uses as 
key step a ring-closure metathesis reaction. The sultams were synthesized (Scheme 2-11) 
varying in the size of the second ring (5,6 and 7 members) and he studied the application to the 
design of potential thrombin inhibitors and its activity against the enzyme thrombin  
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Human neutrophil elastase (HNE) is a serine enzyme which is one of the most destructive 
proteolytic enzymes, being able to catalyze the hydrolysis of the components of connective 
tissue. It has been implicated in the development of diseases, such as emphysema, cystic 
fibrosis, and rheumatoid arthritis. In a recent paper20 is demonstrated the activity of β-sultams 
as serine protease inhibitor, moreover is reported the use of a 3-oxo β-sultams that, acting both 
as sultam that lactam, represent a novel class of inactivators of elastase which can act by either 
sulfonylation or acylation of the active site serine residue. 
Alzheimer’s disease (AD) is a progressive and chronic neurodegenerative disease that leads to 
loss of intellect and memory in those afflicted. AD affects around 18 million people worldwide, 
and with the limited therapies currently available, this represents a major unmet medical need. 
One of the main pathological characteristics of this disease is the production of the 40-42 amino 
acid amyloid-β (Aβ) peptide, in which the protease enzyme γ-secretase plays a critical role 
through cleavage of the β-amyloid precursor protein (βAPP). γ-Secretase, therefore, represents 
a potential target for AD therapeutic intervention and this theme is faced in a paper by Scott21 in 
which, exploiting as the key transformation a highly diastereoselective intramolecular nitrile 
oxide cycloaddition, a practical asymmetric synthesis of a γ-secretase inhibitor is described 
(Scheme 2-12).  
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Scheme 2-12 
Several recently approved biologics have revolutionized the treatment of 
autoimmune/inflammatory conditions, including rheumatoid arthritis (RA) and Crohn’s 
disease. These agents work by sequestering tumor necrosis factor-α (TNF-α), which is an 
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inflammatory cytokine overproduced in these diseases. There is a great deal of interest in 
finding a bioavailable small molecule that can mimic these marketed biologics. As a member of 
the ADAM (a disintegrin and metalloproteinase) family, MMPs is contained within the 
metzincin superfamily and it was shown that MMP inhibitors could prevent the release of TNF-
α from cells through their interaction with TACE. 
Hence, many groups searched for MMP inhibitors and in 2004 Cherney and coworkers22 
described a novel set of sultam hydroxamates binding the active site zinc by the classical 
bidentate ligation with hydroxamate; the rest of the inhibitor sulfonyl of the sultam can be 
positioned within the hydrogen bond distance of Leu-185 (Scheme 2-13). 
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Scheme 2-13 
Malaria is the major life-threatening parasitic disease in tropical and sub-tropical regions. 
Worldwide, there are at least 300 million acute cases of malaria and more than 1 million deaths 
each year, mostly young children infected with Plasmodium falciparum. With the rapid spread 
of multidrug-resistant P. falciparum strains, the development of safe and effective antimalarials 
has become an important strategy towards achieving effective control of malaria. Cysteine 
proteases, like Falcipain-2, regulate a broad spectrum of physiological functions and. in 
humans, elevated levels of these enzymes can lead to disease states such as osteoporosis, 
rheumatoid arthritis and cancer. 
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Scheme 2-14 
In parasites, they play a crucial role in reproductive function and metabolism as it is likely 
involved in the hydrolysis of haemoglobin that produces free amino acids required for parasite 
survival. Moreira, Iley and coworkers23 in a 2006 paper, describe the synthesis of a dipeptide 
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vinyl sultams consisting in the preparation of a γ- and δ-sultam core derivatives via the Wittig–
Horner reaction and then its coupling with the dipeptide moiety (Scheme 2-14). Although 
weakly active, vinyl sultams are selective for recombinant falcipain-2 and Plasmodium falciparum 
W2.over papain.  
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2.2 Sultams as chiral auxiliaries 
 
Since early ’80, with the introduction of Oppolzer’s camphorsultam, the use of 1,2-
isothiazolidine 1,1-dioxides as an instrument to control the stereochemical course of many 
reactions has been widespreading more and more and they rank today among the most 
practical chiral auxiliaries available for organic chemistry, having important applications in 
asymmetric version of several reactions. 
Camphorsultam, readily available from camphor sulfonyl chloride (Scheme 2-15), find for  
 
 
Scheme 2-15 
example application in Diels-Alder reaction and was initially conceived with the scope to 
electronally enhance the dienophilicity ot the N-enoyl derivative; indeed in the presence of 
EtAlCl2 or TiCl4, cyclopentadiene adds redily both with acryloyl and with crotonyl derivative24. 
The adducts were formed with excellent endo- and facial selectivities; moreover EtAlCl2 
promoted cycloaddition of butadiene and isoprene too (Scheme 2-16). 
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M
Lewis Acid R
O NX*
 
Scheme 2-16 
R Diene Lewis Acid 
T 
(°C) 
Yield 
(%) 
d.e. (%) 
H Cyclopentadiene EtAlCl2 -130 83 99 
Me Cyclopentadiene TiCl4, -78 83 >99 
H 1,3-butadiene EtAlCl2 -78 85 99 
H isoprene EtAlCl2 -94 68 >99 
 
Table 2-1 
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Even trienoyl sultams cyclize, on treatment with EtAlCl2, with exceptional endo- selectivity to 
give bicylcic compounds each one in >99% d.e. (Scheme 2-17);  
N
S
O2 O
n
n
H
H
O*XN
n = 1, 75% >99% d.e.
n = 2, 53% >99% d.e.
EtAlCl2
-20°C
 
Scheme 2-17 
all this results prove that reactions conducted with sultams are in great consistence with the 
prediction.25  
Camphorsultams has been used too for the synthesis of β-silylcarboxyl derivatives by 1,4-
addition of organocopper reagents: this useful and versatile building block has been 
synthesized by Oppolzer and coworkers26 treating N-(β-silylenoyl) sultams with alkenyl- and 
alkyl-copper reagents obtaining good diasterofacial selectivities (86-96%, Scheme 2-18Table 2-2); 
quite interesting is the obtainment of the epimer only by changing the lewis acid:  
N
S
O2
O
SiPhMe2
Lewis Acid
R'Li, CuI, PBu3 *XN R'
O SiPhMe2
*XN R'
O SiPhMe2
MeO R'
O SiPhMe2
Me
S
O2
N
O
R
Al
N
S
O2
O
R
BF3
MeOMgCl
MeOH
A B
Monochelated TS
Si Attak
Bichelated TS
Re Attak
+
Scheme 2-18 
R Lewis Acid Yield (%) Ratio A/B 
Vinyl BF3.OEt2 60 97:3 
Vinyl EtAlCl2 57 2:98 
(Z) Prop-1-enyl EtAlCl2 65 1:99 
(Z) Prop-1-enyl EtAlCl2 67 2:98 
Me EtAlCl2 61 3.3:96.7 
i-Pr EtAlCl2 64 3:97 
Ph EtAlCl2 86 0:100 
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Table 2-2 
this striking difference was attribute by the authors to the mono-coordinated transition state 
with BF3, with anti disposition of SO2/CO groups instead of the Al-di-chelated transition state 
favoring reverse side attack. 
Always Oppoltzer27 proposed the use of N-(ε-ketoacyl) or N-(δ-ketoacyl) sultam acetal as the 
starting compound for an asymmetric electrophilic –hydroxyamination for the synthesis of N-
hydroxy-piperidines or -pyrrolidines;  
N
S
O2 O
O O
Rn
1) NaN(SiMe3)2
2) NO2Cl
3) H3O+ O
O
R
n
*XN
NH
OH
N
O O
*XN R
n
N
O OH
*XN R
nRed
 
Scheme 2-19 
R n 
Reducing 
agent 
Yield of 
nitrone (%) 
Yield 
(%) 
n-C11H23 2 H2, Pd/C 70 90 
n-C3H7 2 H2, Pd/C 72 92 
n-C7H15 1 NaCNBH3 64 97 
 
Table 2-3 
treatment of acylsultam with sodium hexamethyldisilazide, 1-chloro-1-nitrocyclohexane and 
HCl furnishes the diasteromerically pure nitrone which, in turn, is reduced to the cis-2,6-
disubstituted piperidine, by palladium catalyzed hydrogenation, or to the cis-2,5-disubstituted 
pyrrolidine by treatment with sodium cyanoborohydride. The heterocycles obtained can also 
undergo deoxigenative decarboxylation leaded by trapping with hydride or organometal 
addition28: this methodology allow the obtainment of important key intermediate for the 
synthesis natural compound as (-)-Coniine, (-)-Solenopsin A and (-)-Xenovenine. 
N-enoyl camphorsultam has been employed also in oxidation reaction:29 treatment of the over 
and over quoted β-substituted α,β-enoyl sultam with N-methyl morpholine-N-oxide in the 
presence of OsO4 provided glycols with good diasteroselectivities (80-90%) and acceptable 
yields (63-79%); in addition, even the catalytic hydrogenation of β,β-disubstituted sultams30 
gave, in those days, unprecedented results with great topological control (91-98% d.e.) and 
excellent yields (93-99%). 
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Finally alkylation, one of the most simple but at the same time one of the most important 
methods for the asymmetric formation of carbon-carbon bond, can be carried out on acyl 
camphorsultam.31  
N
S
O2 O
R N
S
O2 O
R
R'
1) Base
2) R'X,
 
Scheme 2-20 
R R’ X Base Yield d.e. 
Me PhCH2 I NaHDMS 100 96.5 
Me Me2C=CHCH2 Br BuLi/10%ICA 82 98.8 
Me HC≡CHCH2 Br BuLi 82 98.3 
Me tBuO2CCH2 Br NaHDMS 80 98.5 
Me Me2CH(CH2)3 I NaHDMS 89 99 
OMe PhCH2 I NaHDMS 81 99 
 
Table 2-4 
In 1990, to gain a deeper understanding and an even broader scope of the stereofacial directing 
bias of sultams, Oppolzer and coworkers32 designed a related chiral sultam with the following 
characteristics: it is simple, but crystalline sultam containing a single stereogenic centre instead 
of the bornane skeleton; it does not contain any acidic proton at the carbon atom vicinal to the 
sulfinamido group; it allows easier NMR analysis and HPLC detection (having an aryl 
chromophore) of substrate and products. 
The first approach to obtain this molecule provides enantiomerically pure sultams from achiral 
saccharine; addition of MeLi in Et2O to saccharine provide, after crystallization, the imine that, 
after asymmetric reduction, furnishes enantiomerically pure sultam 
NH
S
O O
O
N
S
O O
Me
NH
S
O O
Me
Ru2Cl4[(R)-BINAP]2(Et3N)
CH2Cl2, EtOH, 4 atm H2
MeLi
THF, -78°C
73% 72%  
Scheme 2-21 
A second approach starts from α-phenethylamine and pass through its acylation with pivaloyl 
chloride leaded by ortho deprotonation using n-BuLi followed by t-BuLi and trapping of the di-
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lithiated intermediate with SO2; the so obtained sulfinic acid is converted into the sulfinyl 
chloride then cyclized with sodium hydride. Finally oxidation and reductive elimination of the 
protecting group lead to the desired product with an overall yield of 37%. 
NH
S
O O
Me
NH2
Me
Et3N,
Me3COCl
CH2Cl2, 0°C
H
N
Me O
n-BuLi, t-BuLi,
SO2
-78°C
H
N
Me O
SO2H
1) SOCl2, Et3N
2) NaH
CH2Cl2, -78-0°C
N
S
O
Me O
LiOH, H2O2
aq.THF, r.t.
94% 80%
50% >99%
 
Scheme 2-22 
Oppolzer initially, in order to explore the potentiality of the new saccharine-derives sultam, 
used the N-acyl benzosultam in reaction of alkylation, acylation and aldol condensation:33 in 
particular C-acylation, accomplished by subsequent treatment with NaHDMS and a carboxyl 
acid chloride, afford the 1,3-dicarbonyl compound in high yield and d.e.(Scheme 2-23, Table 
2-5). 
S
O2
N
Me
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R
NaN(TMS)2 *NX R'
O O
R
S
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Me
O
O O
R
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R'COCl..
 
Scheme 2-23 
R R’ Yield d.e. 
Me Ph >99 99.4 
Me CH2CHMe2 >97 97 
Et Me 97.5 97.6 
 
Table 2-5 
The obtained compounds can be subjected to chelate-control reduction both with zinc 
borohydride, obtaining selectively the syn-aldol, while reduction with sodium tri-s-butyl 
borohydride afford the anti-aldol (Scheme 2-24, Table 2-6). 
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Scheme 2-24 
R R’ 
Reducing 
agent 
Yield Ratio A/B 
Me Me Zn(BH4)2 81 91.3 : 8.7 
Me Ph Zn(BH4)2 82 99.1 : 0.9 
Me Me NaHB(s-Bu)3 80 0.2 : 99.8 
Me CH2CHMe2 NaHB(s-Bu)3 53 2.1 : 97.9 
 
Table 2-6 
Treatment of acyl benzosultam with dialkylboryl triflate and an aldehyde, produced the syn-
aldols; again we observe an electrophilic attack to the opposite enolate face than observed in 
acylation but also in alkylation: this dichotomy is ascribed to the transition state (again 
involving a (Z)-enolate) in which the boron atom, being fully coordinated thus incapable of 
chelation with SO2 (see Scheme 2-18), forces the enolate to adopt an electrostatically favored N-
SO2/CO-B s-trans conformation.  
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..
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R
R''R' CHO, -78°C
Scheme 2-25 
R R’ R’’ Yield d.e. 
Me Ph Et 100 >99 
Me Me Et 100 >99 
Me i-Pr Et 99 >99 
Me i-Bu Et 92 >99 
 
Table 2-7 
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In the same year optically pure 3-methyl benzosultam has been employed also in asymmetric 
version of Diels-Alder cycloaddition34  
S
O2
N
Me
O Me2AlCl,
-5°C
CH2Cl2, -78°C
Me
O NX*
Me
74%, Ratio endo-exo 97:3
d.e.,59%
 
Scheme 2-26 
Oppolzer, basing on the challenging attempt made by Curran et Al.35 who obtained good face 
selectivities in the addition of nitrile oxides to the N-acryloyl sultam, decided to investigate the 
reaction using the new auxiliary: unfortunately, 1,3-dipolar cycloaddition to N-acryloyl 
benzosultam proceeded with only moderate stereoface discrimination, giving products in ratio 
79:21 at most; Oppolzer decided then to modify the substituent in position 3 of the 
benzosultam:36 addition of t-BuLi to saccharine provided t-butyl imine that undergoes 
asymmetric hydrogenation only in negligible yield. On the other hand, reduction with the 
hydride obtained from LiAlH4, N-Methylephedrine and 3,5-dimethylphenol afforded 3-t-butyl 
benzosultam in 81 % e.e. (then purified to the enantiomerically pure compound by fractional 
distillation); alternatively the racemic compound obtained by the reduction with NaBH4 has 
been resolved by crystallization after the conversion into the N-camphorsulfonyl derivative. 
The so obtained chiral auxiliary has been tested in the cycloaddition of various nitrile oxides to 
N-acryloyl 3-tert-butyl benzosultam giving dramatic increase in diasteroselectivities exerted by 
the sterically more demanding auxiliary, even exceeding values provided by the classical 
camphorsultam (Scheme 2-27, Table 2-8). 
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Scheme 2-27 
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R Yield Product ratio 
t-Bu 87 98 : 2 
Ph 77 95 : 5 
Et 81 95 : 5 
Me 81 96 : 4 
 
Table 2-8 
Some years later, when enantiomerically pure 3-alkyl benzosultam become more accessible,37 
with the new reductive methodology introduced by Ahn and coworkers, it has been possible to 
study the influence of substituent in position 3, in reaction like asymmetric azidazion. 
S
N
O O
R
O
R1 S
N
O O
R
O
R1
N3NaHMDS,THF, -78°C
Trisyl-N3
 
Scheme 2-28 
R R’ Yield Product ratio 
Me All 72 95 : 5 
i-Pr All 73 95 : 5 
t-Bu All 96 98 : 2 
t-Bu Bn 95 99 : 1 
 
Table 2-9 
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2.3 Sultams as fluorinating agent 
 
The introduction of fluorine substituents in strategical position of organic compound is an 
extremely effective tool for modifying reactivity both for biological application38 and for 
analytical chemistry. Enormous effort have been made to solve the synthetic problems and to 
avoid the use of the potentially hazardous perchloryl fluoride or fluorooxy compounds, 
reagents commonly used until then. From the 80’s on, new N-fluoro compounds have been 
developed as new fluorinating agents effective, for example, to fluorinate a metal enolate and to 
convert it into a α-fluoro carbonyl compound; among these new molecules we must mention N-
fluoro-2-pyridone,39 N-fluoro quinuclidinium fluoride,40 N-fluoro sulfonamides41 and N-fluoro-
pyridinium triflate42 all molecules that for the enolate approach, displayed good control of 
regioselectivity whereas stereoselectivity still remained an unsolved problem. 
In 1988 Nang and Differding43 described the synthesis and the application of two camphor 
derived N-fluoro sultams as the first example of enantioselective reagents; the camphorsultam, 
readily obtained according to Oppolzer’s procedure, is fluorinated by treatment with 10% F2/N2 
in a CHCl3/CFCl3 solution at -40°C. Their pioneering results showed both a good reactivity with 
various metal enolates and good enantiomeric excesses even if depending strongly on the 
structure of the enolate (Scheme 2-29).  
NH
S
O2
N
S
O2
F
F2/N2
CHCl3/CFCl3
30 min., -40°C
70%
O N-Fluoro sultam
NaH
Et2O, 0°C - r.t.
O
CO2Et
F
CO2Et
y = 63%,
e.e. 70%
 
Scheme 2-29 
The enantioselectivity was improved by the same authors, up to 75% for the fluorination of 2-
methyl-1-tetralone by the use of N-fluoro-3,3-dichlorocamphorsultam.44 In a more recent paper, 
Takeuchi and coworkers45 describe a simple synthesis of enantiomeric N-fluoro-3-cyclohexyl-3-
methyl-2,3-dihydrobenzo[1,2-d]- isothiazole 1,1-dioxide, an agent that effects asymmetric 
fluorinations of ketone metal enolates to furnish optically active fluoroketones with 
enantioselectivity reaching 88% ee. The starting imine, which was prepared from saccharin by 
Oppolzer’s method32, was subjected to alkylation with cyclohexylmagnesium bromide to give 
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the 3-cyclohexyl-3-methyl benzo[d]sultam in 70% yield. Its optical resolution carried out by 
derivatization with (-)-menthoxyacetyl chloride, gave the enantiopure compound subsequently 
fluorinated (Scheme 2-30).  
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Scheme 2-30 
The best results, with e.e. as high as 88%, represents a significant advance in agent-controlled 
asymmetric fluorination. The following year, the same author proposed a novel method46 for a 
facile construction of 3,3-disubstituted and 3,3-spiro 2H,4H-benzo[e]sultam in which N-Boc-o-
toluenesulfonamide is taken as starting material. o-Methyl lithiation, followed by reaction with 
a variety of ketones, gave the corresponding carbinol sulfonamides which underwent 
cyclization under acidic or neutral conditions (Scheme 2-31). The resulting sultams were 
subjected to FClO3 fluorination to give the N-fluorosultams which were tested for electrophilic 
asymmetric fluorination; results reached lower enantiomeric excesses (70%) for enantioselective 
fluorination of the lithium enolate of 2-methyl-1-tetralone but no kinetic resolution is required 
in the synthetic pathway to for the sultam construction.  
SO2NH
Me
Boc
SO2NH
Boc
R R'
OH
N
O2
S F
*
1) BuLi
2) RCOR'
 
Scheme 2-31 
Another type of benzosultam that has been employed as a template for developing a N-F agent, 
is the 3,3-disubstituted 2H-benzo[e][1,2]thiazine 1,1,4-trione synthesized by Takeuchi;47 
saccharine was converted in three steps consisting in sequential alkylation with s-BuLi, 
bromination and ring expansion according to Abramovitch procedures. Racemic sultam in 
general showed good reactivity towards lithium and sodium enolates generated from  
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indanones, tetralones and benzosuberones to give the corresponding α-fluoro derivatives in 
good tields (64-100%). 
NS
Et
Me
F
NH
S
O O
O
s-BuLi
N
S
O O
Et
Me
1) NaH
N
S
O O
Et Me
Br
KOH
O
O O
NHS
Et
Me
O
O O
Br2
2) FClO3
 
Scheme 2-32 
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2.4 Strategies used in sultam synthesis 
 
Many effort are made to find new strategies for the synthesis of an important class of 
heterocycles like that of sultams and benzosultams; in the next pages are exposed the most 
significant progresses appeared in the last years. 
In 2000 Metz and coworkers48 proposed a Diels–Alder cyclization of vinylsulfonic esters and 
amides bearing acyclic and carbocyclic 1,3- diene moieties by application of high pressure. This 
methodology leads to excellent yields of sultones and sultams, respectively, at ambient 
temperature with modest diastereoselectivities (Table 2-10).  
 
 
Scheme 2-33 
 
R R’ R’’ y (%) Ratio 
H H H 79 1 : 1.6 
H H H 76 1 : 1 
Me H Me 81 1 : 1.6 
Me H Me 61 1.6 : 1 
Table 2-10 
 
Just on the same year a similar methodology proposed by Tozer49, consisted in the synthesis of 
both δ- and γ-sultams (Scheme 2-34).  
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Scheme 2-34 
Always considering Diels-Alder cyclization as a tool to obtain sultams, we must mention 
reaction with purely thermal activation and under high pressure of vinylsulfonamides bearing 
furan moiety proposed always by Metz and coworkers50. This methodology allows the 
obtainment of δ- and γ-sultams with good diasteromeric excesses while enantiopure 
compounds were readily prepared by reaction of optically pure N-1-phenylethyl substituted 
vinylsulfonamides (Scheme 2-35).  
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Scheme 2-35 
In 2003 Lee51 exposed a practical and high yielding method for the synthesis of sultams starting 
from β-amino alcohols. The synthetic pathway consists in the N,O-bis-methanesulfonylation of 
amino alcohols followed by SN2 displacement with sodium halide in DMF to give the desired 
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haloalkanesulfonamide; finally, the key step, the sulfonamide dianion alkylation, was applied 
to obtain successfully five-membered sultam synthesis (Scheme 2-36).  
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Scheme 2-36 
The same idea has been resumed by Cleator et Al. using the reaction between an epoxide and a 
sulfonylamide to obtain in one step the desired β-amido alcohol.52 In 1999 Paquette proposed,53 
as the first examples of bridgehead bicyclic sultams, the radical displacement reactions on 
halosulfonamides; despite this kind of reaction are generally not feasible for steric and 
stereoelectronic reasons, sulfonyl radicals are not stabilized, and they are prone to rapid 
intramolecular cyclization (Scheme 2-37). 
 
HN
BrCH2SO2Cl NBrCH2SO2 NBrCH2SO2 NSO
O
Bu3SnH,
AIBN
C6H6, 60 °C
Grubbs I
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CH2Cl2
 
Scheme 2-37 
Always in 1999 and always Paquette extended his previous work54 demonstrating his reaction a 
preparatively useful route to sultams. He prepared homologous of sulfonamidyl radicals, 
generated by the well known reaction of halomethyl precursors with tri-n-butyltin hydride 
under AIBN catalysis. Moreover he evaluated the intramolecular cyclization capability of these 
highly reactive intermediates studying exo and endo transition state for the regioselectivity 
understandment (Scheme 2-38). 
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Scheme 2-38 
The radical addition- cyclization-trap reaction of a substrate having a vinyl sulfonamide and an 
hydrazonic or olefinic moiety group was studied by Naito55 as a potential method to obtain 
sultams; tandem carbon-carbon bond-forming reactions were studied in aqueous media by 
using indium as a single-electron-transfer radical initiator in the absence of toxic tin hydride. 
Therefore the radical addition-cyclization reaction gave the functionalized cyclic iodomethyl or 
hydrazino sultams (Scheme 2-39). 
 
Scheme 2-39 
RI Solvent y (%) RI Solvent y (%) 
i-PrI H2O 81 i-PrI H2O-MeOH 93 
i-PrI H2O-CH2Cl2 42 i-PrI H2O-CH2Cl2 94 
c-PentylI H2O 84 c-PentylI H2O-MeOH 86 
t-BuI H2O 79 t-BuI H2O-MeOH 42 
 
Table 2-11 
Finally, even RMC has been considered as an efficient methodology for the construction of 
sultamic ring: the reaction has been studied initially by Hanson and coworkers56 taking as 
starting material allyl or vinylsulfonamides, easily synthesized from the styrene derived 
sulfonyl chloride57 and allylsulfonyl chloride58 This compounds were cyclized in good to 
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excellent yield via the ring closing methatesis with Grubbs I cat. demonstrating the feasibility of 
the RCM strategy en route to complex sulfonamides (Scheme 2-40). 
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Scheme 2-40 
The same author developed, some year later, a similar method in which the allyl or omo allyl 
amine is substituted by chiral unsaturated amines deriving from natural amino acids (Scheme 
2-41).59  
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Scheme 2-41 
Moreover, as in the past years were reported a range of nonconventionally fused β-lactams 
including the N-sulfonyl compounds showed in Scheme 2-7 and Scheme 2-8. Metz60 developed 
β-lactams fused to a sultam from low cost, commercially available starting materials, always  
using ring closing metathesis as the key operation. Lactams were synthesized by cycloaddition 
of chlorosulfonyl isocyanate with 1,3-butadiene or isoprene and the resulting compounds were 
converted to N-sulfonyl derivatives with olefinic sulfonyl chlorides, readily derived from 
commercially available 2-chloroethanesulfonyl chloride or from the corresponding olefinic 
bromides; finally RCM strategy allowed the formation of unsaturated sultams with different 
ring size (from 5 to 8 members, Scheme 2-42). 
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Scheme 2-42 
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Even β-sultams themselves can be seen as a building blocks for the synthesis of new synthetic 
drugs, for example corresponding to β-lactam antibiotics In general, β-sultams can be 
synthesised by [2+2] cycloaddition of sulfene intermediates with imines,61 of alkenes with N-
sulfonylamines62 or by intramolecular cyclization.63 
Kataoka et al., for example, described the diastereoselective [2+2] cycloaddition using mesyl 
chloride and chiral imines.64 However, the adaptable substrates are not only restricted in the 
choice of substituents, the cycloaddition also yields unsatisfactory stereoselectivities. Another 
access to enantiomerically pure β-sultams is the synthesis starting from natural amino acids. 
Initially Otto et al. utilized cysteine derivatives65 as precursors, but recently also embarked on 
other amino acids followed by introduction of the sulfur moiety.66  
Among all these protocols, quite interesting is the asymmetric synthesis of cis-3,4-disubstituted 
β-sultams reported by Enders and Moll67. The protocol is based on the initial synthesis of the 
anti-1,2-benzylsulfanyl amines previously reported by the same author68: key steps are the 
diastereoselective α-alkylation of α-sulfanylated acetaldehyde-SAMP-hydrazone, reaction 
conducted with various electrophiles and subsequent nucleophilic 1,2-addition of organocerium 
compounds to the hydrazone C=N double bond. The resulting hydrazines were converted to 
the corresponding protected amines by reductive N–N bond cleavage-oxidation of 1,2-
aminothiols with H2O2 and ammonium heptamolybdate. The obtained anti-1,2-benzylsulfanyl 
amines has been cleaved to the deprotected thiol and sequently oxidized; chlorination of the 
resulting β-amino sulfonic acids was achieved with phosgene and the β-aminosulfonyl 
chlorides obtained were cyclized to the title compounds under basic conditions without 
epimerisation and good overall yields (Scheme 2-43). 
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Scheme 2-43 
Certainly, when is possible, the most simple way to obtain sultams is the direct formation of S-
N bond: as an example we can mention the work of the above mentioned author69 in which the 
synthesis of a five or six membered heterocycle is carried out with a final step consisting in a 
simple amidation (Scheme 2-44). 
c-HexO
S H
O O
N
N
OMe
c-HexO
S R
O O
NH
N
OMe
c-HexO
S R
O O
NH
CbzRLi, CeCl3
-100°C
1) BH3.THF,
∆
2) CbzCl,
K2CO3, ∆
HN S
R
O O
3. COCl2, r.t.
4) HBr/AcOH, r.t.
5). Et3N, 0 °C
1) EtOH/H2O, ∆
2) NaOAc, r.t.
n n n
n
n = 1,2
 
Scheme 2-44 
Metz again reported in 200570 a concise access to α-methylene-γ-sultams via the intramolecular 
Heck reaction of α-bromovinylsulfonamides which, in turn, are readily available from 
isethionic acid sodium salt by a known three-step sequence.71 The synthesis of the sulfonamide 
substrates with cyclic and acyclic allyl amine moieties employed in this study is carried out as 
shown in Scheme 2-45 and is quite important even in the light of the structural similarity of α-
Methylene-γ-sultams to α-methylene-γ-butyrolactones, which display a wide range of 
interesting biological activities.72  
Synthesis of polyfluorobenzo[d]sultams 
 
42 
 
OH
1) MsCl,
Et3N
2) BnNH2,
80°C
N
S
Bn
Br
O
O
SO2Cl
Br
Et3N, DMAPNHBn
S
N
Bn
O
O
Pd(OAc)2,
P(o-Tol)3,
TlOAc,
MeCN, reflux. 73%
S
N
H
H
O
O
Bn
64%
S
N
H
H
O
O
Bn
72%
S
N O
O
Bn
74%
 
Scheme 2-45 
Moreover, inspired by recent work of Roush with vinylsulfonyl compounds73, they 
demonstrated the reactivity of bicyclic α-Methylene-γ-sultams as potent Michael acceptors 
towards the sulfur nucleophiles. 
Among the newest strategies, intramolecular aziridinations of unsaturated sulfonamides and 
metal-catalysed amidation has received much attention as a method for the sultam synthesis: 
for instance [N-(alkylsulfonyl)imino]phenyliodinanes, derived from ω-unsaturated 
sulfonamides, react intramolecularly in the presence of a catalytic quantity of copper (I) or (II) 
triflate to give bicyclic aziridines74 of the type showed in Scheme 2-46 which, in turn, can be 
opened by a variety of nucleophiles. 
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Scheme 2-46 
The same authors explored too the possibility of applying an intermolecular bromine-catalyzed 
aziridination of olefins using N-chloramine salts of sulfonamides (Scheme 2-47).75 
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Scheme 2-47 
As a proof of the versatility of the aziridination methodology, even rhodium76 has been proven 
to be a valid catalys giving the corresponding sultam products in excellent yields (up to 98%) 
and with good to excellent conversions. The successful employ of rhodium opened the way to 
the an enantioselective version of this protocol77 that is potentially useful for effecting 
intramolecular aziridination in a stereocontrolled manner. In 2001 Chiacchio and coworkers 
proposed a stereoselective sultams synthesis using intramolecular cycloaddition reaction as the 
key step78: their methodology starts form commercially available L-amino acids and leads, in 
few steps, to various α-sulfonamido aldehydes; their subsequent treatment with different N-
substituted hydroxylamines furnishes the unstable nitrones which immediately underwent 1,3 
dipolar cycloaddition to give the bicycle sultam-isoxazolidinic compound (Scheme 2-48). The 
same authors investigated too the possibility to obtain the pyrazolidinic analogue employing 
hydrazine derivatives instead of hydroxylamine. 
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Scheme 2-48 
In a similar way Chan et Al.79 proposed a trans amidation to obtain bicyclic sultam starting from 
the corresponding sultans which in turn are obtained via cycloaddition reaction (Scheme 2-49). 
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Scheme 2-49 
The relative effectiveness as new chiral auxiliaries in asymmetric synthesis of these compounds 
was evaluated for the asymmetric Diels–Alder reactions with cyclopentadiene obtaining good 
chemical yield and excellent endo selectivity. 
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2.5 Strategies used in benzosultam synthesis 
 
 
As we have seen before, also benzosultams make up an important class of molecules, both as 
chiral auxiliaries and for medicinal chemistry: however few examples are reported for the 
synthesis of these heterocylces and the following pages have the purpose to illustrate the most 
important improvements80.  
As regards four membered ring, Wu has reported a synthesis via demethylative cyclization:81 
when ortho-dimethylamino benzan sulfonic acid are heated with phosphorus oxychloride in the 
presence of phosphorus pentachloride , β-benzo[c]sultam was formed in good yield (Scheme 
2-50); 
PCl5, POCl3
N
SO3H
Me
Me
R R S
N
Me
O
O
 
Scheme 2-50 
also Snieckus and coworkers82 proposed a simple synthesis of six-and seven-membered ring by 
intramolecular anionic “Friedel-Crafts” cyclization of α–sulfonamido amides readily available 
from the condensation of amides deriving from natural α-amino acids with benzene or p-
toluene sulfonyl chlorides; in addition, higher membered benzosultams can be approached 
using methodology based on the direct ortho-metalation (DoM) together with RCM (Scheme 
2-51)  
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Scheme 2-51 
as an extention of this methodology, even ene-yne RCM has been carried out on o-alkynyl N-
allyl sulfonamides with the purpose to allow further anellation via Diels-Alder reaction 
(Scheme 2-52).83 
Synthesis of polyfluorobenzo[d]sultams 
 
46 
 
Up to today, few methods for the construction of 3,4-dihydro-2,1-benzothiazine 2,2-dioxide 
skeleton are known, i.e., the cyclization of 2-(o-aminophenyl) ethanesulfonic acid,84 the 
cyclization of N-benzyl-N-methanesulfonyl(o-chloromethyl)aniline,85 and the cyclization of N-
phenylsulfamoylacetic acid and subsequent reduction of the carbonyl group;86 
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Scheme 2-52 
however these obsolete methods (Scheme 2-53) require many steps, and the yields of the 
cyclized products are not good. 
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Scheme 2-53 
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Togo et al reported in 2000 a new preparative method87 of 3,4-dihydro-2,1-benzothiazine 2,2-
dioxides from N-alkyl 2-(aryl)ethanesulfonamides with (diacetoxyiodo) arenes under 
photochemical conditions (Scheme 2-54).  
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Scheme 2-54 
Always in 2005 Piva et Al.88 proposed a new one-pot procedure to prepare tri- or tetracyclic 
sultams starting from readily available unsaturated sulfonamides,.combining a ring-closing 
metathesis, an isomerization step and a radical cyclization (Scheme 2-55).  
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Even the previously seen methodology of aziridination77 has been employed for the synthesis of 
benzosultams, obtaining good yield and good e.e.’s accompanied with only modest conversions 
(Scheme 2-56).  
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Cobalt complexes of porphyrins are effective catalysts for intramolecular C−H amination with 
arylsulfonyl azides. In 2007 Zhang and coworkers89 used a cobalt-catalyzed process for the 
synthesis of benzo[d]sultmas that can proceed efficiently under mild and neutral conditions in 
low catalyst loading without the need of other reagents or additives, generating nitrogen gas as 
the only byproduct. The catalytic system can be applied to primary, secondary, and tertiary 
C−H bonds and is suitable for a broad range of arylsulfonyl azides, leading to high-yielding 
syntheses of various benzosultams (Scheme 2-57).  
 
 
Scheme 2-57 
As we have seen before, 3-substituted γ-benzo[d]sultams have received much attention because 
of their excellent stereofacial discrimination when used as chiral auxiliaries: however their 
usefulness has not been explored fully, probably owing to its tedious preparation involving, for 
example for the 3-tert-Butyl substituted sultam, a necessary chemical resolution of the racemic 
mixture via N-(S)-camphorsulfonylated compound (Scheme 2-58) 
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Scheme 2-58 
3-alkyl γ-benzo[d]sultams became more accessibles in 90’s, because of the development of a 
more efficient synthesis via the asymmetric hydrogenation of the sulfonylimine (a synthetic 
route just exploited by Oppolzer for R = Me, Scheme 2-59); anyway the requirement of an 
asymmetric reduction step made with an expansive and hazardous catalyst like Ru-BINAP, 
make the whole approach not much achevable especially for a large-scale synthesis. 
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Scheme 2-59 
The most important work appeared in 2000 and described for the first time the attempt of the 
synthesis of 3-carboxy γ-benzo[d]sultam;90 although the direct nucleophilic addition approaches 
are useful for the synthesis of 3-alkyl- or 3-arylsubstituted derivatives, all the attempt to 
introduce directly a functional moiety such as cyano group were unsuccessful. To synthesize 3-
carboxy analogues Ahn has studied both an asymmetric approach and a racemic synthesis 
followed by chemical resolution.  
The asymmetric route use (Scheme 2-60) as starting material, sodium o-formylbenzenesulfonate 
and pass through an aqueous Wittig-Horner-Emmons reaction followed by the conversion of 
the resulting cinnamate derivative into a sulfonamide. Reduction of the ester group leads to the 
o-(aminosulfonyl)-trans-cinnamyl alcohol employed in the key steps, the Sharpless asymmetric 
epoxidation and a subsequent intramolecular epoxide opening by the sulfonamido group.  
The final step, an oxidative conversion of the diol functionality into the carboxy group, was  
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Scheme 2-60  
found to be difficult due to the instability of the reaction intermediate. Treatment of diol with 
sodium periodate produced the corresponding aldehyde, and subsequent in situ oxidation with 
potassium permanganate produced decomposed products instead of the desired 3-
carboxysultam. Treatment with sodium periodate followed by sodium borohydride leads to the 
corresponding alcohol, compound impossible to oxidize with PDC, KMnO4, or Ru(IV) reagents. 
Again when N-protected diol was subjected to the RuCl3-NaIO4 oxidation (Scheme 2-61), the  
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major product was not the desired carboxylic acid but saccharine: these results indicate that 3-
formylsultam and its N-protected derivatives have limited stability and may undergo 
deformylation and pushes the authors to turn their attention to a racemic route. 
This one starts from the N-Protected saccharin, and proceed through conversion to the semi 
aminal by treatement with DIBALH and subsequent conversion of the hydroxy group into the 
cyano group with TMSCN in the presence of BF3.OEt2 ; after hydrolyzation to the corresponding 
methyl ester, deprotection of the MPM group and hydrolysis of the ester group, racemic 3-
carboxysultam was obtained (Scheme 2-62) and the two single enantiomers were prepared by 
coupling with (S)-(-)-α-methylbenzylamine and chromatographic separation of the mixture of 
diastereomeric amide. 
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Scheme 2-62 
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3  RESULTS 
 
 
 
 
Our interest in the synthesis of benzosultams starts with an observation that we made during 
the study of a particular class of reactions: the intramolecular degradative rearrangement of the 
N-(4-nitrobenzene)sulfonamido derivatives 1 of natural α-amino esters; we discovered that 
treatment of these compounds with an excess of sodium hydride, followed by addition of an 
alkylating agent, furnished the corresponding N-alkyl-α-4-nitrophenyl-α-amino esters 2 
(Scheme 3-1). 
 
Scheme 3-1 
The reaction needs a strong electron withdrawing substituent in the para position to the sulfonyl 
group, in order to stabilize the Meisenheimer intermediate, which evolves to the rearranged 
product, loosing sulfur dioxide. In the screening of various sulfonamido esters activated to this 
transposition, we tested the N-(pentafluorobenzene)sulfonyl derivative. In fact, we supposed 
that this compound, bearing the strongly electronegative five fluorine atoms, could easily give 
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the bicyclic Meisenheimer activated  structure, through the aromatic intramolecular 
substitution. 
 
Preliminary tests showed a particularly interesting behavior of 3a: the molecule, after the initial 
N-alkylation with an alkyl halide, cyclizes by displacement of the fluorine atom in the ortho 
position to the sulfonyl group furnishing the N-alkyl benzo[d]isothiazole-1,1-dioxide (4, Scheme 
3-2)  
 
 
 
Scheme 3-2 
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3.1 Synthesis of Benzosultams 
 
Sulfonamide 3a has been prepared by condensation of the commercially available 
pentafluorobenzene sulfonyl chloride (5a) and phenylglycine methyl ester hydrochloride 6a. 
The reaction, conducted at 0−25 °C, in dichloromethane with di-(iso-propyl)ethylamine (DIEA) 
as a base to neutralize the hydrogen chloride formed during the condensation, gave the desired 
product 3a in good yield after crystallization of the crude (Scheme 3-3). 
 
Scheme 3-3 
Sulfonamide 3a was the starting point for an extensive study devoted to find the best reaction 
conditions for the cyclization. In a preliminary step, we studied the alkylation of the open chain 
sulfonamide and our attention was focused on the alkylation with benzyl bromide, an activated 
alkylating agent. Analogously to that obtained with (4-nitrobenzene)sulfonamides, we found 
that solid-liquid phase transfer catalysis (SL-PTC) conditions provide great reactivity. The 
reaction was carried out in acetonitrile at room temperature, using a solid, anhydrous alkaline 
metal carbonate, in the presence of a catalytic amount of triethylbenzylammonium chloride 
(TEBA), as PTC agent. Results (Table 3-1) indicate good yield of the N-benzyl derivative 7b 
together with small but indicative amounts of the cyclized product 4b (Scheme 3-4). In the 
screening for the best reaction solvent, this behavior was invariable in all cases (DMF, DME), 
but in DMSO, in which an increased yield of the sultam 4b (Table 3-2, entries 1-2) has been 
obtained at 50°C in 20h. As indicated by these preliminary data, DMSO shows the better solvent 
ability toward the cyclization process.  
 
 
Scheme 3-4 
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 M2CO3 T[°C] t[h] 7b (%) 4b (%) 
1 Na2CO3 25 40 62 13 
2 K2CO3 25 44 52 22 
3 Na2CO3 25 20 75 15 
4 Na2CO3 50 18 72 12 
5 Cs2CO3 25 24 15 15 
6 CaCO3 25 48 33 22 
Table 3-1 
Additional experiments were performed on the N-benzylsulfonamide 7b cyclization, by 
changing reaction solvent, base, temperature and time. The most active bases were the alkaline 
metal carbonates (entries 1-5, 11-13) while DMSO was confirmed the most effective solvent 
(entries 1-2). 
 
 Solvent M2CO3 T[°C] t[h] 4b (%)  Solvent M2CO3 T[°C] t[h] 4b (%) 
1 DMSO Na2CO3 25 20 32 8 DME NaOH 50% 25 8 -- 
2 DMSO K2CO3 25 6 45 9 DME Na2CO3 0 1 -- 
3 DME Na2CO3 25 20 27 10 DME NaH -20 5 10 
4 DME K2CO3 25  20 28 11 MeCN Na2CO3 25 20 23 
5 DME KHCO3 25 48 32 12 MeCN K2CO3 25 20 24 
6 DME KHCO3 80 20 10 13 MeCN Na2CO3 acq 25 20 26 
7 DME NaOH 25 5 -- 14 DMF KHCO3 25 40 -- 
Table 3-2 
In summary, an excess of potassium carbonate as a base in DMSO at room temperature 
represents the best reaction conditions. However, the non satisfactory yields achieved 
prompted us to change the alkylating agent, in order to reduce the steric hindrance around the 
nucleophilic carbon atom, and our choice fell on the smaller but, at the same time, reactive 
methyl iodide.   
 
Scheme 3-5 
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 M2CO3 eq. MeI t[h] 4a (%) 
1 KHCO3 1.5 48 70 
2 Na2CO3 1.5 48 75 
3 K2CO3 1 20 72 
4 K2CO3 1.5 20 92 
Table 3-3 
The collected data, illustrated in Table 3-3, indicated that effectively the cyclization is strongly 
influenced by the nature of the alkylating agent: moreover, we performed several reaction by 
changing the alkyl halide and the results, summarized in Table 3-4, indicate good to acceptable 
yields of 3 with ethyl, n-propyl and n-butyl iodide, in DMSO at room temperature (entries 1-4). 
We observed no reaction with more crowded alkyl halides (entries 5-6), while the cyclization in 
other non hydrogen bonding donor (non-HBD) solvents gave comparable yields (entries 7-8). 
The data demonstrate also the dependence of reactivity on the increasing dimension of the 
alkylic substituent on the nitrogen atom. 
 
Scheme 3-6 
 RX t[h] Sultam (%) 
1 EtI 20 4d   83 
2 n-PrI 24 4e   51 
3 n-BuBr 48 4f   37 
4 n-BuI 48 4fe   61 
5 t-BuI 72 --- 
6 BnCl 96 --- 
7 n-BuI 20, NMP 4f  62 
8 n-BuI 48, DMPU 4f  58 
9 BnBr 6 4b  45 
10 AllBr 24 4c  46 
Table 3-4 
The successive stage consisted in determine the mechanism for this “one-pot” reaction, since the 
N-alkylated sultam can be obtained through two different pathways (Scheme 3-7): 
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a) cyclization of the amidide-enolate, followed by N-alkylation;  
b) alkylation of the open-chain sulfonamide then cyclization. 
For this purpose, we decided to investigate the formation of 4a by mean of HPLC analysis, 
monitoring the amount of the starting sulfonamide 3a, of the products 4a and of the supposed 
intermediates, the N-alkyl sulfonamide 7a and the non-alkylated sultam 8a. 
 
Scheme 3-7 
Analysis of the reaction conducted in DMSO using potassium carbonate (Graphic 3-1) or cesium 
carbonate (Graphic 3-2) indicates the absence of the non-alkylated sultam and meanwhile, the 
process showed a typical consecutive trend, in which the N-methyl sulfonamide 7a is the 
intermediate.  
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Graphic 3-2 
As a confirm that the initial step of the optimized SL-PTC procedure was the nitrogen 
alkylation, the N-methyl sulfonamide 7a was synthesized, isolated and, in a subsequent step, 
cyclized to 4a. Compound 3a was then reacted with methyl iodide in MeCN, in the presence of 
anhydrous K2CO3 and a catalytic amount (0.1 mol equiv.) of TEBA. 
 
Scheme 3-8 
The resulting N-methyl sulfonamide 7a was then transformed into the corresponding N-methyl-
tetrafluorobenzo[d]sultam 4a by generating the enolate, under SL-PTC in DMSO, which rapidly 
cyclizes. Having determined the optimal reaction conditions and with a better comprehension 
of the facts, we were able to study the role of the solvent that is particularly crucial, as we have 
seen for the selectivity of the ring closing step. Actually, rapid conversion and high cyclization 
yield of sultam were reached by operating in pure DMSO (Table 3-5, entry 1) or in MeCN 
containing at least 1 molar equivalent of DMSO as an additive (entry 3), whereas a low 4a yield 
was obtained with a catalytic amount of DMSO (entry 4), indicating the formation of an 
equimolar adduct sulfonamide/DMSO as the plausible activated species. 
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Graphic 3-3 
 
 Solvent DMSO t [min] 4a (%) 
1 DMSO - 15 91 
2 MeCN 5 90 89 
3 MeCN 1 90 86 
4 MeCN 0.1 90 68 
5 MeCN - 90 - 
Table 3-5 
As a natural consequence, and in light of the low yields obtained in the “one-pot” cyclization-
alkylation, we decided to apply this methodology to the synthesis of the bulkier N-allyl (4c) and 
N-benzyl (4b) sultams, but N-alkylation of the open-chain sulfonamide 3a with benzyl and allyl 
bromide (Scheme 3-9, Table 3-6) gave low yields (45%), of the corresponding N-
alkylsulfonamides 7b,c, probably due to the steric hindrance around the nucleophilic center. In 
addition, the cyclization of these sulfonamides gave not acceptable yields of the desired 
compounds 4b,c (Scheme 3-10, Table 3-7), preventing the application of this protocol to the 
synthesis of bulky N-alkyl derivatives.  
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Scheme 3-9 
 RX t [h] Sulfonamide (%) 
1 BnBr 20 7b  88 
2 AllBr 40 7c  48 
Table 3-6 
 
Scheme 3-10 
 R t [h] Sultam (%) 
1 Bn 12 4b  45 
2 All 12 4c  61 
Table 3-7 
In order to solve this problem, we thought that the ring closure of the sulfonamide 3a without 
the alkylating agent (Scheme 3-7, path a), would lead to the non-alkylated sultam 8a, a much 
more interesting compound. This molecule, in fact, is the single scaffold which could eventually 
be N-alkylated in a subsequent step, therefore this way represents a valid alternative to the 
“one-pot” cyclization.  
A screening of reaction conditions showed that PTC technique failed (Table 3-8, entry 1) even 
when drastic conditions were applied (entry 2); 
 
Scheme 3-11 
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 solvent Base T[°C] t [h] 8a (%) 
1 DMSO Na2CO3 25 90 --- 
2 DMSO Na2CO3 80 90 28 
3 DMSO K2CO3 50 90 10 
4 DMSO Cs2CO3 50 90 8 
5 DMF Na2CO3 80 60 --- 
6 MeCN Na2CO3 80 60 --- 
Table 3-8 
a change in the anhydrous alkaline carbonate indicates a decreasing yield along the series 
Na>K>Cs (entries 2-4), while any attempt to change the reaction solvent (entries 5,6) was 
unsuccesful. 
After these negative results obtained under PTC conditions, we turned our attention to the 
cyclization under homogeneous conditions, considering that many organic soluble bases are 
well known to enolize carboxylic compounds: among the bases tested, 1,8-diazabicycloundec-7-
ene (DBU) gave the best yields (Table 3-9, entries 4,5); on the other hand 1,4-
diazabycyclo[2.2.2]octane (DABCO, entry 3) gave low yields, while tetramethylguanidine 
(TMG, entry 2) gave good yields but in very long time reaction. Moreover, the choice of the 
solvent is important as demonstrated by the different yields obtained passing from DMSO 
(entry 1) to a less polar solvent like, e.g., DME (entries 4,5). 
 
 
Scheme 3-12 
 solvent Base t [h] 8a (%) 
1 DMSO DBU 48 62 
2 MeCN TMG 80 96 
3 MeCN DABCO 24 54 
4 DME DBU 16 96 
5 MeCN DBU 20 98 
Table 3-9 
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The application of the homogeneous methodology to the “one-pot” synthesis of the N-methyl 
benzosultam 4a by cyclization of the corresponding open-chain sulfonamide 3a in the presence 
of excess MeI, gave only low yields of the non-alkylated benzosultam 8a. Analogously, the 
cyclization of the N-methyl sulfonamide 7a failed, producing the correspondent sultam 4a only 
in modest yield (Scheme 3-13). 
 
Scheme 3-13 
To complete the synthetic procedure, the N-H sultam 8a has been reacted under SL-PTC 
conditions with a series of alkyl halides RX (Scheme 3-14), and the desired N-alkyl 
tetrafluorobenzo sultams 4a-f were obtained in very good overall yields (74-90%), starting from 
sulfonamide 3a. 
 
Scheme 3-14 
 RX t [h] Sultam (%) 
1 MeI 18 4a  99 
2 EtI 48 4d  95 
3 n-PrI 48 4e  88 
4 n-BuI 48 4f  82 
5 BnBr 20 4b  85 
6 AllBr 20 4c  82 
Table 3-10 
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These results clearly show that homogeneous cyclization followed by nitrogen alkylation 
emerges as the best protocol to produce N-alkyl benzo[d]sultams, and preferred alternative to 
the “one-pot” cyclization, especially in the case of bulky benzyl and allyl derivatives 4b and 4c. 
In order to check the reaction scope, we decided to synthesize several different 3-aryl 
substituted benzo[d]sultams, starting from the correspondent 2-aryl-2-aminoacetic acids. 
Arylglycines are both commercially available and easily obtainable by Strecker reaction on 
aromatic aldehydes (Scheme 3-15);  
 
Scheme 3-15 
Variously substituted arylglycines methyl ester 9a-h, bearing both an electron withdrawing 
group and an electron donor group, were then synthesized and condensed with 
(pentafluorobenzene)sulfonyl chloride to give the corresponding sulfonamides 10a-h (Scheme 
3-16, Table 3-11). 
 
Scheme 3-16 
 X Sulfonamide (%) 
1 3-F 10a  81 
2 4-F 10b  80 
3 4-Cl 10c  78 
4 4-Br 10d  82 
5 4-Me 10e  90 
6 3-OMe 10f  85 
7 4-OMe 10g  80 
8 4-OBn 10h  83 
Table 3-11 
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All these sulfonamides were then cyclized to the corresponding 3-aryl substituted 
benzo[d]sultams 11a-h in good to excellent yields, or quantitative yields in the case of m-fluoro, 
p-fluoro, p-methyl, m-methoxy , and p-methoxy derivatives (Scheme 3-17, Table 3-12). 
 
 
Scheme 3-17 
 X Sultam (%) 
1 3-F 11a  98 
2 4-F 11b  98 
3 4-Cl 11c  97 
4 4-Br 11d  93 
5 4-Me 11e  99 
6 3-OMe 11f  98 
7 4-OMe 11g  98 
8 4-OBn 11h  81 
Table 3-12 
 
With this methodology91, even heterocyclic derivatives can be synthesized, as demonstrated by 
the cyclization of the 3-thyenyl derivative 10i (Scheme 3-18), which in turn has been obtained 
from 3-thienylglycine methyl ester 9i. 
 
 
Scheme 3-18 
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The influence of the acidity of the proton in the C-α position to the carbonyl functional group, 
has been investigated, by reacting, under the ring closing conditions, the sulfonamides 12a,b 
and 13a,b deriving from glycine and phenylalanine methyl esters 14a, 15a and tert-butyl esters 
14b, 15b. 
The N-sulfonylation of these esters, especially in the case of methyl glycinate, gave modest 
yields (Table 3-13, entry 3) of the sulfonamides 12,13. The condensation process was 
investigated by varying the base and the reaction conditions, and we found that the best result 
was obtained by reacting the free amino ester with an equimolar amount of sulfonyl chloride 
and pyridine, as the activating agent, in DCM solution and in the presence of TEA as a base 
(Table 3-14, entries 3,4). 
 
Scheme 3-19 
 R R’ Sulfonamide (%) 
1 CH2Ph Me 12a  70 
2 CH2Ph t-Bu 12b  62 
3 H Me 13a  45 
Table 3-13 
 
 
Scheme 3-20 
 R Base Sulfonamide (%) 
1 Me TEA 13a  38 
2 Me N-Me Morpholine 13a  45 
3 Me Pyridine-TEA 13a  94 
4 t-Bu Pyridine-TEA 13b  75 
Table 3-14 
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Sulfonamides 12a,b and 13a,b were reacted both under PTC conditions (Table 3-15, entry 1) and 
under many other anhydrous basic conditions (entries 2-9,11), varying the nature of the solvent 
and the base. Results indicate, for the phenylalanine derivative, a good reactivity for the N-
alkylation (entries 1,8), but a very scarce reactivity toward the ring closure, and the desired 
compound 16 was isolated only as a side product (entries 2,5).  
 
The results are even worst with the methyl sulfonamidoglycinate 13a,b. In fact, no trace of the 
expected 3-carboxy mono-substituted benzosultam were detected, but the 3-methyl-3-carboxy 
derivative 20 was isolated as the sole cyclized product (Scheme 3-22).  
 
 
Scheme 3-21 
 Substrate R R’ Solvent Base t [h] Sultam 
(%) 
Sulfonamide 
(%) 1 12a CH2Ph Me MeCN K2CO3, TEBAcat 20 --- 17a  80 
2 12a CH2Ph Me MeCN NaH 16 16a  12 17a  44 
3 12a CH2Ph Me DMSO NaH 18 --- 17a  35 
4 12a CH2Ph Me DMA NaHMDS 2 --- --- 
5 12b CH2Ph t-Bu THF-DMF NaH 16 16b  15 17b  34 
6 13a H Me DMA NaH 20 --- 18a  35 
7 13a H Me DMA NaH 1,5 --- 18a  37 
8 13a H Me DMA NaH 20 --- --- 
9 13b H t-Bu DMA NaH 2 --- 18b  72 
10 13b H t-Bu MeCN K2CO3, TEBAcat 40 --- 18b  60 
11 13b H t-Bu THF-DMF NaH 22 20  12 18b  18 
Table 3-15 
 
The presence of 20, arising from C-methylation of the mono-N-methylated sultam 19, proves 
that 19 under strong basic conditions is rapidly deprotonated and then methylated: this 
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behavior is probably due to the increased acidity of the C-α proton that, after the cyclization, is 
adjacent to the electron withdrawing aromatic fluorinated moiety.  
 
Scheme 3-22 
Some additional tests were performed on the N-methyl sulfonamides 17b and 18b, obtained 
under SL-PTC conditions, in acetonitrile (Scheme 3-23, Table 3-16). 
 
Scheme 3-23 
 R Sulfonamide (%) 
1 CH2Ph 17b  80 
2 H 18b  65 
Table 3-16 
 
The cyclization of these compounds (Scheme 3-24, Table 3-17) furnished large amounts of 21 
(Figure 3-1) and unidentified by-products (entries 1-4), proving that this reaction is not 
applicable to derivatives of amino acids different from phenylglycine and indicating the 
probable fundamental role of the aromatic ring for the success of the cyclization. 
 
 
Scheme 3-24 
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 R Solvent Base T [°C] t [h] Sultam (%) 
1 CH2Ph DMA NaH 0-r.t. 20 --- 
2 CH2Ph MeCN DBU r.t. 16 --- 
3 H THF LDA -78-0 10 --- 
4 H DMA NaH 0-r.t. 20 21  18* 
Table 3-17 
 
Figure 3-1 
Intra-intermolecular aromatic disubstitution product 
The high acidity of the C-α proton seems one of the determining features for the ring-closure of 
sulfonamides to benzosultams and to verify this postulate, we decided to synthesize another 
sulfonamide containing a strongly acid proton. Our choice fell on the sulfonamide 23 derived 
from the commercially available diethylaminomalonate 22 that was sulfonylated in 50% non-
optimized yield (Scheme 3-25, Table 3-18) In the sulfonamide 23, two electron-withdrawing 
ester groups activate the C-α proton, i.e., with respect to the arylglycinate derivatives, one ester 
group substitutes the aromatic ring in determining the acidity of the Cα-proton, which can be 
removed by the mild bases used until now.  
 
 
Scheme 3-25 
 Base T[°C] 23 (%) 
1 K2CO3 25 7 
2 DIEA 0 --- 
3 Pyridine-TEA 0 35 
4 Pyridine-TEA 0-25 50 
Table 3-18 
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Cyclization of this sulfonamide gave the 3,3-dicarboxy-N-methylsultam 24a in low, but 
significative yield (36%), confirming that the acidity of the proton effectively influences the 
formation of the sultam (Scheme 3-26); 
 
Scheme 3-26 
Higher yields were reached by cyclization of the diethylaminomalonate derivative 23 under the 
optimized homogeneous conditions with DBU (Scheme 3-27, Table 3-19). 
 
Scheme 3-27 
 Solvent Base T[°C] t [h] 25 (%) 
1 DMF K2CO3, TEBAcat 0 48 48 
2 DMA NaH 0-25 16 61  
3 MeCN DBU 25 4 66 
Table 3-19 
 
Even sultam 25, as done for the phenylglycine derived benzosultam, was N-alkylated under SL-
PTC conditions, obtaining the correspondent N-alkyl sultams in good yields (Scheme 3-28, 
Table 3-20). 
 
Scheme 3-28 
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 RX t [h] Sultam (%) 
1 MeI 5 24a  88 
2 AllBr 12 24b  95 
3 BnBr 18 24c  70 
Table 3-20 
With the sultams 25 and 24a-c in our hand, we investigated the decarboxylative conditions, to 
obtain the mono-3-carboxy-benzosultams. Despite that many authors describe the use of strong 
nucleophile under heating for the decarboxylation of malonate derivatives92, we found that our 
substrate under these conditions gave by-products through replacement of the aromatic 
fluorine atoms (Table 3-21, entries 1-2).  
 
 
Scheme 3-29 
 R Sulfonamide Reagents Solvent T[°C] t [h] Sultam 
(%) 1 H 25 NaCl, H2O DMSO 180 0,2 --- 
2 H 25 NaF, TBAF THF 80 2 --- 
3 H 24a H2O, H2SO4cat AcOH 100 3 26a  95 
4 Me 24b H2O, H2SO4cat AcOH 100 18 26b  79 
5 All 24c H2O, H2SO4cat AcOH 100 50 26c  85 
6 Bn 24d H2O, H2SO4cat AcOH 100 100 --- 
7 Bn 24d H2O, H2SO4cat CH3CH3CO2H 120 72 26d  83 
Table 3-21 
 
On the other hand, treatment of the (tetrafluorobenzo)sultams 24,25 with strong acids under 
heating gave quite complete conversion into the desired carboxylic acid, that can be isolated 
without any purification. While N-methyl 24b and N-allyl 24c derivatives showed the same 
behavior under these decarboxylative conditions (entries 4-5), giving the corresponding acids in 
good yields, even if in longer reaction times, the N-benzyl derivative 24d is not reactive (entry 
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6), probably due to its low solubility in AcOH. This problem was easily solved by hydrolyzing 
benzosultam 24c using propionic acid instead of acetic acid (entry 7). 
Finally, the carboxylic acids 26 have been converted into the corresponding methyl esters 27 by 
Fisher esterification with methanol and sulfuric acid as catalyst (Scheme 3-30, Table 3-22). 
 
Scheme 3-30 
 R Sultam (%) 
1 H 27a  90 
2 Me 27b  93 
3 Bn 27c  75 
Table 3-22 
 
These (tetrafluorobenzo)sultams present a high degree of chemical diversity. Actually, they can 
be functionalized both on the fluorinated moiety, on the nitrogen atom, on the carboxylic 
functional group and, eventually, on the aromatic ring present in the 3-position. However, in 
order to synthesize new and more versatile compounds and to go deeper inside into the 
reaction mechanism, we decided to investigate the role of the fluorine substituents by preparing 
and reacting differently halogenated sulfonamides. The commercially available 
(polyfluorobenzo)sulfonyl chlorides 5b-e (Figure 3-2), even if show a large variety of 
substitution, do not allow a complete screening, thus we prepared a series of sulfonyl chlorides 
bearing different substituents on the aromatic fluorinated moiety. 
 
 
Figure 3-2 
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We choose, as starting compounds, the commercially available (polyfluoro)halobenzenes vv 
that were sulfonated with 20% oleum, following a literature procedure applied on several 
chlorinated analogues.93 Good yields were obtained for all the sulfonic acids (Scheme 3-31, 
Table 3-23), but o-bromo substituted ones 28a,e, due to the bulky ortho substituent that partially 
inhibits the aromatic electrophilic attack (entries 1,5).  
 
 
Scheme 3-31 
 
 
t [h] Sulfonic acid (%)  
 
t [h] Sulfonic acid (%) 
1 
 
7 29a  77 4 
 
4,5 29d  90 
2 
 
6 29b  90 5 
 
7 29e  60 
3 
 
 29c  82 6 
 
20 --- 
Table 3-23 
 
In the case of deactivated 3-nitro derivative 28f, no reaction was observed (entry 6), even in 
longer reaction times. The sulfonic acids were subsequently chlorinated (Scheme 3-32, Table 
3-24) by reaction at 110-120 °C for 15 minutes with neat phosphorus pentachloride, followed by 
a rapid quench in ice and extraction. With this protocol, we do not observe any substitution at 
the aromatic ring by the chloride anion. 
 
Scheme 3-32 
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Sulfonyl chloride (%)  
 
Sulfonyl chloride (%) 
1 
 
5f  80 4 
 
5i  78 
2 
 
5g  89 5 
 
5l  78 
3 
 
5h  73    
Table 3-24 
For the more activated 1-bromo-3,4,5-trifluorobenzene (28e) and 1,3,5-trifluorobenzene (28g) we 
performed also a direct chlorosulfonation (Scheme 3-33, Table 3-25). 
 
 
Scheme 3-33 
 
 
t [h] Sulfonyl chloride (%) 
1 
 
7 5l  60 
2 
 
5 5m  62 
Table 3-25 
The sulfonyl chlorides 5 were condensed with phenylglycine methyl ester to give the 
corresponding pure sulfonamides 30a-l in good yield, after crystallization or chromatographic 
purification (Scheme 3-34, Table 3-26). 
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Scheme 3-34 
 
 
Sulfonamide (%)  
 
Sulfonamide (%) 
1 
 
30a  82 6 
 
30f  70 
2 
 
30b  86 7 
 
30g  89 
3 
 
30c  61 8 
 
30h  93 
4 
 
30d  67 9 
 
30i  88 
5 
 
30e  60 10 
 
30l  81 
Table 3-26 
 
From the literature is known that, in the nucleophilic aromatic substitution, the attack of the 
nucleophile on fluorinated substrates is governed by fluorine atom positions, rather than by the 
activating affects of other functional groups eventually present in the aromatic ring (Scheme 
3-35);  
 
Scheme 3-35 
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Moreover, considering the basis of the orientating preferences of fluorine atoms, it has been 
determined that (from the analysis of the relative rate constants, Figure 3-3), for an aromatic 
fluorine leaving group, the fluorine in meta-position is powerfully activating, while the ortho-
fluorine is less activating, and the para-fluorine has an effect similar to a hydrogen substituent. 
 
 
Figure 3-3 
Cyclization of the differently halogenated sulfonamides, in effect, gave a decreasing yield with 
the decrease of the activation of the ortho-fluorine atom toward the SNAr (Scheme 3-36, Table 
3-27). 
In particular, sulfonamides which lack of a fluorine substituent in meta to the leaving group, do 
not give the corresponding sultam (entries 3, 8-9). On the contrary, 2,4,6 trihalosulfonamides 
gave the desired compounds in good yields, and particularly good in the case of the 5-
bromosubstituted benzosultam, obtained in a 64% overall yield from the starting halobenzene. 
Another interesting feature is the reaction of sulfonamide 30d which would lead to two 
different regioisomers, but we isolated only the regioisomer derived from the major activation 
of the fluorine in ortho-position to the leaving group, proving that the fluorine in 2-position is 
much more activated in a SNAr reaction. 
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Scheme 3-36 
 
 
t [h] Sultam (%)  
 
t [h] Sultam (%) 
1 
 
24 31a  78 6 
 
30 31f  72 
2 
 
24 31b  92 7 
 
24 31g  64 
3 
 
160 31c  30 8 
 
30 --- 
4 
 
20 31d  92 9 
 
30 --- 
5 
 
24 31e  92 10 
 
30 --- 
Table 3-27 
 
For the less activated sulfonamides 30h-l, i.e. containing less fluorine atoms, neither stronger 
bases, nor harsher conditions gave acceptable results and, e.g., only 23% yield of 7-fluoro 
benzosultam 31l was obtained (Scheme 3-37): 
 
Scheme 3-37 
Regarding the SL-PTC “one-pot” cyclization of these less fluorinated sulfonamides, results 
confirmed the superiority of homogeneous conditions. In fact, the expected sultams are isolated 
Synthesis of polyfluorobenzo[d]sultams 
 
78 
 
in poor yields, especially in the case of the less activated (5,7-difluorobenzo)sultam 33 and (5-
fluoro-7-bromobenzo)sultam 34 (Scheme 3-38, Table 3-28). 
 
Scheme 3-38 
 RX t 
[h] 
Sultam (%) 
1 MeI 18 
 
32  89 
2 MeI 45 
 
33  51 
3 MeI 26 
 
34  68 
Table 3-28 
 
Sultams 31a,d,f were SL-PTC N-alkylated in good yields, as usual. The results, on the whole,  
 
 
Scheme 3-39 
 
 RX t [h] sultam (%)  RX t [h] Sultam (%) 
1 MeI 20 
 
35a  94 4 MeI 16 
 
32  92 
2 AllBr 16 
 
35b  77 5 MeI 40 
 
34  82 
3 MeI 20 
F
F
Br
F
N
S
O O
Me
Ph CO2Me  
36  90      
Table 3-29 
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confirmed that the combination between homogeneous cyclization and consecutive SL-PTC N-
alkylation is much more interesting for the preparation of N-alkyl benzosultams (Scheme 3-39, 
Table 3-29). 
N-Methyl (tetrafluorobenzo)sultam 4a has been employed in the study of aromatic nucleophilic 
substitution of fluorine atoms. Regarding the mono-substitution, we obtained good results in 
the introduction of a nitrogen atom by treatment of 4a with trifluoroacetamide, under SL-PTC 
conditions. The most labile position is the fluorine in 5-position, probably due the activation 
both by fluorine in 7-position and by the sulfonyl group in 1-position, and the 5-
trifluoroacetamido derivative 37 was isolated as sole product in good yield (Scheme 3-40).  
 
 
Scheme 3-40 
In a similar way, treatment of 4a with sodium metoxyde at -78°C in THF gave the analogous 
oxygenated substitution product 38 (Scheme 3-41). 
 
 
Scheme 3-41 
When an excess of the alcolate is used and harsher conditions are employied, the only observed 
product were the 5,7 disubstituted compounds 39 (Scheme 3-42, Table 3-30) proving that, for 
the previously seen reasons, even the fluorine atom in 7-position is enough activated as leaving 
group. As a conclusion, in the mono-substitution the preference for the 5-position is probably 
due to the steric hindrance given by the sulfonyl functional group. 
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Scheme 3-42 
 R Sultam (%) 
1 Me 39a  82 
2 Ph 39b  92 
Table 3-30 
 
While the reaction of benzosultam 4a with reducing agents, such as sodium naphtalenide and 
Red-Al® at room temperature, gave only decomposition products, quite interesting are the 
results obtained with Red-Al® at -78°C. Under these conditions, in fact, we obtained selective 
removal of the fluorine in 5-position, along with a minor amount of the sultam in which 
fluorine in 7-position was removed (Scheme 3-43). 
 
 
Scheme 3-43 
For the brominated sultams 31b and 36, we tested the reactivity of the bromine-carbon bond, 
despite few coupling reactions on fluorinated aromatic rings are reported in literature.94  
The first reaction analyzed was the Sonogashira coupling with 1-octine (Scheme 3-44, Table 
3-31) but the scarce results prompt us to take as standard an easier reaction and our attention 
fell on the Suzuki coupling with phenylboronic acid. 
 
 
Scheme 3-44 
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 Solvent t [h] R Sultam (%) 
1 DMF 8 Me 40b  12 
2 THF 9 H 40a  31 
3 THF 7 Me 40b  39 
Table 3-31 
 
Preliminary results gave a good conversion of the substrate but a low selectivity and, together 
with the coupling product 41, one third of the products is the decarboxylated sultam 42 
(Scheme 3-45). After a brief screening for anhydrous Suzuki coupling conditions, we found that 
cesium fluoride is the base of choice and the biaryl derivative 43 has been obtained in 68% yield. 
 
 
Scheme 3-45 
The presence of the decarboxylative product 42 prompted us to investigate the behavior of 4a 
under aqueous basic conditions: preliminary results gave a 51% yield of 44 opening the way to 
the obtainment of 3-aryl monosubstituted benzosultams. 
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Scheme 3-46 
Finally, the aromatic proton in the fluorinated moiety of sultam 32 is acid enough to be 
lithiated. Actually, few examples are reported in literature for the lithiation of simple aromatic 
polyfluoro compounds like pentafluorobenzene (Scheme 3-47) or 1,3-difluorobenzene, and 
reaction with a series of electrophilic reagents (metallic and metalloidal halides, ethyl formate, 
N-methylformanilide, benzaldehyde, halogens, sulfur, water, and carbon dioxide).95 
 
 
Scheme 3-47 
As a consequence, treatment of 32 with buthyl lithum at -78°C followed by the addition of the 
reactive p-nitro benzaldehyde, gave an interesting yield of the secondary alcohol (Scheme 3-48): 
this preliminary result open the way to further functionalizations of the less fluorinated 
sultams, not only as electrophiles but also as nucleophiles. 
 
 
Scheme 3-48 
As an extension of our work, we  decided to apply the whole methodology to the synthesis of 
the lactamic analogues: in a preliminary investigation, commercially available pentafluoro 
benzoic acid 46 has been converted into the corresponding sulfonyl chloride then condensed 
with phenylglicine methyl ester (Scheme 3-49).  
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Scheme 3-49  
The desired amide 47, obtained in 47% overall yield, has been cyclized under the homogeneous 
conditions and gave interesting yields of the tetrafluoro isoindolones 48a-c. 
 
Scheme 3-50 
 RX t [h] Lactam (%) 
1 MeI 26 48a  86 
2 AllBr 20 48b  56 
3 BnBr 20 48c  40 
 
Table 3-32 
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3.2 Stereochemistry of Benzosultams 
 
After having defined the optimal conditions to reach the highest yields for the cyclization step, 
we turned our attention to the stereoselective synthesis of our sultams: in fact, as we have seen 
in the previous chapter, the synthesis of optically pure benzo[d]sultams is a subject of great 
interest, even in the light of the very small number of synthetic methods available in literature.  
When we performed the SL-PTC “one pot” reaction on the optically pure sulfonamide S-3a, we 
found small but encouraging enantiomeric excess (e.e.) of benzosultams (Scheme 3-51) with the 
prevalence of the (-) isomer. 
 
Scheme 3-51 
Moreover, the variation of the alkylating agent led to a continuous, even if low, increase of e.e.’s 
with the increasing dimension of the alkylic residue, along with decreasing yields (Scheme 3-52, 
Table 3-33). 
 
Scheme 3-52 
 Solvent RX t[h] y e.e. 
1 DMSO EtI 20 83 16 
2 DMSO n-PrI 24 50 25 
3 DMF MeI 48 47 13 
Table 3-33 
The complete absence of an external source of stereochemical information, suggested to 
investigate the nature and the determinant parameters of the auto-induced stereoselectivity in 
the cyclization process. 
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 Firstly, the phase transfer agent was changed, but it did not lead to any substantial 
modification in the e.e. values and, on the contrary,  lower yields were found in the case of 
more lipophilic onium salts (Table 3-34) probably due to their scarce solubility in DMSO. Even 
the use of chiral PT agent, such as N-methyl-N-dodecylephedrinium bromide (MDE-Br-) or the 
cinchonidine derived “Corey’s catalyst”, failed and we obtained the corresponding sultam in 
low yields and e.e.’s (entries 5-6).  
 
 PT catalyst t[h] y e.e. 
1 Et3BnN+Cl- 20 94 8 
2 Me4N+OH- 5H2O 40 62 0 
3 Me3BnN+F-  H2O 40 73 <5 
4 C12Me25N Me3+Cl-  H2O 40 73 15 
5 MDE-Br- 40 65 10 
6 Corey’s Catalyst 30 72 <5 
Table 3-34 
 
In the light of the very scarce results obtained under heterogeneous conditions, we turned our 
attention to the cyclization under homogeneous conditions.  
Since the ring-closing of  sulfonamide S-3a with DBU as a base, as described here before, leads 
to the racemic benzosultam, we decided to evaluate the use of an additive in the system 
sulfonamide-DBU, looking for possible interactions additive-base-substrate capable to induce 
the formation of a chiral adduct, which can evolve enantioselectively toward the desired 
benzosultam. 
Preliminary positive results have been obtained by reacting S-3a with DBU, in acetonitrile at 25 
°C in the presence of 0.2 molar equivalents of a diamine (Scheme 3-53): the choice fell both on 
simple diamines (Table 3-35, entries 1-4) and on more complex chiral diamines (entries 5-8). All 
these reactions gave an almost quantitative yield of 8a and the e.e. ranging from 19 to 23%. 
Results show that the bases induces a general effect, maybe due to a modulation of the DBU 
basicity, rather than to the chiral complex formation; this can be deduced from the reaction of 
the achiral bases (entries 1-4) and from the use of both the enantiomers of 1,2-
diaminocyclohexane (entries 6-7), and of their racemic mixture (entry 8).  
Synthesis of polyfluorobenzo[d]sultams 
 
87 
 
 
All these reactions, in fact, lead to nearly identical e.e. values, with prevalence of the same 
enatiomer (-)-8a. 
 
Scheme 3-53 
 Diamine y e.e. 
1 
NH2
NH2  
98 21 
2 
NMe2
NMe2 
98 20 
3 NEt2
NH2
 
98 19 
4 
NH2
NH2
 
98 23 
5 
NH2
NH2
 
98 21 
6 
NH2
NH2
 
97 23 
7 
NH2
NH2
 
98 22 
8 rac-diamino cyclohexane 98 22 
Table 3-35 
 
Similar results were obtained by addition, as an additive, both of a chiral amino alcohol 
(Scheme 3-54, Table 3-36) and of cinchona alkaloid derivatives (entries 4-6), compounds that are 
often used in asymmetric synthesis. The use of α-amino acids (entries 7-8) gave the desired 
sultam 8a with unchanged e.e. values, even if in longer reaction times (respectively 80 and 120 
h). 
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Scheme 3-54 
 
 Amino alcohol y e.e. 
1 
NH2
OH
 
95 23 
2 
NH
OH
Ph Ph
 
95 16 
3 Me2N
OH
Me
 
98 22 
4 
NHO
N  
98 22 
5 
NHO
N
MeO
 
95 19 
6 
N
OH
N
OMe  
95 23 
7 
CO2H
NH2
N
NH  
90 20 
8 
NH
CO2H
 
96 23 
Table 3-36 
 
Taking the (1R,2S)-N-methylephedrine (NME) as the standard additive, we conducted several 
experiments varying the solvent (Table 3-37): the best e.e.’s were obtained in ethereal solvents 
like THF (entry 2) and DME (entry 3). In DCM (entry 4) we found both e.e.’s and yields very 
Synthesis of polyfluorobenzo[d]sultams 
 
89 
 
low, while in the aromatic solvents chlorobenzene and toluene quantitative yields and,  
conversely, poor e.e. values were obtained (entries 5-6). 
 
Scheme 3-55 
 Solvent y e.e. 
1 MeCN 98 22 
2 THF 98 24 
3 DME 98 33 
4 DCM 85 14 
5 4-Cl-Ph 98 18 
6 Toluene 95 18 
Table 3-37 
 
Experiments carried out with DBU and NME at different concentrations of the starting 
sulfonamide S-3a (Table 3-38) , confirmed that the previously used molarity (0.25 mol l-1) is the 
best one, even if the values do not change significantly in the range between 0.25—1.0 mol l-1; in 
very diluted solution (0.025 mol l-1, entry 5) we obtained much lower values of e.e. for 8a. 
 
 
Scheme 3-56 
 M [mol l-1] y e.e. 
1 1 98 28 
2 0.5 96 29 
3 0.25 98 33 
4 0.05 98 24 
5 0.025 90 17 
Table 3-38 
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In Table 3-39 are summarized the results reached with different amines (entries 1-3), diamines 
(entry 4), guanidines (entry 5) and amidines (entry 6): these compounds, used with the system 
S-3a−DBU in DME at 25°C, gave the same yields of benzosultam 8a with the same e.e.  
 
 Diamine y e.e. 
1 TEA 97 36 
2 DIA 97 35 
3 Pyridine 97 36 
4 
Me2N NMe2
 
97 34 
5 
NMe2Me2N
N
 
97 35 
Table 3-39 
 
This behavior, rather than to the formation of complexes, is therein ascribable to the overall 
effect of the added second base on the system and to the formation of adducts [enolate]-[basic 
system]-[starting sulfanamide], in which the optically pure starting material S-3a acts as a chiral 
auxiliary.  
Moreover, the reaction of the racemic sulfonamide rac-3a under the enantioselective conditions, 
confirmed our hypothesis, giving quantitative yield of the racemic compound rac-8a (Scheme 
3-57). 
 
 
Scheme 3-57 
Other chiral additives have been employed (Scheme 3-58), but we found similar stereochemical 
efficiency: the best effects were reached always with diamines (Table 3-40, entries 1-3) while the 
bis(phenol) (entry 4) completely stopped the reaction and the bis(phosphine) (entry 5) gave 
analogue results to that obtained with (triphenyl)phosphine (entry 6). 
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Scheme 3-58 
  Additive y e.e. 
1 (R) 
Me
Me
H2N
H2N
 
97 36 
2 (R) H2N
H2N
 
96 34 
3 (R,R) 
NH2
NH2
 
98 33 
4 (R) OH
OH
 
--- --- 
5 (R) Ph2P
Ph2P
 
98 28 
6  PPh3 90 27 
Table 3-40 
 
In order to analyze the influence of the steric hindrance of the ester, sulfonamides bearing 
different ester groups have been synthesized. The condensation of ethyl, propyl, butyl, benzyl, 
and metoxyethyl phenylglycinates with (pentafluorobenzene)sulfonyl chloride, under the 
previously optimized conditions, gave the desired sulfonamides 3b-f in good yields (Scheme 
3-59, Table 3-41). 
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Scheme 3-59 
 R sulfonamide (%) 
1 Et S-3b  74 
2 i-Pr S-3c  75 
3 t-Bu S-3d  89 
4 Bn S-3e  52 
5 CH2CH2OMe S-3f  77 
Table 3-41 
 
These sulfonamides S-3b-f have been cyclized with DBU/BINAM in DME (Scheme 3-60, Table 
3-42);  
 
Scheme 3-60 
 R T [°C] t [h] Sultam (%) e.e. 
1 Me 25 16 (-)-8a  96 34 
2 Et 25 16 (-)-8b  94 43 
3 i-Pr 25 20 (-)-8c  97 47 
4 t-Bu 25 20 (-)-8d  91 51 
5 Bn 25 16 (-)-8e  91 18 
6 MeOCH2CH2 25 18 (-)-8f  97 17 
7 Me 0 40 (-)-8a  80 (83) 49 
8 Et 0 70 (-)-8b  91 53 
9 t-Bu 0 160 (-)-8d  66 (73) 64 
10 Me -20 160 --- --- 
Table 3-42 
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A significant increase of sultam (-)-8a e.e. was reached - from the 34% to the 51% - passing from 
methyl to t-butyl sulfonamido ester (entries 1-4). Quite unexpected have been the low e.e.’s 
obtained with benzyl (entry 5) and methoxyethyl (entry 6) esters. In the case of the benzylic 
ester S-3e, this behavior is probably due to a unfavourable π-interactions between the aromatic 
rings present in the molecule. An analogous interaction of the electrons of the non-bonding 
orbital in the methoxyethyl ester S-3f can be responsible for the low e.e. Lowering the reaction 
temperature to 0 °C (entries 7-9) drastically decreased the reaction rate, while at -20 °C (entry 
10) the ring-closing process was completely stopped. Finally, the analysis of sulfonamide (-)-8a 
and (-)-8d cyclizations at non-complete conversion times (entries 7, 9) detected higher e.e.’s (e.e. 
≥ 10). In the light of the possibility to choose between chiral and achiral base/additive, we 
focused our attention on the good results obtained with t-BuTMG (Table 3-39, entry 5). 
Interesting results were achived using the system t-BuTMG/DBU in variable molar ratios 
(Scheme 3-61, Table 3-43): a large molar amount of t-BuTMG (entries 1−3) with decreasing 
quantity of DBU led to a prolongation of the reaction time, but gave good e.e.’s. The best e.e. for 
the methyl ester (-)-8a was obtained using equimolar amount of the two bases (entry 5) and, 
similarly, the t-butyl ester S-3d gave the desired sultam (-)-8d in a similar e.e. in longer times 
(entry 6), proving one more time the dependence of the reaction rate on the steric hindrance. 
 
Scheme 3-61 
 R t-BuTMG (mol) DBU (mol) t [h] Sultam (%) e.e. 
1 Me 4 2 20 (-)-8a  96 50 
2 Me 4 0,5 20 (-)-8a  96 48 
3 Me 4 0,25 30 (-)-8a  93 47 
4 Me 2 1 20 (-)-8a  95 48 
5 Me 1 1 20 (-)-8a  91 53 
6 t-Bu 1 1 144 (-)-8d  90 54 
Table 3-43 
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The mechanism of the cyclization of sulfonamides to sultams, that envisages the corresponding 
achiral enol species as an intermediate and the long reaction times (Table 3-42, entries 5-7 or 
Table 3-43, entry 6) suggested us to monitor the product’s e.e. variation along the reaction time. 
The HPLC monitoring of sulfonamide S-3d cyclization with DBU and BINAM (0,2 eq.) (Graphic 
3-4) indicated effectively a decrease in the (-)-8d e.e., probably due to a partial racemization of 
the starting sulfonamide S-3d. 
 
 
Graphic 3-4 
 
To study the influence of the base nature on the sultam stereoselective formation, S-3a  was 
cyclized in the presence of a series of organic soluble bases,  having comparable pKb, and 
catalytic amounts of BINAM or DMAP (Table 3-44). Results were not encouraging and all the 
desired sultams were obtained with lower e.e.’s (entries 2-7) or, in some cases, as racemic 
compounds. Moreover, very poor yields were obtained with N-methyl-triazabycyclodecene 
(entry 2). On the contrary (entry 7), very interesting results were reached with t-
butyltetramethylguanidine (t-BuTMG) that, in the presence of a catalytic amount of DMAP, 
gave in a longer reaction time the sultam 8a in higher e.e. and, as the most surprising and 
interesting feature, in the opposite configuration (+) to that obtained with the other bases.  
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 Diamine Additive t [h] Sultam (%) e.e. 
1 
N
N
 
(R)-BINAM 18 (-)-8a  97 36 
2 
N
N
N
Me  
(R)-BINAM 20 (-)-8a  56 38 
3 
N
N
 
(R)-BINAM 16 (-)-8a  94 14 
4 
 
DMAP 16 (-)-8a  97 36 
5 
N
N
N
H  
DMAP 16 (-)-8a  95 < 5 
6 
NMe2Me2N
NH  
DMAP 16 (-)-8a  90 < 5 
7 
NMe2Me2N
N
 
DMAP 16 (+)-8a  25 55 
Table 3-44 
 
Our attention was then focused on the cyclization with t-BuTMG by varying temperature, steric 
hindrance of the ester, and additive (Scheme 3-62, Table 3-45). Results indicated that, under all 
the conditions used, the cyclization is very slow. This can be effectively a problem given that the 
longer the reaction time, the higher the probability that the starting sulfonamide racemizes. The 
final and astounding result we found was that no additive is required when t-BuTMG is used as 
a base! Under these conditions, (+)-3d in 90% yield and 80% e.e - the higher e.e. for this process 
attained until now – was isolated. Unfortunately, t-butyl ester S-3d, that is expected to give 
higer e.e., cyclized very slowly giving after 1 week 37% of the desired product (+)-8d  having 
87% e.e. 
 
Scheme 3-62 
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R T [°C] t [h] Additive Sultam (%) e.e.(%) 
1 Me 25 20 DMAP (+)-8a  25 55 
2 Me 25 20 BINAM (+)-8a  67 77 
3 t-Bu 25 20 BINAM (+)-8d  < 10 84 
4 Me 0 168 BINAM --- --- 
5 t-Bu 25 144 --- (+)-8d  37 87 
6 Me 25 90 --- (+)-8a  95 80 
Table 3-45 
 
We can concude that this reaction, passing through an achiral intermediate and cyclizing with 
achiral bases and/or additives, is a clear example of self-induction of chirality. What makes this 
reaction much particular is the possibility to obtain both the enantiomers of the desired sultam 
from a unique enantiomer of the sulfonamide, simply by changing the achiral base.  
The real problem is that the complete understanding of all the factors that influence the 
stereochemistry of this cyclization seems very difficult, consequently we are far from a proposal 
of the transition state.  
The best base/additive conditions, i.e. the DBU/t-BuTMG basic system, were applied to the 
cyclization of the differently halogenated sulfonamides S-30a-e (Scheme 3-63, Table 3-46), 
reaching good yields and modest e.e.’s of the resulting benzosultams.  
 
Scheme 3-63 
 
 
sultam (%) e.e.(%)  
 
sultam (%) e.e.(%) 
1 
 
(-)-8a  95 53 3 
 
(-)-30b  98 38 
2 
 
(-)-30a  87 38 4 
 
(-)-30e  93 38 
Table 3-46 
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As found in the case of the (pentafluorobenzene)sulfonamide S-3a, the cyclization of 
(polyhalobenzene)sulfonamides S-30a,b,d,e using t-BuTMG alone, gave (+)-31a,b,d,e in very 
good yield and e.e., that decreases with the decrease of the activation toward the aromatic 
nucleophilic substitution. Furthermore, analogously to that found for (+)-8a, the 
(polyhalobenzo)sultams (+)-31a,b,d,e presented an inversion of configuration, respect to that 
observed with other bases (Scheme 3-64, Table 3-47). 
 
Scheme 3-64 
 
 
sultam (%) e.e.(%)  
 
sultam (%) e.e.(%) 
1 
 
(+)-8a  95 80 4 
 
(+)-31d  94 79 
2 
 
(+)-31a  92 82 5 
 
(+)-31e  89 50 
3 
 
(+)-31b  93 76     
Table 3-47 
 
Finally an important step forward in the obtainment of enantiopure benzosultams, was the N-
alkylation of our heterocycles. The non-racemic sultams were reacted with different alkyl 
halides, under SL-PTC conditions, and the N-alkyl derivatives 4a,c-e were recrystallized: all 
these benzosultams crystallized preferentially and were isolated in pratically enantiopure form 
(Scheme 3-65, Table 3-48). 
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Scheme 3-65 
 
 R R’X num sultam starting e.e. final e.e. Solvent 
1 Me Me (-)-4a 
 
34 95 iPA 
2 Me Et (-)-4d 
 
22 99 iPA 
3 Me n-Pr (-)-4e 
 
44 99 iPA 
4 Me All (-)-4c 
 
38 99 i-Pr2O-ETP 
5 Me Me (-)-36 
F
F
Br
F
N
S
O O
Me
Ph CO2Me  
33 95 iPA 
6 Me All (-)-35b 
 
35 81 i-Pr2O-ETP 
Table 3-48 
 
The non-alkylated sultam (-)-8a was the unique compound that did not crystallize with this 
technique, but was obtained through deprotection of the N-allyl derivative (-)-4c (Scheme 3-66). 
 
 
Scheme 3-66 
Synthesis of polyfluorobenzo[d]sultams 
 
99 
 
The single crystal X-ray analysis allowed us to assign the right configuration: so, for the 
cyclization with DBU and t-BuTMG we observed (Figure 3-4) the retention product R-4e 
starting from S-3a (Scheme 3-67); the descriptor change occurs only for a change in priority and 
the reaction, even if occurring with retention, formally goes through inversion of configuration.  
 
Scheme 3-67 
 
 
Figure 3-4 
On the other hand, cyclization with t-BuTMG as the unique base, led to the inversion product S- 
(Figure 3-5). 
 
Scheme 3-68 
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Figure 3-5 
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Materials and Methods. 
All reactions were carried out in flame-dried glassware with magnetic stirring. Isolated 
yields refer to homogeneous materials (TLC, HPLC, NMR). Reagent-grade commercially 
available reagents and solvents were used; anhydrous solvents (DMSO, MeCN, DME, NMP, 
and DMPU) were used as purchased. TLC was performed using 0.25 mm silica-gel pre-
coated plates and visualized by UV-254 light and CAM staining. Silica-gel (particle size 
0.040–0.063 mm) was used for flash column chromatography (FCC) and medium pressure 
liquid chromatographic (MPLC). Melting points are corrected. HPLC analyses were 
performed using an EC 250/4.6 NUCLEOSIL 100-5 column and,  for chiral HPLC analyses, a 
250/4.6 Chiracel OD column. IR spectra are reported in frequency of absorption (cm–1). [α]D’s 
were measured at 589 nm, using a 10 cm x 5 ml cell and c is in g/100 ml. NMR spectra were 
recorded at: 500.13, 300.13 and MHz  for 1H; 125.77, 75.00 MHz for 13C; 282.407 MHz for 19F. 
TMS was used as external reference; δ are in ppm and J are in Hz.  
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Amino-arylacetic Acids and Methyl Amino-arylacetate Hydrochlorides 
Starting amino-phenyl-,96 amino-(3-fluoro-phenyl)-,97 amino-(4-fluoro-phenyl)-,1,2 
amino-(4-chlorophenyl)-,1,2 amino-(4-bromo-phenyl)-,1 amino-p-tolyl-,2 amino-(3-
methoxy-phenyl)-,1 amino-(4-methoxy-phenyl)-,2 and amino-(4-benzyloxy-phenyl)-
acetic acids98 were synthesised  following literature methods, amino-(thiophen-3-yl)-
acetic acid was purchased from Sigma. The α-amino acids were then converted into 
the corresponding methyl ester hydrochlorides by reaction with SOCl2 and dry 
MeOH,99 whereas L-phenylglycine methyl ester hydrochloride was purchased from 
Aldrich. To compare with literature products, several free esters were obtained by 
neutralization of the corresponding hydrochlorides with cold, saturated NaHCO3 
solution and Et2O extraction. The physical and/or spectroscopic characteristics of the 
isolated products are as follows. 
 
 Methyl amino-phenylacetate hydrochloride (6a). Mp 220-223 °C 
(dec.) (lit.100 mp 223-224 °C). 
 
Methyl amino-(3-fluorophenyl)-acetate hydrochloride (9a). Free 
amino ester, oil (lit.101 21 °C). 
 
 
Methyl amino-(4-fluorophenyl)-acetate hydrochloride (9b). Free 
amino ester, mp 37-38 °C (lit.6 mp 39 °C). 
 
 
Methyl amino-(4-chlorophenyl)-acetate hydrochloride (9c). Mp 
193-196 °C (dec.) (lit.102 194-197 °C). 
 
NH3+Cl-
CO2Me
NH3+Cl-
CO2MeF
NH3+Cl-
CO2Me
F
NH3+Cl-
CO2Me
Cl
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Methyl amino-(4-bromophenyl)-acetate hydrochloride (9d). Free 
amino ester, mp 54 °C  (lit.6 54 °C). 
 
Methyl amino-p-tolyl-acetate hydrochloride (9e). Mp 192-193 °C 
(dec.). 1H NMR (300 MHz, D2O) δ 7.37 (s, 4H), 5.26 (s, 1H), 3.83 (s, 
3H), 2.87 (s, 3H). 103 Anal. Calcd. for C10H14ClNO2: C, 55.69; H, 6.54; 
N, 6.49. Found C, 55.72; H, 6.56; N, 6.44. 
 
Methyl amino-(3-methoxyphenyl)-acetate hydrochloride (9f). 
Mp 182-183 °C (dec.). 1H NMR (300 MHz, D2O) δ 7.50 (t, 1H, J = 
8.0 Hz), 7.17-7.09 (m, 3H), 5.29 (s, 1H), 3.88 (s, 3H), 3.85 (s, 3H). 
Anal. Calcd. for C10H14ClNO3: C, 51.84; H, 6.09; N, 6.05. Found: C, 51.80; H, 6.13; N, 
6,09. 
 
Methyl amino-(4-methoxyphenyl)-acetate hydrochloride (9g). 
Mp 185-187 °C (dec.) (lit.104 187-189 °C). 
 
  
Methyl amino-(4-benzyloxyphenyl)-acetate hydrochloride 
(9h). Mp 210-212 °C (dec.) (lit.105 212-213 °C). 
 
 
Methyl amino-(thiophen-3-yl)-acetate hydrochloride (9i). Mp 
230-232 °C (dec.). 1H NMR (300 MHz, CD3OD) δ 7.63 (d, 1H, J = 3.0 
Hz), 7.30 (dd, 1H, J = 5.1, 3.0), 7.12 (d, 1H, J = 5.1 Hz), 5.50 (s, 1H), 
3.85 (s 3H).106 Anal. Calcd. for C7H10ClNO2S: C, 40.48; H, 4.85; N, 6.74. Found C, 40.52; 
H, 4.88; N, 6.69. 
 
 
NH3+Cl-
CO2Me
Br
NH3+Cl-
CO2Me
Me
NH3+Cl-
CO2Me
MeO
NH3+Cl-
CO2MeMeO
NH3+Cl-
CO2Me
BnO
NH3+Cl-
CO2Me
S
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Amino-phenylacetate Hydrochlorides 
Starting (R) Ethyl 2-amino-phenylacetate (6b),107 (R) i-Propyl 2-amino-phenylacetate 
(6c),108 (R) t-Butyl 2-amino-phenylacetate (6d),109 (R) Benzyl 2-amino-phenylacetate 
(6e),110 (R) (2-methoxy)ethyl 2-amino-phenylacetate (6f),111 were synthesised  
following literature methods,  
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Synthesis of Sulfonic Acids 29a-e: General Procedure. 
 
X1
X3
X4
F
oleum 20%
100-110°C
X2
X1
X3
X4
F
S OH
O O
X2
 
To the halobenzene is added fuming sulfuric acid (20% SO3) and the resulting 
solution is heated at 110 °C until no starting material was not detectable by TLC; the 
solution is then carefully poured into ice and extracted with Et2O. After drying over 
MgSO4 and evaporation of the solvent under vacuum (RV), the sulfonic acid 29a-e is 
obtained and used without any further purification in the next step. Starting 
materials, product, yield, physical and analytical data are as follows. 
Synthesis of polyfluorobenzo[d]sultams 
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2-Bromo-3,4,5,6-tetrafluorobenzenesulfonic acid (29a).  
 
7h, 2,4 g, 77%;  
brown solid, mp 79-82°C,  
• 19F NMR (282 MHz, CDCl3) δ -125.6 (m, 1F), -134.6 (m, 
1F), -149.8 (m, 1F), 153.9 (m, 1F).  
• Anal. Calcd. for C6HBrF4O3S: C, 23.32; H, 0.33. Found: 
C, 23.34; H, 0.31.  
 
 
4-Bromo-2,3,5,6-tetrafluorobenzenesulfonic acid (29b).  
 
6h, 3,16 g, 90%;  
white solid, mp 79,5-80,5°C,  
• 19F NMR (282 MHz, CDCl3) δ -133.1 (m, 2F), -137.6 (m, 
2F).  
• Anal. Calcd. for C6HBrF4O3S: C, 23.32; H, 0.33. Found: 
C, 43.37; H, 0.36.  
 
Compound PM mmol g mL 
1-Bromo-2,3,4,5-tetrafluoro benzene (28a) 228,98 10 2,28  
20 % oleum     10 
Compound PM mmol g mL 
3-Bromo-1,2,4,5-tetrafluoro benzene (28b) 228,98 10 2,28  
20 % oleum    10 
Br
F
F
F
S
OH
O O
29a, C6HBrF4O3S
MW 309,03
F
F
F
Br
F
F
S
OH
O O
29b, C6HBrF4O3S
MW 309,03
Synthesis of polyfluorobenzo[d]sultams 
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2,3,4,5-Tetrafluorobenzenesulfonic acid (29c).  
 
4 h, 2,45 g, 82%;  
white solid, mp 63-64°C,  
• 1H NMR (300 MHz, CDCl3) δ 7.05 (m, 1H). 
• 19F NMR (282 MHz, CDCl3) δ -113.1 (m, 1F), -126.7 (m, 
1F), -132.0 (m, 1F), -164.2 (m, 1F).  
 
 
 
2,3,4,6-Tetrafluorobenzenesulfonic acid (29d).  
 
4.5 h, 2,68 g, 90%;  
white solid, mp 63-64°C,  
• 1H NMR (300 MHz, CDCl3) δ 6.68 (m, 1H). 
• 19F NMR (282 MHz, CDCl3) δ -113.1 (m, 1F), -126.7 (m, 
1F), -132.0 (m, 1F), -164.2 (m, 1F).  
• Anal. Calcd. for C6H2F4O3S: C, 31.31; H, 0.88. Found: C, 
31.34; H, 0.91.  
 
 
Compound PM mmol g mL 
1,2,3,4-Tetrafluoro benzene (28c) 150,08 13 1,95  
20 % oleum     12 
Compound PM mmol g mL 
1,2,3,5-Tetrafluoro benzene (28d) 150,08 13 1,95  
20 % oleum     12 
F
F
F
S
OH
O O
29c, C6H2F4O3S
MW 230,14
F
F
F
F
F
S
OH
O O
29d, C6H2F4O3S
MW 230,14
Synthesis of polyfluorobenzo[d]sultams 
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2-Bromo-4,5,6-trifluorobenzenesulfonic acid (29e).  
 
7h, 655 mg, 60%;  
brown solid, mp 86-88°C,  
• 1H NMR (300 MHz, CDCl3) δ 7.43 (ddd, J = 9.1, 6.5, 2.5  
Hz). 
• 19F NMR (282 MHz, CDCl3) δ -124.2 (m, 1F), -126.9 (m, 
1F), -156.9 (m, 1F).  
• Anal. Calcd. for C6H2BrF3O3S: C, 24.76; H, 0.69. Found: 
C, 24.75; H, 0.72.  
Compound PM mmol mg mL 
5-Bromo-1,2,3-trifluoro benzene (28e) 210,98 3,79 800  
20 % oleum    10 
Br
F
F
F
S
OH
O O
29e, C6H2BrF3O3S
MW 289,89
Synthesis of polyfluorobenzo[d]sultams 
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Synthesis of Sulfonyl Chlorides 5f-l: General Procedure. 
 
115°C, 15'
X1
X3
X4
F
S Cl
O O
X2
X1
X3
X4
F
S OH
O O
X2 PCl5, neat
 
To the sulfonic acid and phosphorus pentachloride are put together in a round 
bottom flask and heated until complete fusion of the two compounds; the mixture is 
heated for further 15 min than rapidly cooled and carefully poured into ice and 
extracted with Et2O. After drying over MgSO4 and evaporation of the solvent under 
vacuum (RV), the sulfonyl chloride 5f-l is obtained and used without any further 
purification in the next step. Starting materials, product, yield, physical and 
analytical data are as follows. 
Synthesis of polyfluorobenzo[d]sultams 
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2-Bromo-3,4,5,6-tetrafluorobenzene sulfonyl chloride (5f).  
 
 
2,4 g, 80%;  
brown solid, mp 62,5-63,5°C,  
• 19F NMR (282 MHz, CDCl3) δ -121.4 (m, 1F), -127.9 (m, 
1F), -140.5 (m, 1F), 150.3 (m, 1F).  
 
 
4-Bromo-2,3,5,6-tetrafluorobenzene sulfonyl chloride (5g).  
 
 
1,13g, 89%;  
white solid, mp 48-49°C,  
• 19F NMR (282 MHz, CDCl3) δ -127.9 (m, 2F), -134.2 (m, 
2F).  
 
Compound PM mmol g mL 
2-Bromo-3,4,5,6-tetrafluorobenzenesulfonic acid 
(29a) 
309,03 7,76 2,4  
Phosphorus pentachloride 208,24 32,2 6,7  
Compound PM mmol g mL 
4-Bromo-2,3,5,6-tetrafluorobenzenesulfonic acid 
(29b) 
309,03 3,88 1,2  
Phosphorus pentachloride 208,24 16 3,35  
Br
F
F
F
F
S
Cl
O O
5f, C6BrClF4O2S
MW 327,48
F
F
Br
F
F
S
Cl
O O
5g, C6BrClF4O2S
MW 327,84
Synthesis of polyfluorobenzo[d]sultams 
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2,3,4,6-Tetrafluorobenzene sulfonyl chloride (5h).  
 
 
2,03 g, 73%;  
brown wax,  
• 1H NMR (300 MHz, CDCl3) δ 7.27 (m, 1H). 
• 19F NMR (282 MHz, CDCl3) δ -130.8 (m, 1F), -133.5 (m, 
1F), -143,4 (m, 1F), -148.9 (m, 1F).  
 
2,3,4,6-Tetrafluorobenzene sulfonyl chloride (5i).  
 
 
2,16 g, 78%;  
brown wax,  
• 1H NMR (300 MHz, CDCl3) δ 7.05 (ddt, J = 9.6, 5.7, 2.4  
Hz). 
• 19F NMR (282 MHz, CDCl3) δ -107.8 (m, 1F), -116.9 (m, 
1F), -125,9 (m, 1F), -159.6 (m, 1F).  
 
 
Compound PM mmol g mL 
2,3,4,5-Tetrafluorobenzenesulfonic acid 
(29c) 
230,14 11,2 2,59  
Phosphorus pentachloride 208,24 45 9,38  
Compound PM mmol g mL 
2,3,4,6-Tetrafluorobenzenesulfonic acid 
(29d) 
230,14 11,2 2,59  
Phosphorus pentachloride 208,24 45 9,38  
F
F
F
S
Cl
O O
5h, C6HClF4O2S
MW 248,58
F
F
F
F
F
S
Cl
O O
5i, C6HClF4O2S
MW 248,58
Synthesis of polyfluorobenzo[d]sultams 
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2-Bromo-4,5,6-trifluorobenzene sulfonyl chloride (5l).  
 
 
502 mg, 78%;  
brown wax,  
• 1H NMR (300 MHz, CDCl3) δ 7.56 (ddd, J = 8.9, 6.7, 2.4  
Hz). 
• 19F NMR (282 MHz, CDCl3) δ -120.0 (m, 1F), 121.1 (m, 
1F), -154.0 (m, 1F).  
Compound PM mmol mg mL 
6-Bromo-2,3,4-trifluorobenzenesulfonic acid 
(29e) 
289,89 2,07 0,600  
Phosphorus pentachloride 208,24 10,5 2,16  
Br
F
F
F
S
Cl
O O
5l, C6HBrClF3O2S
MW 309,49
Synthesis of polyfluorobenzo[d]sultams 
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Synthesis of Sulfonyl Chlorides 5l,m: General Procedure. 
 
CH3Cl,
115°C, 15'
X1
F F
S Cl
O OX1
F F
HSO3Cl
X2 X2  
To a solution of the halobenzene in chloroform at 0°C, is carefully added the 
chlorosulfonic acid under magnetic stirring; once the addition is complete, the 
resulting solution is heated until completion (TLC analysis). The mixture is then 
warmed and carefully poured into ice then extracted with chloroform. The organic 
phase is dryed over MgSO4 and after evaporation of the solvent under vacuum (RV), 
the sulfonyl chloride 5l,m is obtained and used without any further purification. 
Starting materials, product, yield, physical and analytical data are as follows. 
Synthesis of polyfluorobenzo[d]sultams 
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6-Bromo-2,3,4-trifluorobenzene sulfonyl chloride (5l).  
 
 
 
371,4 mg, 60%;  
Analytical data identical to that of page 12  
 
 
 
2,4,6-trifluorobenzene sulfonyl chloride (5m).  
 
 
 
285,9 mg, 62%;  
• brown oil,  
• 1H NMR (300 MHz, CDCl3) δ 6.89 (t, 2H, J = 8.1 Hz). 
• 19F NMR (282 MHz, CDCl3) δ -92.5 (m, 1F), -100.7 (m, 
2F).  
 
Compound PM mmol mg mL 
5-Bromo-1,2,3-trifluorobenzene (28e) 210,98 2 422  
Chlorosulfonic acid 116,52 10 1,16g  
Chloroform    10 
Compound PM mmol mg mL 
1,3,5-trifluorobenzene (28g) 132,08 2 264,2  
Chlorosulfonic acid 116,52 5 1,16g  
Chloroform    10 
F
F F
S
Cl
O O
5m, C6H2F3O2S
MW 230,59
Br
F F
S
Cl
O O
5l, C6HBrClF3O2S
MW 309,49
F
Synthesis of polyfluorobenzo[d]sultams 
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Synthesis of Sulfonamides 3a-e, 10a-i, 30a-l, 12a,b: General Procedure 
 
X1
X3
X4
F
S N
H
O O
CO2R
ArylX1
X3
X4
F
S Cl
O O
NH2.HCl
CO2RAryl
+
DIEA
DCM, 0-25°C
X2 X2
 
To a suspension of alkyl 2-arylaminoacetate hydrochloride (10 mmol) in dry 
dichloromethane (40 mL), DIEA (21 mmol) was added at 25 °C in 10 min. The 
reaction mixture was stirred for furhter 10 min, then cooled to 0°C and sulfonyl 
chloride (10 mmol) was added dropwise. The resulting solution was allowed to reach 
25 °C and stirred until no starting material was not detectable by TLC, then was 
diluted with dichloromethane (20 mL), washed with 3% HCl (3×15 mL), saturated 
NaHCO3 solution (2×15 mL) and brine (20 mL), dried over MgSO4, filtered. After 
evaporation of the solvent under vacuum (RV), the crude recrystallized from 
ethanol/water (1 : 9), or purified by FCC or MPLC, gave the desired sulfonamides. 
Starting materials, product, yield, chromatographic eluant, physical and analytical 
data are as follows. 
 
 
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-3a).  
 
 
 
20h, 3.56 g, 90%;  
Ethanol-water (9 : 1), white solid, mp 120-121°C,  
• [α]D20 +79.8 (c 1, CHCl3), (EtOH/water – 9 : 1). 
• 1H NMR (300 MHz, CDCl3) δ 7.29-7.19 (m, 5H), 6.42 (d, 
1H, J = 7.5 Hz), 5.28 (d, 1H, J = 7.5 Hz), 3.72 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.9 (m, 
1F), -159.8 (m, 2F).  
• 13C NMR (75 MHz, CDCl3) δ 169.6, 143.9 (dm, J = 258.6 
Hz), 143.6 (dm, J = 261.6 Hz), 137.4 (dm, J = 258.4 Hz), 
133.8, 129.2, 128.9, 127.3, 116.7, 59.9, 53.4.  
• IR (nujol) 3331, 1741, 1644, 1522, 1300, 1214, 1101, 985, 
885 cm-1  
• Anal. Calcd. for C15H10F5NO4S: C, 45.58; H, 2.55; N, 
3.54. Found: C, 45.52; H, 2.58; N, 3.59.  
Compound PM mmol g mL 
S-Methyl 2-amino-2-phenylacetate 
 hydrochloride (S-6a) 
201,65 10 2,02  
Pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
F
F
F
F
F
S
N
H
O O
CO2Me
S-3a, C15H10F5NO4S
MW 395,30
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Ethyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-3b). 
 
Compound PM mmol mg mL 
S-Ethyl 2-amino-2-phenylacetate 
hydrochloride (S-6b) 
215,68 1 215,7  
Pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 266,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
20h, 302,9 mg, 74%;  
• FCC - AcOEt/hexane (1 : 6), white solid, mp 100-102°C 
• [α]D20 +71.5 (c 1, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.26-7.20 (m, 5H), 6.25 (d, 
1H, J = 7.5 Hz,), 5.24 (d, 1H, J = 7.8 Hz), 4.27-4.06 (m, 2H), 
1.73 (t, 3H, J = 7.2 Hz).  
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.9 (m, 
1F), -159.8 (m, 2F).  
• IR (nujol) 3342, 1746, 1642, 1522, 1301, 1216, 1110, 973 
cm-1.  
• Anal. Calcd. for C16H12F5NO4S: C, 43.11; H, 2.94; N, 
3.14. Found: C, 43.08; H, 2.92; N, 3.12. 
F
F
F
F
F
S
N
H
O O
CO2Et
S-3b, C16H12F5NO4S
MW: 409,33
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Isopropyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-3c). 
 
Compound PM mmol mg mL 
S-isopropyl 2-amino-2-
phenylacetate hydrochloride 
(S-6c) 
229,70 1 229,7  
Pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 266,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
20h, 317,5 mg, 75%;  
• FCC - AcOEt/hexane (1 : 8), white solid, mp 91-92°C 
• [α]D20 +54.9 (c 1, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.25-7.17 (m, 5H), 6.27 (d, 
1H, J = 7.6 Hz), 5.21 (d, 1H, J = 7.6 Hz), 5.05-4.97 (m, 1H), 
1.22 (d, 3H, J = 6.3 Hz), 1.04 (d, 3H, J = 6.3 Hz).  
• 19F NMR (282 MHz, CDCl3) δ -136.6 (m, 2F), -147.0 (m, 
1F), -159.9 (m, 2F). 
• 13C NMR (75 MHz, CDCl3) δ 168.6, 144.1 (dm, J = 261.7 
Hz), 143.6 (dm, J = 259.5 Hz), 137.4 (dm, J = 257.3 Hz),  
134.1, 129.0, 128.8, 127.2, 119.0, 70.9, 60.1, 21.5, 21.1.  
• Anal. Calcd. for C17H14F5NO4S: C, 48.23; H, 3.33; N, 
3.31. Found: C, 45.24; H, 2.34; N, 3.33. 
F
F
F
F
F
S
N
H
O O
CO2Pr
i
S-3c, C17H14F5NO4S
MW: 423,35
Synthesis of polyfluorobenzo[d]sultams 
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(R)-tert-butyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-3d). 
 
Compound PM mmol mg mL 
R-tert-butyl 2-amino-2-
phenylacetate hydrochloride 
(S-6d) 
243,73 1 243,7  
Pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 266,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
24h, 389,3 mg, 89%;  
• FCC - AcOEt/hexane (1 : 12), white solid, mp 91-92°C 
• [α]D20 +82.4 (c 1, CHCl3). 
•1H NMR (300 MHz, CDCl3) δ 7.24-7.17 (m, 5H), 6.23 (d, 
1H, J = 7.6 Hz), 5.14 (d, 1H, J = 7.7 Hz), 1.34 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -147.3 (m, 
1F), -160.1 (m, 2F). 
• 13C NMR (75 MHz, CDCl3) δ 168.5, 144.4 (dm, J = 266.0 
Hz), 144.0 (dm, J = 258.4 Hz), 138.0 (dm, J = 265.9 
Hz),134.8, 129.3, 129.2, 127.6, 119.3, 84.4, 60.8, 28.0.  
• IR (nujol) 3333, 1739, 1645, 1526, 1298, 1218, 1106, 981, 
888 cm-1.  
• Anal. Calcd. for C18H16F5NO4S: C, 49.43; H, 3.69; N, 
3.20. Found: C, 49.40; H, 3.70; N, 3.21.  
F
F
F
F
F
S
N
H
O O
CO2Bu
t
S-3d, C18H16F5NO4S
MW: 437,38
Synthesis of polyfluorobenzo[d]sultams 
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(R)-Benzyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-3e). 
 
Compound PM mmol mg mL 
(R)-Benzyl 2-amino-2-
phenylacetate hydrochloride 
(S-6e) 
277,75 1 277,8  
Pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 266,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
20h, 245,1 mg, 52%;  
• FCC - AcOEt/hexane (1 : 8), white solid, mp 125-127°C, 
[α]D20 +51.1 (c 0.4, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.29-7.20 (m, 8H), 7.15-
7.12 (m, 2H), 6.42 (d, 1H, J = 7.8 Hz), 5.32 (d, 1H, J = 7.8 
Hz), 5.18 (d, 1H, J = 12.2 Hz), 5.07 (dt, 1H, J = 12.2 Hz). 
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.6 (m, 
1F), -159.8 (m, 2F). 
• Anal. Calcd. for C21H14F5NO4S: C, 53.51; H, 2.99; N, 
2.97. Found: C, 53.52; H, 3.02; N, 2.99. 
F
F
F
F
F
S
N
H
O O
CO2
S-3e, C21H14F5NO4S
MW: 471,40
Synthesis of polyfluorobenzo[d]sultams 
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(R)-2-Metoxyethyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-
3f). 
 
Compound PM mmol mg mL 
(R)-2-Metoxyethyl 2-amino-2-
phenylacetate hydrochloride 
(S-6f) 
245,70 1 245,7  
Pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 266,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
24h, 338,3 mg, 77%;  
• FCC - AcOEt/hexane (1 : 4), white solid, mp 94.5-
95.5°C, [α]D20 +29.7 (c 1, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.25-7.23 (m, 5H), 6.26 (d, 
1H, J = 7.7 Hz), 5.31 (d, 1H, J = 7.7 Hz), 4.32 (dt, 1H, J = 
12.0, 4.7 Hz), 4.19 (dt, 1H, J = 12.0, 4.5 Hz), 3.47 (t, 1H, J = 
4.6 Hz),  3.23 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.8 (m, 
1F), -159.8 (m, 2F). 
• Anal. Calcd. for C17H14F5NO5S: C, 46.47; H, 3.21; N, 
3.19. Found: C, 43.45; H, 3.22; N, 3.19.  
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(3-fluorophenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate 
(10a). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(3-
fluorophenyl) acetate 
hydrochloride (9a) 
219,64 10 2,20  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
20h, 3.35 g, 81%;  
• white solid, mp 108.5-109.5°C (EtOH/water – 9 : 1).  
• 1H NMR (300 MHz, CDCl3) δ 7.30-7.22 (m, 1 H), 7.05-
6.92 (m, 3 H), 6.34 (d, 1H, J = 7.4 Hz), 5.27 (d, 1H, J = 7.4 
Hz), 3.73 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -111.3 (s, 1F), -136.5 (m, 
2F), -146.1 (m, 1F), -159.3 (m, 2F).  
• IR (nujol) 3238, 1747, 1643, 1519, 1329, 1201, 1101, 991, 
897 cm-1. 
• Anal. Calcd. for C15H9F6NO4S: C, 43.59; H, 2.19; F, 
27.58; N, 3.39. Found: C, 43.63; H, 2.15; N, 3.41. 
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(4-fluorophenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate 
(10b). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(4-
fluorophenyl) acetate 
hydrochloride (9b) 
219,64 10 2,20  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
20h, 3.30 g, 80%;  
• white solid, mp 125-126 °C (EtOH/water – 9 : 1). 
• 1H NMR (300 MHz, CDCl3) δ 7.23-7.20 (m, 2H), 6.99-
6.93 (m, 2H), 6.30 (d, 1H, J = 7.2 Hz), 5.27 (d, 1H, J = 7.2 
Hz), 3.71 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -111.6 (s, 1F), -136.5 (m, 
2F), -146.1 (m, 1F), -159.4 (m, 2F). 
• IR (nujol) 3274, 1746, 1649, 1520, 1305, 1171, 1107, 991, 
892 cm-1.  
• Anal. Calcd. for C15H9F6NO4S: C, 43.59; H, 2.19; F, 
27.58; N, 3.39. Found: C, 43.65; H, 2.21; N, 3.37. 
F
F
F
F
S
N
H
O O
CO2Me
F
10b, C15H9F6NO4S
MW: 413,29
F
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(4-chlorophenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate 
(10c). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(4-
chlorophenyl) acetate 
hydrochloride (9c) 
236,10 10 2,36  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
20h, 3.35 g, 78%; 
• FCC - AcOEt/hexane (1 : 9), pasty wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.26-7.23 (m, 2H), 7.19-
7.16 (m, 2H), 6.23 (d, 1H, J = 7.2 Hz), 5.25 (d, 1H, J = 7.2 
Hz), 3.72 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.0 (m, 
1F), -159.2 (m, 2F). 
• IR (nujol) 3268, 1738, 1634, 1509, 1294, 1160, 1100, 990 
cm-1.  
• Anal. Calcd. for C15H9ClF5NO4S: C, 41.92; H, 2.11; N, 
3.26. Found: C, 42.00; H, 2.08; N, 3.21. 
F
F
F
F
S
N
H
O O
CO2Me
F
Cl
10c, C15H9ClF5NO4S
MW: 429,75
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(4-bromophenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate 
(10d). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(4-
bromophenyl) acetate 
hydrochloride (9d) 
280,55 10 2,81  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
20h, 3.89 g, 82%;  
• FCC - AcOEt/hexane (1 : 9), white solid, mp 110-111°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.38 (m, 2H), 7.13-
7.10 (m, 2H), 6.33 (d, 1H, J = 7.3 Hz), 5.24 (d, 1H, J = 7.3 
Hz), 3.72 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.0 (m, 
1F), -159.2 (m, 2F). 
• IR (nujol) 3271, 1748, 1522, 1363, 1286, 1253, 1180, 1110, 
989, 617 cm -1. 
• Anal. Calcd. for C15H9BrF5NO4S: C, 37.99; H, 1.91; N, 
2.95. Found: C, 38.03; H, 1.94; N, 2.95. 
F
F
F
F
S
N
H
O O
CO2Me
F
Br
10d, C15H9BrF5NO4S
MW: 474,20
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(4tolyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate (10e). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(4-tolyl) 
acetate hydrochloride (9e) 
215,68 10 2,16  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
20h, 3.68 g, 90%; 
• FCC - AcOEt/hexane (1 : 9), white solid, mp 115,5-
116,5 °C. 
• 1H NMR (300 MHz, CDCl3) δ 7.10-7.07 (m, 2H), 7.03-
7.01 (m, 2H), 6.40 (d, 1H, J = 7.2 Hz), 5.24 (d, 1H, J = 7.2 
Hz), 3.71 (s, 3H), 2.26 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -136.4 (m, 2F), -147.7 (m, 
1F), -160.2 (m, 2F).  
• 13C NMR (75 MHZ, CDCl3) δ 169.8, 144.1 (dm, J = 255.5 
Hz), 143.8 (dm, J = 255.6 Hz), 139.4, 137.3 (dm, J = 265.4 
Hz), 130.7, 129.4, 127.3, 116.9, 59.7, 53.3, 20.8. 
• IR (nujol) 3251, 1744, 1643, 1519, 1298, 1210, 1176, 1099, 
992, 897 cm-1.  
• Anal. Calcd. for C16H12F5NO4S: C, 46.95; H, 2.95; N, 
3.42. Found: C, 46.99; H, 3.00; N, 3.38. 
F
F
F
F
S
N
H
O O
CO2Me
F
Me
10e, C16H12F5NO4S
MW: 409,33
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(3-methoxyphenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) 
acetate (10f). 
 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(3-methoxy 
phenyl) acetate hydrochloride (9f) 
231,68 10 2,32  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
20h, 3.61 g, 85%; 
• FCC - AcOEt/hexane (1 : 9), white solid, mp 88-89 °C. 
• 1H NMR (300 MHZ, CDCl3) δ 7.16-7.11 (m, 1H), 6.79-
6.70 (m, 3H), 6.56 (d, 1H, J = 7.7 Hz), 5.23 (d, 1H, J = 7.7 
Hz), 3.72 (s, 3H), 3.71 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -147.2 (m, 
1F), -160.2 (m, 2F).  
• 13C NMR (75 MHz, CDCl3) δ 169.5, 159.9, 143.9 (dm, J = 
256.5 Hz), 143.5 (dm, J = 259.5 Hz), 137.4 (dm, J = 251.2 
Hz), 135.1, 130.1, 119.5, 116.9 (t, J = 12.0 Hz), 114.4, 112.8, 
59.9, 55.1, 53.3.  
• IR (nujol) 3295, 3244, 1740, 1729, 1644, 1520, 1311, 1179, 
1101, 995, 891 cm-1.  
• Anal. Calcd. for C16H12F5NO5S: C, 45.18; H, 2.84; N, 
3.29. Found: C, 45.23; H, 2.87; N, 3.25. 
  
F
F
F
F
S
N
H
O O
CO2Me
F
10f, C16H12F5NO5S
MW: 425,33
OMe
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(4-methoxyphenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) 
acetate (10g). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(4-methoxy 
phenyl) acetate hydrochloride (9g) 
231,68 10 2,32  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
20h, 3.40 g, 80%; 
• FCC - AcOEt/hexane (1 : 9), white solid, mp 115-116 
°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.13-7.10 (m, 2H), 6.74-
6.71 (m, 2H), 6.27 (d, 1H, J = 7.5 Hz), 5.22 (d, 1H, J = 7.5 
Hz), 3.74 (s, 3H), 3.71 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -147.2 (m, 
1F), -160.0 (m, 2F).  
• IR (nujol) 3263, 1748, 1610, 1518, 1303, 1174, 1091, 990 
cm-1.  
• Anal. Calcd. for C16H12F5NO5S: C, 45.18; H, 2.84; N, 
3.29. Found: C, 45.21; H, 2.89; N, 3.31. 
F
F
F
F
S
N
H
O O
CO2Me
F
10g, C16H12F5NO5S
MW: 425,33
OMe
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(4-(benzyloxy)phenyl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) 
acetate (10h). 
 
Compound PM mmol g mL 
rac- Methyl 2-amino-2-(4-
(benzyloxy) phenyl)acetate 
hydrochloride (9h) 
307,77 10 3,08  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 10 2,67  
DIEA ( ρ = 0,755 g/mL) 129,24 21  3,59 
DCM    40 
 
 
24h, 4.16 g, 83%;  
• FCC - AcOEt/hexane (1 : 12), white solid, mp 103,5-
104,5 °C. 
• 1H NMR (300MHz, CDCl3) δ 7.40-7.33 (m, 5H), 7.13-
7.10 (m, 2H), 6.83-6.79 (m, 2H), 6.20 (d, 1H, J = 7.1 Hz), 
5.22 (d, 1H, J = 7.1 Hz), 4.97 (s, 2H), 3.71 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -147.0 (m, 
1F), -159.8 (m, 2F).  
• IR (nujol) 3275, 1741, 1627, 1518, 1310, 1176, 1100, 996, 
884 cm-1.  
• Anal. Calcd. for C22H16F5NO5S: C, 52.70; H, 3.22; N, 
2.79. Found: C, 52.74; H, 3.19; N, 2.83. 
F
F
F
F
S
N
H
O O
CO2Me
F
10h, C22H16F5NO5S
MW: 501,42
OBn
Synthesis of polyfluorobenzo[d]sultams 
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rac- Methyl 2-(thiophen-3-yl)-2-(2,3,4,5,6-pentafluorophenylsulfonamido) 3-
phenylpropanoate (10i). 
 
Compound PM mmol mg mL 
rac- Methyl 2-amino-2-(thiophen-
3-yl)acetate hydrochloride (9i) 
207,68 1 208  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 267  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
20h, 301 mg, 75%; 
• FCC - AcOEt/hexane (1 : 9), white solid, mp 150-151 
°C. 
• 1H NMR (300MHz, CDCl3) δ 7.26 (d, 1H, J = 3.0 Hz), 
7.20 (dd, 1H, J = 5.0, 3.0 Hz), 6.89 (dd, 1H, J = 5.0, 0.9 Hz), 
6.17 (d, 1H, J = 7.8 Hz), 5.41 (d, 1H, J = 7.8 Hz), 3.74 (s, 
3H).  
• 19F NMR (282 MHz, CDCl3) δ -136.6 (m, 2F), -146.5 (m, 
1F), -159.5 (m, 2F).  
• IR (nujol) 3288, 1729, 1615, 1530, 1340, 1165, 982, 895 
cm-1. 
• Anal. Calcd. for C13H8F5NO4S2: C, 38.91; H, 2.01; N, 
3.49. Found: C, 38.96; H, 2.07; N, 3.44. 
  
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(2-Bromo-3,4,5,6-tetrafluorophenylsulfonamido)-2-phenylacetate 
(30a). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1 201,6  
2-bromo-3,4,5,6-
tetrafluorobenzene sulfonyl 
chloride (5f) 
327,48 1 327,5  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
30h, 374,1 mg, 82%; 
• FCC - AcOEt/hexane (1 : 9), white solid, mp 74-76°C 
• [α]D20 +68.1 (c 1, CHCl3).  
• 1H NMR (300 MHz, CDCl3) δ 7.25-7.17 (m, 5H), 6.49 (d, 
1H, J = 7.1 Hz,), 5.24 (d, 1H, J = 7.3 Hz), 3.72 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -124.3 (m, 1F), -130.1 (m, 
1F), -146.9 (m, 1F), -152.9 (m, 1F). 
• 13C NMR (75 MHz, CDCl3) δ 170.0, 148.5-138.5 (m, 4 C-
F Ar), 134.1, 129.5, 129.1, 127.8, 126.7, 105.5 (d, J = 17.1 
Hz), 60.5, 53.8. 
• Anal. Calcd. for C15H10BrF4NO4S: C, 39.49; H, 2.21; N, 
3.07. Found: C, 39.47; H, 2.19; N, 3.08. 
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(4-Bromo-2,3,5,6-tetrafluorophenylsulfonamido)-2-phenylacetate 
(30b). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1 201,6  
4-bromo-2,3,5,6-
tetrafluorobenzene sulfonyl 
chloride (5g) 
327,48 1 327,5  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
24h, 392,3 mg, 86%;  
• FCC - AcOEt/hexane (1 : 9), white solid, mp 107-108°C, 
[α]D20 +51.3 (c 1, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.25-7.19 (m, 5H), 6.21 (d, 
1H, J = 5.7 Hz), 5.27 (d, 1H, J = 5.3 Hz), 3.72 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -130.9 (m, 2F), -136.2 (m, 
2F).  
• 13C NMR (75 MHz, CDCl3) δ 170.1, 145.3 (dd, J = 256.1, 
15.2 Hz), 143.7 (dd, J = 257.7, 16.5 Hz), 134.3, 129.5, 129.3, 
126.7, 120.7, 105.5 (t, J = 22.1 Hz), 60.4, 53.8.  
• Anal. Calcd. for C15H10BrF4NO4S: C, 39.49; H, 2.21; N, 
3.07. Found: C, 39.51; H, 2.24; N, 3.09.  
F
F
Br
F
F
S
N
H
O O
CO2Me
30b, C15H10BrF4NO4S
MW: 456,21
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(2,3,4,5-tetrafluorophenylsulfonamido)-2-phenylacetate (30c). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1 201,6  
2,3,4,5-tetrafluorobenzene 
sulfonyl chloride (5h) 
248,58 1 248,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
24h, 230,2 mg, 61%; 
• FCC - AcOEt/hexane (1 : 9), white wax, 
• 1H NMR (300 MHz, CDCl3) δ 7.35-7.25 (m, 5H), 7.03-
6.94 (m, 1H), 6.32 (d, 1H, J = 7.6 Hz,), 5.24 (d, 1H, J = 7.6 
Hz), 3.73 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -134.6 (m, 1F), -136.4 (m, 
1F), -146.8 (m, 1F), -151.6 (m, 1F). 
• Anal. Calcd. for C15H11F4NO4S: C, 47.75; H, 2.94; N, 
3.71. Found: C, 47.79; H, 2.95; N, 3.74.  
Synthesis of polyfluorobenzo[d]sultams 
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 (S)-Methyl 2-(2,3,4,6-tetrafluorophenylsulfonamido)-2-phenylacetate (30d). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1 201,6  
2,3,4,6-tetrafluorobenzene 
sulfonyl chloride (5i) 
248,58 1 248,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
20h, 252,8 mg, 67%; 
• FCC - AcOEt/hexane (1 : 9), white solid, mp 61-62°C, 
• [α]D20 +83.1 (c 1, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.23-7.18 (m, 5H), 6.73-
6.63 (m, 1H), 6.23 (d, 1H, J = 7.6 Hz,), 5.26 (d, 1H, J = 7.7 
Hz), 3.70 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -110.6 (m, 1F), -124.1 (m, 
1F), -128.3 (m, 1F), -162.4 (m, 1F). 
• Anal. Calcd. for C15H11F4NO4S: C, 47.75; H, 2.94; N, 
3.71. Found: C, 47.73; H, 2.91; N, 3.72.  
F
F
F
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CO2Me
30d, C15H11F4NO4S
MW: 377,31
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(6-Bromo-2,3,4-trifluorophenylsulfonamido)-2-phenylacetate (30e). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1,6 325  
6-Bromo-2,3,4-trifluorobenzene 
sulfonyl chloride (5l) 
309,49 1,6 500  
DIEA ( ρ = 0,755 g/mL) 129,24 3,36  0,445 
DCM    7 
 
 
24h, 424 mg, 60%; 
• FCC - AcOEt/hexane (1 : 9), white wax, 
• 1H NMR (300 MHz, CDCl3) δ 7.23-7.16 (m, 6H), 6.61 (d, 
1H, J = 7.6 Hz,), 5.22 (d, 1H, J = 7.6 Hz), 3.66 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -123.3 (m, 1F), -126.6 (m, 
1F), -157.0 (m, 1F). 
• 13C NMR (75 MHz, CDCl3) δ 169.6, 151.6 (dm, J = 262.9 
Hz), 150.1 (dm, J = 256.1 Hz), 150.1 (dt, J = 255.4, 16.1 
Hz), 133.7, 128.9, 128.6, 127.2, 118.7 (d, J = 20.0 Hz), 115.0, 
59.9, 53.1. 
• Anal. Calcd. for C15H11BrF3NO4S: C, 44.11; H, 2.53; N, 
3.20. Found: C, 44.12; H, 2.51; N, 3.22.  
Br
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30e, C15H11BrF3NO4S
MW: 438,22
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(2,4,6-trifluorophenylsulfonamido)-2-phenylacetate (30f). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1 201,6  
2,4,6-trifluorobenzene sulfonyl 
chloride (5m) 
230,59 1 230,6  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
24h, 251,5 mg, 70%; 
• white solid, mp 119-121°C, (EtOH) 
• [α]D20 -99.2 (c 1, CHCl3), (EtOH). 
•1H NMR (300 MHz, CDCl3) δ 7.21-7.17 (m, 5H), 7.13 (dt, 
2H, J = 7.9, 2.2 Hz), 6.10 (d, 1H, J = 7.8 Hz,), 5.25 (d, 1H, J 
= 7.8 Hz), 3.68 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -99.6 (m, 1F), -103.6 (m, 
2F). 
• 13C NMR (75 MHz, CDCl3) δ 170.4, 165.3 (dt, J = 255.7, 
15.5 Hz), 160.5 (ddd, J = 257.8, 15.1, 6.6 Hz), 134.8, 129.3, 
129.2, 127.6, 116.0, 102.0 (t, J = 28.1 Hz), 60.2, 53.6. 
• Anal. Calcd. for C15H12F3NO4S: C, 50.14; H, 3.37; N, 
3.90. Found: C, 50.13; H, 3.38; N, 3.92.  
Synthesis of polyfluorobenzo[d]sultams 
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(S)-Methyl 2-(2-Bromo-4,6-difluorophenylsulfonamido)-2-phenylacetate (30g). 
 
Compound PM mmol mg mL 
S-Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
201,65 1 201,6  
2-Bromo-4,6-difluorobenzene 
sulfonyl chloride (5e) 
291,50 1 291,5  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
24h, 374 mg, 89%; 
• FCC - AcOEt/hexane (1 : 5), pale brown solid, mp 71.5-
72.5°C 
• [α]D20 +91.5 (c 1, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.25-7.17 (m, 5H), 7.13 
(dt, 1H, J = 7.8, 2.2 Hz), 6.67 (ddd, 1H, J = 10.6, 8.3, 2.5 
Hz), 6.38 (d, 1H, J = 7.7 Hz,), 5.22 (d, 1H, J = 7.7 Hz), 3.67 
(s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -98.2 (m, 1F), -102.7 (m, 
1F). 
• 13C NMR (75 MHz, CDCl3) δ 170.3, 164.3 (dd, J = 208.4, 
14.0 Hz), 164.3 (dd, J = 211.4, 14.2 Hz), 134.5, 129.3, 129.2, 
127.6, 123.3 (d, J = 11.9 Hz), 119.3 (d, J = 22.9 Hz), 105.5 (t, 
J = 26.6 Hz), 60.3, 53.7. 
• Anal. Calcd. for C15H12BrF2NO4S: C, 42.87; H, 2.88; N, 
3.33. Found: C, 42.85; H, 2.89; N, 3.29. 
Synthesis of polyfluorobenzo[d]sultams 
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(R)-tert-butyl 2-(2-Bromo-4,6-difluorophenylsulfonamido)-2-phenylacetate (50). 
 
Compound PM mmol mg mL 
R-tert-butyl 2-amino-2-
phenylacetate hydrochloride 
(S-6d) 
243,73 1 243,7  
2-Bromo-4,6-difluorobenzene 
sulfonyl chloride 5e 
291,50 1 291,5  
DIEA ( ρ = 0,755 g/mL) 129,24 2,1  0,359 
DCM    4 
 
 
30h, 379,1 mg, 82%; 
• FCC - AcOEt/hexane (1 : 10),wax  
• [α]D20 +43.2 (c 0.2, CHCl3). 
• 1H NMR (300 MHz, CDCl3) δ 7.21-7.17 (m, 5H), 7.13 
(dt, 1H, J = 7.9, 2.2 Hz), 6.67 (ddd, 1H, J = 10.7, 8.2, 2.6 
Hz), 6.33 (d, 1H, J = 7.8 Hz,), 5.09 (d, 1H, J = 7.9 Hz), 1.31 
(s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -98.1 (m, 1F), -103.0 (m, 
1F). 
• Anal. Calcd. for C18H18BrF2NO4S: C, 46.76; H, 3.03; N, 
3.33. Found: C, 46.77; H, 3.06; N, 3.32. 
Br
F F
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50, C18H18BrF2NO4S
MW: 462,31
Synthesis of polyfluorobenzo[d]sultams 
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Synthesis of Methyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido) 3-
phenylpropanoate (12a). 
 
Compound PM mmol mg mL 
Phenylalanine methyl ester 
hydrochloride (13a) 
225,64 1 225,6  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 267  
DIEA ( ρ = 0,755 g/mL)  1,05   
DCM    6 
 
 
1,5 h, 286,5 mg, 70%; 
Ethanol-water (1 : 1), white solid, mp 130-131 °C. 
• 1H NMR (300MHz, CDCl3) δ 7.22-7.19 (m, 3H), 7.11-
7.07 (m, 2H), 5.60 (d, 1H, J = 9.2 Hz), 4.54-4.47 (m, 1H), 
3.73 (s, 3H), 3.19 (dd, 1H, J = 13.9, 4.8 Hz), 2.97 (dd, 1H, J 
= 13.9, 8.1 Hz). 
• 19F NMR (282 MHz, CDCl3) δ -136.5 (m, 2F), -146.8 (m, 
1F), -159.5 (m, 2F).  
• IR (nujol) 3225, 1722, 160’, 1501, 1342, 1171, 1110, 1096, 
998 cm-1. 
• Anal. Calcd. for C16H12F5NO4S: C, 46.95; H, 2.95; N, 
3.42. Found: C, 46.96; H, 2.98; N, 3.44. 
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12a, C16H12F5NO4S
MW: 409,33
Synthesis of polyfluorobenzo[d]sultams 
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Synthesis of tert-Butyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido)-3-phenyl 
propanoate (12b). 
 
Compound PM mmol mg mL 
Phenylalanine tert-butyl ester 
hydrochloride 13b 
257,76 1 211,6  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 267  
DIEA ( ρ = 0,755 g/mL)  1,05   
DCM    6 
 
 
 18 h, 279,7 mg, 62%; 
• FCC - AcOEt/hexane (1 : 10), white solid, mp 103.5-
104.5°C. 
• 1H NMR (300MHz, CDCl3) δ 7.27-7.11 (m, 5H), 5.75 (d, 
1H, J = 6.5 Hz), 4.45-4.33 (m, 1H), 3.13 (dd, 1H, J = 13.9, 
5.5 Hz), 2.96 (dd, 1H, J = 13.9, 7.6 Hz), 1.38 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -136.4 (m, 2F), -147.1 (m, 
1F), -159.6 (m, 2F).  
• IR (nujol) 3218, 1726, 1602, 1498, 1348, 1177, 1116, 1097, 
990 cm-1. 
• Anal. Calcd. for C19H18F5NO4S: C, 50.55; H, 4.02; N, 
3.10. Found: C, 50.57; H, 4.03; N, 3.12. 
F
F
F
F
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Synthesis of Alkyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate 
(14a,b): General Procedure. 
 
 
 
To a suspension of glycine ester hydrochloride 15a,b (1 mmol) in dry DCM (4 mL) 
cooled at 0°C, triethylamine (1,1 mmol) was added dropwise; the mixture was stirred 
for 15’ then a solution of pentafluorobenzene sulfonyl chloride (1 mmol) and pyridine 
(1 mmol) in DCM (1 mL) was added slowly and the resulting yellow mixture was 
stirred at 0°C. The reaction was monitored until completion (TLC control) and the 
solution was then diluted with DCM (10 mL) and washed with aqueous 3% 
hydrochloric acid (1×5 mL). The organic phase was dried over MgSO4, filtered, 
concentrated under reduced pressure (RV), and purified by FCC. Yield, 
chromatographic eluant, physical and analytical data are as follows. 
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Synthesis of Methyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate (14a). 
 
1 h, 399,1 mg, 94%; 
• FCC - AcOEt/hexane (1 : 7),  white solid, mp 93-94 °C. 
• 1H NMR (300MHz, CDCl3) δ 5.58 (t, 1H, J = 5.5 Hz), 
4.06 (d, 2H, J = 5.5 Hz), 3.72 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -136.9 (m, 2F), -146.0 (m, 
1F), -158.9 (m, 2F).  
• IR (nujol) 3252, 1737, 1644, 1521, 1376, 1169, 1131, 1102, 
997, 862 cm-1. 
• Anal. Calcd. for C9H6F5NO4S: C, 33.86; H, 1.89; N, 4.39. 
Found: C, 33.88; H, 1.92; N, 4.40. 
 
 
Synthesis of tert-Butyl 2-(2,3,4,5,6-pentafluorophenylsulfonamido) acetate (14b). 
 
24 h, 271 mg, 75%; 
• FCC - AcOEt/hexane (1 : 16),  white solid, mp 104.5-
105.5 °C. 
• 1H NMR (300MHz, CDCl3) δ 5.52 (t, 1H, J = 5.6 Hz), 
3.92 (d, 2H, J = 5.6 Hz), 1.40 (s, 9H). 
• 19F NMR (282 MHz, CDCl3) δ -136.6 (m, 2F), -146.5 (m, 
1F), -159.4 (m, 2F).  
• IR (nujol) 3309, 1740, 1644, 1521, 1377, 1180, 1158, 1105, 
992, 885 cm-1. 
• Anal. Calcd. for C12H12F5NO4S: C, 39.89; H, 3.35; N, 
3.88. Found: C, 39.91; H, 3.36; N, 3.90. 
Synthesis of polyfluorobenzo[d]sultams 
 
145 
 
Synthesis of Diethyl 2-(pentafluorophenylsulfonamido) malonate (23). 
 
 
 
Compound PM mmol mg mL 
Diethylamino malonate 
hydrochloride (22) 
211,64 1 211,6  
pentafluorobenzene sulfonyl 
chloride (5a) 
266,57 1 267  
TEA (ρ = 0,725 g/mL)  1,05   
Pyridine  1,05   
DCM    6 
 
To a suspension of diethylamino malonate hydrochloride 22 in dry DCM cooled at 0°C, 
triethylamine was added dropwise; the mixture was stirred for 15’ then a solution of 
pentafluorobenzene sulfonyl chloride and pyridine in DCM was added slowly and the 
resulting yellow mixture was allowed to warm to room temperature. The reaction was 
monitored until completion (16 h, TLC control) and the solution was then diluted with 
DCM (10 mL) and washed with aqueous 3% hydrochloric acid (1×5 mL). The organic 
phase was dried over MgSO4, filtered, concentrated under reduced pressure (RV), and 
purified by FCC (AcOet/Hexane 1 : 9) giving the sulfonamide 23 as a white solid. 
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20h, 202,7 mg, 50%; 
• FCC - AcOEt/hexane (1 : 9),  white wax. 
• 1H NMR (200MHz, CDCl3) δ 6.37 (d, 1H, J = 8.6 Hz), 4.95 (d, 1H, J = 6.8 Hz), 5.41 
(q, 4H, J = 7.1 Hz), 3.74 (t, 6H, J = 7.1 Hz). 
•19F NMR (282 MHz, CDCl3) δ -136.6 (m, 2F), -146.0 (m, 1F), -159.3 (m, 2F).  
•Anal. Calcd. for C13H12F5NO6S: C, 38.52; H, 2.98; N, 3.46. Found: C, 38.52; H, 3.01; 
N, 3.47. 
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Synthesis of (S)-Methyl 2-(perfluorobenzamido)-2-phenylacetate (47). 
 
 
Compound PM mmol g mL 
pentafluorobenzoic acid (46) 212,06 10 2,12  
SOCl2 ( ρ = 1,638 g/mL)    3 
(S)- Methyl 2-amino-2-
phenylacetate hydrochloride (6a) 
207,68 10 2,08  
DIEA ( ρ = 0,755 g/mL) 129,24 22 2,84  
DCM    30 
 
The pentafluorobenzoic acid is dissolved in SOCl2 and the resulting mixture was 
heated under magnetic stirring for 20h; then the solution is cooled, the excess of 
SOCl2 removed by RV evaporation and the residue dissolved in DMC (10 mL). This 
solution is dropped into a solution of the phenylglycine, DIEA in DCM (20 mL) 
cooled at 0°C and the reaction was monitored until completion (16 h, TLC control 
AcOEt : hexane – 1 : 3). The mixture was then diluted with DCM (30 mL) and washed 
with aqueous 3% hydrochloric acid (2×15 mL), saturated NaHCO3 solution (2×15 mL) 
and brine (20 mL), dried over MgSO4, filtered. After evaporation of the solvent under 
vacuum (RV), the crude purified by FCC or MPLC, gave sulfonamide 47 as a white 
solid. 
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• 24h, 1,62 g, 47%;  
• white solid, mp 137,5-138,5 °C. 
• [α]D20 +92.9 (c 1, CHCl3). 
• 1H NMR (300MHz, CDCl3) δ 7.71 (d, 1H, J = 7.2 Hz), 7.32-7.30 (m, 5H), 5.63 (d, 
1H, J = 7.2 Hz), 3.68 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -140.9 (m, 2F), -151.5 (m, 1F), -161.1 (m, 2F).  
• IR (nujol) 3303, 1731, 1660, 1556, 1520, 1495, 1359, 1330, 1312, 1274, 1224, 1186, 
1095, 1070, 994, 789, 727, 695 cm-1. 
• Anal. Calcd. for C16H10F5NO3: C, 53.49; H, 2.81; N, 3.90. Found: C, 53.51; H, 2.81; 
N, 3.92. 
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SL-PTC N-Alkylation of Sulfonamides 3a, 12b, 13b: General Procedure. 
 
 
To a solution of sulfonamide (1 mmol) and TEBA (23 mg, 0.1 mmol) in dry MeCN (2 mL) at 25 
°C, anhydrous K2CO3 (276 mg, 2 mmol) was added. This suspension was stirred for 10 min, 
then a solution of the alkylating agent (1.5 mmol) in MeCN (1 mL) was added under vigorous 
stirring, and the reaction was monitored by TLC (AcOEt : hexane – 1 : 9) until completion. The 
mixture was then diluted with AcOEt (5 mL), washed with brine (2 × 2 mL), dried over MgSO4 
and filtered. The solvent was removed under vacuum, the crude was purified by FCC – 
AcOEt/hexane (1 : 15); alkylating agent, product, yield, chromatographic eluant, physical and 
analytical data are as follows. 
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(S)-Methyl 2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)-2-phenylacetate 
(S-7a) 
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-phenylacetate (S-3a). 
395,30 1 395  
Potassium carbonate 138,21 2 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 1,5 213  
Acetonitrile    3 
 
 
24 h, 368 mg, 90%;  
• white solid, mp 67-69 °C (EtOH/water – 9 : 1). 
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.23 (m, 5H), 6.04 (s, 
1H), 3.72 (s, 3H), 2.84 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -135.3 (m, 2F), -146.4 (m, 
1F), -159.7 (m, 2F).  
• IR (nujol) 1744, 1644, 1541, 1296, 1271, 1222, 1173, 1098, 
1025, 699, 678 cm-1.  
• Anal. Calcd. for C16H12F5NO4S: C, 46.95; H, 2.95; N, 
3.42. Found: C, 47.02; H, 3.00; N, 3.37. 
F
F
F
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(S)-Methyl 2-(N-benzyl-2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate 
(S-7b) 
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-phenylacetate (S-3a). 
395,30 1 395  
Potassium carbonate 138,21 2 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Benzyl Bromide 141,94 1,1 188  
Acetonitrile    3 
 
 
20 h, 427 mg, 88%;  
• FCC - AcOEt/hexane (1 : 12), white solid, mp 106-108 
°C 
• 1H NMR (300 MHz, CDCl3) δ 7.43-7.27 (m, 5H), 7.05-
6.95 (m, 5H), 6.17 (s, 1H), 4.80 (d, 1H, J = 15.4 Hz), 4.25 
(d, 1H, J = 15.4 Hz), 3.79 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -135.3 (m, 2F), -147.0 (m, 
1F), -160.2 (m, 2F). 
• IR (nujol), 1744, 1530, 1351, 1292, 1240, 1106, 669 cm-1. 
• Anal. Calcd. for C22H16F5NO4S: C, 54.43; H, 3.32; N, 
2.89. Found: C, 54.48; H, 3.35; N, 2.92. 
 
F
F
F
F
F
S
N CO2Me
O O
S-7b, C22H16F5NO4S
MW: 485,42
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(S)-Methyl 2-(N-allyl-2,3,4,5,6-pentafluorophenylsulfonamido)-2-phenylacetate (S-
7c) 
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-phenylacetate (S-3a). 
395,30 0,6 237,2  
Potassium carbonate 138,21 1,2 166,2  
Triethylbenzyl ammonium chloride 227,81 0,1 10  
Allyl Bromide 120,98 0,9 98  
Acetonitrile    2,5 
 
 
40 h, 122 mg, 48%;  
• FCC - AcOEt/hexane (1 : 12), white wax 
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.35 (m, 3H), 7.28-
7.26 (m, 2H), 6.06 (s, 1H), 5.42-5.28 (m, 1H), 4.82 (d, 1H, J 
= 17.0 Hz), 4.77 (d, 1H, J = 9.9 Hz), 3.98 (dd, 1H, J = 16.4, 
4.7 Hz), 3.82 (dd, 1H, J = 16.4, 6.9 Hz), 3.74 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -135.0 (m, 2F), -146.4 (m, 
1F), -159.6 (m, 2F). 
• Anal. Calcd. for C18H14F5NO4S: C, 49.66; H, 3.24; N, 
3.22. Found: C, 49.63; H, 3.24; N, 3.20. 
 
F
F
F
F
F
S
N CO2Me
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S-7c, C18H14F5NO4S
MW: 435,37
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(S)-Methyl 2-(2,4,6-trifluoro-N-methylphenylsulfonamido)-2-phenylacetate (51) 
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,4,6-trifluorophenyl 
sulfonamido)-2-phenylacetate (30f). 
359,34 1,8 395  
Potassium carbonate 138,21 3,5 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 2,6 369,4  
Acetonitrile    3 
 
 
28 h, 409 mg, 61%;  
• FCC - AcOEt/hexane (1 : 5), white solid, mp 89.5-
90.5°C  
• 1H NMR (300 MHz, DMSO-d6) δ 7.38-7.34 (m, 3H), 
7.26-7.23 (m, 2H), 6.78 (t, 2H, J = 8.7), 6.00 (s, 1H), 3.68 (s, 
3H), 2.83 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -99.3 (m, 1F), -102.0 (m, 
2F).  
• 13C NMR (125 MHz, CDCl3) δ 169.8, 164.8 (dt, J = 256.6, 
16.1 Hz), 160.6 (ddd, J = 258.2, 15.5, 6.5 Hz), 133.1, 128.8, 
128.7, 128.6, 101.8 (t, J = 18.8 Hz), 62.8, 52.1, 30.5.  
• IR (nujol) 1748, 1647, 1538, 1301, 1270, 1225, 1173, 1099, 
1027, 698, 685 cm-1.  
F
F F
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51, C16H14F3NO4S
MW: 373,35
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tert-Butyl 2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)-3-
phenylpropionate (17b) 
 
Compound PM mmol mg mL 
tert-Butyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-3-phenylpropionate (12b). 
451,09 1 451,1  
Potassium carbonate 138,21 2 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 1,5 213  
Acetonitrile    3 
 
 
24 h, 372,3 mg, 80%;  
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.27-7.16 (m, 5H), 4.86 
(dd, 1H, J = 10.4, 5.3 Hz), 3.30 (dd, 1H, J = 14.5, 5.4 Hz), 
3.05 (s, 3H), 2.91 (dd, 1H, J = 14.5, 10.5 Hz), 1.41 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -134.9 (m, 2F), -147.5 (m, 
1F), -159.9 (m, 2F).  
• IR (nujol) 1738, 1641, 1541, 1299, 1273, 1221, 1176, 1110, 
1024, 699, 675 cm-1.  
• Anal. Calcd. for C20H20F5NO4S: C, 51.61; H, 4.33; N, 
3.01. Found: C, 51.63; H, 4.36; N, 3.02. 
F
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MW: 465,43
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tert-Butyl 2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)-acetate (18b) 
 
Compound PM mmol mg mL 
tert-Butyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-acetate (13b). 
361,28 1 361,3  
Potassium carbonate 138,21 2 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 1,5 213  
Acetonitrile    3 
 
 
20 h, 243,9 mg, 65%;  
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 4.09 (s, 2H), 3.07 (s, 3H), 
1.40 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -135.3 (m, 2F), -147.0 (m, 
1F), -160.0 (m, 2F).  
• IR (nujol) 1742, 1641, 1541, 1298, 1269, 1219, 1175, 1095, 
1024, 695, 677 cm-1.  
• Anal. Calcd. for C13H14F5NO4S: C, 41.60; H, 3.76; N, 
3.73. Found: C, 41.62; H, 3.77; N, 3.71. 
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SL-PTC ‘One-Pot’ Synthesis of N-Alkyl-benzo[d]sultams 7a-f: General 
Procedure. 
 
 
 
 
 
To a solution of sulfonamide and TEBA in dry solvent at 25 °C, anhydrous alkaline 
metal carbonate was added. The resulting heterogeneous mixture was stirred for 10 
min, then the alkylating agent RX was added and the reaction was monitored by TLC 
(AcOEt : hexane – 1 : 6) until completion. The mixture was diluted with water and 
extracted with DCM and concentrated; the residue was diluted with AcOEt (10 mL) 
and washed with brine (5×10 mL), dried over MgSO4 and filtered. After evaporation 
of the solvent (RV), the crude was purified by MPLC. 
Starting alkylating agent (RX), dry solvent, anhydrous base, reaction time, product, 
yield, physical and analytical data are as follows. 
X1
X3
X4
DMSO, 25°C
X2
1) M2CO3
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2) R'X
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Methyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4a).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3a). 
395,30 1 395  
Cesium carbonate 325,82 2 652  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 1,5 213  
DMSO    5 
 
1.5h, 366 mg, 94%; 
 • white solid, mp 166°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.40 (m, 3H), 7.26-
7.23 (m, 2H), 3.91 (s, 3H), 2.84 (s, 3H). 
• 19F NMR (282, MHz, CDCl3) δ -135 (m, 1F), -140.3 (m, 
1F), -145.3 (m, 1F), -149 (m, 1F).  
• 13C NMR (125 MHz, CDCl3) δ 166.8, 144.3 (dt, J = 261.6, 
13.8 Hz), 143.4 (ddd, J = 261.6, 12.6, 3.8 Hz), 141.5 (dt, J = 
261.6, 13.8 Hz), 141.0 (dd, J = 262.8, 13.8 Hz), 132.7, 129.9, 
129.2, 127.4, 122.3 (dd, J = 13.4, 3.5 Hz), 118.2 (dd, J = 
17.5, 3.1 Hz), 71.8, 53.8, 25.4.  
• IR (nujol) 1748, 1638, 1516, 1495, 1296, 1256, 1230, 1170, 
1077, 977, 916, 880, 693, 629, 614 cm-1. 
• Anal. Calcd. for C16H11F4NO4S: C, 49.36; H, 2.85; N, 
3.60. Found: C, 49.31; H, 2.81; N, 3.64. 
• HRMS (ESI positive) Calcd. for C16H11F4NNaO4S 
[M+Na]+: 412.02371. Found: 412.02401. 
F
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Methyl 4,5,6,7-tetrafluoro-2-benzyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4b).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3a). 
395,30 1 395  
Sodium carbonate 105,99 4 424  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Benzyl Bromide 171,03 1,5 257  
DMSO    5 
 
20 h, 149 mg, 32%; 
• white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.31 (m, 5H), 7.25-
7.20 (m, 5H), 4.70 (d, 1H, J = 16.1 Hz), 4.35 (d, 1H, J = 16.1 
Hz), 3.60 (s, 3H).  
• 19F NMR (282 MHZ, CDCl3): δ -135.2 (m, 1F), -140.1 (m, 
1F), -144.9 (m, 1F), -148.9 (m, 1F). 
• 13C NMR (75 MHz, CDCl3): δ 166.6, 144.4 (dt, J = 262.2, 
15.2 Hz), 143.1 (dd, J = 259.9, 12.2 Hz), 141.5 (dm, J = 
262.3 Hz), 141.2 (dm, J = 259.8 Hz), 135.2, 133.1, 129.7, 
129.0, 128.2, 128.0, 127.8, 127.6, 122.3 (d, J = 13.9 Hz), 
118.1 (d, J = 15.2 Hz), 72.5, 53.5, 45.3. 
• IR (nujol) 1747, 1642, 1512, 1504, 1330, 1254, 1174, 1076, 
996, 980, 914, 881, 829, 698, 607 cm-1.  
•Anal. Calcd. for C22H15F4NO4S: C, 56.77; H, 3.25; N, 
3.01. Found: C, 56.81; H, 3.20; N, 3.06. 
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Methyl 4,5,6,7-tetrafluoro-2-allyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4c).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3a). 
395,30 1 395  
Sodium carbonate 105,99 4 424  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Allyl Bromide 120,98 1,5 182  
MeCN    5 
 
 
24 h, 191 mg, 46%;  
• white solid; mp 111-112°C.  
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.38 (m, 3H), 7.31-
7.27 (m, 2H), 5.88-5.75 (m, 1H), 5.20-5.08 (m, 2H), 4.03-
3.78 (m, 2H), 3.89 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -135.2 (m, 1F), -140.5 (m, 
1F), -145.2 (m, 1F), -149.1 (m, 1F).  
• IR (nujol) 1748, 1643, 1516, 1498, 1302, 1262, 1230, 1171, 
1077, 977, 916, 880, 691 cm-1.  
• Anal. Calcd. for C18H13F4NO4S: C, 52.05; H, 3.15; N, 
3.37. Found: C, 52.00; H, 3.19; N, 3.34. 
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Methyl 4,5,6,7-tetrafluoro-2-ethyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4d).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3a). 
395,30 1 395  
Potassium carbonate 138,21 2 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Ethyl Iodide 155,97 1,5 234  
DMSO    5 
 
 
20 h, 334 mg, 83%;  
• white solid, mp 109.5-110.5°C.  
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.38 (m, 3H), 7.30-
7.26 (m, 2H), 3.91 (s, 3H), 3.47-3.27 (m, 2H), 1.21 (t, 3H, J 
= 7 Hz).  
• 19F NMR (282 MHz, CDCl3) δ -135.3 (m, 1F), -140.5 (m, 
1F), -145.3 (m, 1F), -149 (m, 1F).  
• IR (nujol) 1749, 1642, 1511, 1495, 1298, 1268, 1182, 1161, 
1079, 942, 727, 699, 636, 603 cm-1. 
• Anal. Calcd. for C17H13F4NO4S: C, 50.62; H, 3.25; N, 
3.47. Found: C, 50.59; H, 3.29; N, 3.43. 
F
F
F
F
4d, C17H13F4NO4S
MW: 403,35
N
S
O O
CO2Me
Et
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Methyl 4,5,6,7-tetrafluoro-2-propyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4e).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3a). 
395,30 1 395  
Cesium carbonate 325,82 4 1300  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
n-Propyl Iodide 170,01 1,5 255  
DMSO    5 
 
 
16 h, 209 mg, 50%; 
• white solid, mp 56-57°C.  
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.25 (m, 5H), 3.90 (s, 
3H), 3.34-3.10 (m, 2H), 1.71-1.56 (m, 2H), 0.79 (t, 3H, J = 
7.5 Hz).  
• 19F NMR (282 MHz, CDCl3) δ -135.4 (m, 1F), -140.5 (m, 
1F), -145.3 (m, 1F), -149.1 (m, 1F).  
• IR (nujol) 1748, 1639, 1510, 1497, 1300, 1232, 1209, 1167, 
1078, 993, 876, 699 cm-1. 
• Anal. Calcd. for C18H15F4NO4S: C, 51.80; H, 3.62; N, 
3.36. Found: C, 51.75; H, 3.60; N, 3.41.  
F
F
F
F
4e, C18H15F4NO4S
MW: 417,37
N
S
O O
CO2Me
n-Pr
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Methyl 4,5,6,7-tetrafluoro-2-butyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4f).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3a). 
395,30 1 395  
Potassium carbonate 138,21 2 276  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
n-Butyl Iodide 184,04 1,5 276  
NMP    5 
 
20 h, 267 mg, 62%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.36 (m, 3H), 7.29-
7.27 (m, 2H), 3.89 (s, 3H), 3.89-3.14 (m, 2H), 1.63-1.55 (m, 
2H), 1.27-1.15 (m, 2H), 0.80 (t, 3H, J = 7.35 Hz).  
• 19F NMR (282 MHz, CDCl3) δ -135.4 (m, 1F), -140.6 (m, 
1F), -145.4 (m, 1F), -149.2 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.5, 144.3 (dt, J = 262.3, 
14.8 Hz), 143.5 (dd, J = 260.5, 11.5 Hz), 141.5 (dt, J = 261.7, 
14.1 Hz), 141.1 (dd, J = 261.7, 12.5 Hz), 134.1, 130.1, 129.5, 
128.0, 122.7 (d, J = 13.3 Hz), 118.9 (d, J = 18 Hz), 72.8, 54.2, 
43.3, 31.5, 20.4, 13.8. 
• IR (nujol) 1744, 1633, 1510, 1488, 1290, 1248, 1239, 1170, 
1077, 977, 910, 880, 693 cm-1. 
• Anal. Calcd. for C19H17F4NO4S: C, 52.90; H, 3.97; N, 
3.25. Found: C, 52.96; H, 4.00; N, 3.20. 
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Tert-butyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (49).  
 
Compound PM mmol mg mL 
(R)-tert-butyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(3d). 
437,38 0,5 219  
Potassium carbonate 138,21 1 138  
Triethylbenzyl ammonium chloride 227,81 0,05 11  
Methyl Iodide 141,94 0,75 106  
DMSO    1,25 
 
20 h, 86 mg, 40%; 
• white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.27 (m, 5H), 2.84 (s, 
3H), 1.53 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -135.2 (m, 1F), -140.6 (m, 
1F), -146.0 (m, 1F), -149.6 (m, 1F).  
• IR (nujol) 1747, 1628, 1511, 1488, 1295, 1245, 1242, 1173, 
1075, 976, 915, 883 cm-1.  
• Anal. Calcd. for C19H17F4NO4S: C, 52.90; H, 3.97; N, 
3.25. Found: C, 52.88; H, 3.96; N, 3.22. 
F
F
F
F
49, C19H17F4NO4S
MW: 431,40
N
S
O O
CO2Bu
t
Me
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Methyl 4,5,7-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (32).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,6-tetrafluoro 
phenylsulfonamido)-2-phenylacetate 
(30d). 
377,31 0,35 138,7  
Potassium carbonate 138,21 1 138  
Triethylbenzyl ammonium chloride 227,81 0,075 17  
Methyl Iodide 141,94 0,75 106,5  
DMSO    2 
 
 
18 h, 121 mg, 89%; 
• FCC - AcOEt/hexane (1 : 5), white solid; mp 137.5-
138.5°C.  
• 1H NMR (300 MHz, CDCl3) δ 7.44-7.38 (m, 3H), 7.29-
7.25 (m, 2H), 7.14 (ddd, 1H, J = 9.6, 7.5, 5.2 Hz), 3.90 (s, 
3H), 2.82 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -116.6 (m, 1F), -123.8 (m, 
1F), -139.9 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.4, 155.8 (dt, J = 259.1, 
12.6 Hz), 151.4 (dd, J = 256.9, 11.2 Hz), 143.4 (dd, J = 
256.7, 13.9 Hz), 133.4, 130.1, 129.6, 127.9, 126.3, 118.7 (d, J 
= 20.2 Hz), 108.7 (t, J = 23.4 Hz), 72.5, 54.1, 25.7. 
• Anal. Calcd. for C16H12F3NO4S: C, 51.75; H, 3.26; N, 
3.77. Found: C, 51.77; H, 3.29; N, 3.78. 
 
 
F
F
F
32, C16H12F3NO4S
MW: 371,33
N
S
O O
CO2Me
Me
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Methyl 5,7-difluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (33).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,4,6-trifluorophenyl 
sulfonamido)-2-phenylacetate (30f). 
359,32 1 359,3  
Potassium carbonate 138,21 2 275  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 1,5 213  
DMSO    4 
 
 
45 h, 180 mg, 51%; 
• FCC - AcOEt/hexane (1 : 3), white solid; mp 170-171°C.  
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.38 (m, 3H), 7.18-
7.15 (m, 2H), 7.02-6.92 (m, 2H), 3.89 (s, 3H), 2.80 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -99.5 (m, 1F), -111.1 (m, 
1F).  
• IR (nujol) 1742, 1639, 1521, 1495, 1301, 1262, 1235, 1173, 
1071, 979, 915, 889, 692 cm-1.  
• Anal. Calcd. for C16H13F2NO4S: C, 54.39; H, 3.71; N, 
3.96. Found: C, 54.42; H, 3.72; N, 3.98. 
F
F
33, C16H13F2NO4S
MW: 353,34
N
S
O O
CO2Me
Me
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Methyl 5-fluoro-7-bromo-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (34).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2-bromo-4,6-
difluorophenyl sulfonamido)-2-
phenylacetate (30g). 
420,23 0,5 210  
Potassium carbonate 138,21 1 138  
Triethylbenzyl ammonium chloride 227,81 0,05 11  
Methyl Iodide 141,94 1,75 245  
DMSO    4 
 
 
26 h, 140,8 mg, 68%;  
• FCC - AcOEt/hexane (1 : 12), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.47-7.39 (m, 5H), 7.19-
7.12 (m, 2H), 3.89 (s, 3H), 2.84 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -102.8 (m, 1F).  
• Anal. Calcd. for C16H13BrFNO4S: C, 46.39; H, 3.16; N, 
3.38. Found: C, 46.37; H, 3.17; N, 3.36. 
Br
F
34, C16H13BrFNO4S
MW: 414,25
N
S
O O
CO2Me
Me
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Diethyl 4,5,6,7-tetrafluoro-2-methyl-2,3-dihydrobenzo[d]isothiazole-3,3-dicarboxylate 
1,1-dioxide (24a).  
 
 
 
Compound PM mmol mg mL 
Diethyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido) malonate (23). 
405,29 1 405,3  
Potassium carbonate 138,21 2 275  
Triethylbenzyl ammonium chloride 227,81 0,1 23  
Methyl Iodide 141,94 1,5 213  
DMSO    4 
 
5 h, 143,7 mg, 36%; 
• FCC - AcOEt/hexane (1 : 9), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 4.38-4.28 (m, 4H), 3.12 (s, 3H), 2.95 (t, 6H, J = 7.1 
Hz).  
• 19F NMR (282 MHz, CDCl3) δ -133.0 (m, 1F), -139.7 (m, 1F), - 144.9 (m, 1F), -147.4 
(m, 1F).  
• IR (nujol) 1742, 1646, 1501, 1371, 1313, 1242, 1169, 1035, 915, 843 cm-1.  
• Anal. Calcd. for C14H13F4NO6S: C, 42.11; H, 3.28; N, 3.51. Found: C, 42.13; H, 3.29; 
N, 3.53. 
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Synthesis of tert-Butyl 4,5,6,7-tetrafluoro-2-methyl-3-benzyl-2,3-dihydro 
benzo[d]isothiazole-3-carboxylate 1,1-dioxide (16b).  
 
 
Compound PM mmol mg mL 
Diethyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido) malonate (23). 
451,41 0,3 135,4  
Sodium Hydride 60% 24 1,2 48  
Methyl Iodide 141,94 0,9 127,7  
THF - DMF    
2 + 
0,1 
 
In a flame-dried round bottomed flask, 60% sodium hydride was rinsed with 
anhydrous n-pentane and, after cooling at 0°C, a solution of the sulfonylamido ester in 
anhydrous THF was added. The reaction mixture was stirred until hydrogen evolution 
ended (ca. 30 min.) then a solution of methyl iodide in anhydrous THF was added. The 
reaction mixture was stirred at 0°C until the reaction was judged complete by TLC 
analysis then was quenched with saturated NH4Cl solution. After extraction with 
AcOEt and evaporation under reduced pressure, the crude was purified by flash 
column chromatography on silica gel. Yield, reaction time, chromatographic eluant, 
physical spectroscopic and analytical data are as follows 
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4 h, 19,5 mg, 15%; 
• FCC - AcOEt/hexane (1 : 10), white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.18-7.14 (m, 3H), 7.01-6.98 (m, 2H), 3.54 (dd, 1H, J 
= 15.1, 2.2 Hz), 3.47 (d, 1H, J = 15.1 Hz), 3.01 (s, 3H), 1.44 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -137.9 (m, 1F), -139.4 (m, 1F), - 146.5 (m, 1F), -148.9 
(m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 165.4, 143.7 (dt, J = 260.3, 14.0 Hz), 142.3 (dd, J = 
255.5, 11.7 Hz), 141.2 (dd, J = 259.6, 12.5 Hz), 140.9 (dt, J = 260.0, 13.7 Hz), 132.9, 
129.5, 128.5, 127.8, 119.6, 118.4, 85.1, 71.0, 36.3, 27.7, 24.7. 
• Anal. Calcd. for C20H19F4NO4S: C, 53.93; H, 4.30; N, 3.14. Found: C, 53.91; H, 4.31; 
N, 3.13. 
• MS (ESI positive) Calcd. for C20H19F4NNaO4S [M+Na]+: 468.1. Found: 468.2. 
• Anal. Calcd. for C14H13F4NO6S: C, 42.11; H, 3.28; N, 3.51. Found: C, 42.12; H, 3.30; 
N, 3.50. 
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SL-PTC Ring Closing Reactions of N-Alkylsulfonamides 7a-c and 51. 
 
number
DMSO, 25°C
K2CO3, TEBA
F
F
F
F
S N
O O
CO2Me
Ph
F
number
F
F
F
F
N
S
O O
CO2Me
R
R
 
To a solution of N-alkyl-sulfonamide (0.2 mmol) and TEBA (5 mg, 0.02 mmol) in dry DMSO (1 
mL) at 25 °C, anhydrous Cs2CO3 (130 mg, 0.4 mmol) was added. This suspension was 
vigorously stirred for 15 min, monitoring by TLC (AcOEt : hexane – 1 : 9), then diluted with 
water (2 mL), extracted with DCM (3×10 mL). The solvent was removed under vacuum (RV). 
The residue was diluted with AcOEt (10 mL), washed with brine (5×2mL), dried over Mg2SO4 
filtered and, after evaporation of the solvent (RV), purified by MPLC (AcOEt : hexane – 1 : 12) to 
give the desired N-alkyl benzosultam. Starting sulfonamides, product, yield and 
chromatographic eluants are as follows. 
 
 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide 4a. 
 
Starting sulfonamide 7a, 82 mg,  
sultam 4a, 142 mg, 91%,  
MPLC (AcOEt : hexane – 1 : 12) 
 
 
 
F
F
F
F
N
S
O O
CO2Me
Me
4a
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Methyl 4,5,6,7-tetrafluoro-2-benzyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4b). 
 
 
Starting sulfonamide 7b, 97 mg,  
sultam 4b, 42 mg, 45%, 
MPLC (AcOEt : esano – 1 : 12 
 
 
 
Methyl 4,5,6,7-tetrafluoro-2-allyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4c). 
 
 
Starting sulfonamide 7c, 97 mg,  
sultam 4c, 55,6 mg, 61%, 
MPLC (AcOEt : esano – 1 : 9 
 
 
 
Methyl 4,6-difluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide 33. 
 
Starting sulfonamide 51, 75 mg,  
sultam, 43 mg, 61%,  
MPLC (AcOEt : hexane – 1 : 12) 
 
F
F
F
F
N
S
O O
CO2Me
4b
F
F
F
F
N
S
O O
CO2Me
4c
F
F
N
S
O O
CO2Me
Me
33
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Synthesis of Benzo[d]sultams 8a-d, 11a-i, 31a-l: General Procedure.  
 
X1
X3
X4
DME, 25°C
X2DBU
X1
X3
X4
F
S N
H
O O
CO2R
Aryl
X2
NH
S
O O
Aryl CO2R
 
 
To a solution of sulfonamide (1 mmol) in dry DME (4 mL), DBU (4 mmol) in DME 
(1mL) was added and the mixture was stirred at 25 °C until completion (TLC control). 
The solution was then diluted with AcOEt (10 mL), washed with aqueous 5% citric acid 
(3×10 mL), saturated NaHCO3 solution (2×10 mL), and brine (10 mL). The organic phase 
was dried over MgSO4, filtered, and concentrated under reduced pressure (RV), giving 
the sultams, in some case without any further purification. Starting sulfonamides, 
reaction time, product, yield, physical and analytical data are as follows. 
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Methyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (8a).  
 
Compound PM mmol g mL 
(S)-Methyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate  
(S-3a). 
395,30 10 3,95  
DBU ( ρ = 1,018 g/mL) 152,24 40 6,09  
DME    50 
 
 
4 h, 3.60 g, 96%; 
• white solid; mp 98-99°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.34 (m, 5H), 6.38 (s, 
1H), 3.93 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -132.5 (m, 1F), -140.1 (m, 
1F), -144 (m, 1F), -147.9 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.0, 144.6 (dt, J = 262.2, 
14.3  Hz), 143.6 (ddd, J = 261.8, 12.4, 3.3 Hz), 141.6 (dt, J = 
262.1, 14.2 Hz), 140.9 (dd, J = 261.6, 12.5 Hz), 135.4, 129.6, 
129.0, 126.2, 121.8 (d, J = 14.3 Hz), 119.6 (d, J = 17.8 Hz), 
69.9, 54.3.  
• IR (nujol) 3280, 1748, 1637, 1512, 1376, 1319, 1257, 1173, 
1035, 914 cm-1. 
• Anal. Calcd. for C15H9F4NO4S: C, 48.01; H, 2.42; N, 3.73. 
Found: C, 47.96; H, 2.44; N, 3.73. 
F
F
F
F
8a, C15H9F4NO4S
MW: 375,29
NH
S
O O
CO2Me
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Ethyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (8b).  
 
Compound PM mmol mg mL 
(R)-Ethyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(S-3b). 
409,33 1 409,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
16 h, 366 mg, 94%; 
• white solid; mp 83.5-84.5°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.43-7.37 (m, 5H), 5.98 (s, 
1H), 4.50-4.08 (m, 2H), 3.93 (t, 3H, J = 6.3  Hz).  
• 19F NMR (282 MHz, CDCl3) δ -132.1 (m, 1F), -139.6 (m, 
1F), -143.8 (m, 1F), -147.5 (m, 1F).  
• IR (nujol) 3245, 1742, 1643, 1518, 1369, 1314, 1252, 1173, 
1033, 909 cm-1. 
• Anal. Calcd. for C16H11F4NO4S: C, 49.36; H, 2.85; N, 
3.60. Found: C, 49.34; H, 2.82; N, 3.59. 
 
F
F
F
F
8b, C16H11F4NO4S
MW: 389,32
NH
S
O O
CO2Et
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Isopropyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (8c).  
 
Compound PM mmol mg mL 
(R)-Isopropyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(S-3c). 
423,36 1 423,4  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
20 h, 379,1 mg, 94%; 
• white solid; mp 95.5-96.5°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.36 (m, 5H), 6.09 (s, 
1H), 5.27-5.18 (m, 1H), 1.34 (d, 3H, J = 6.3  Hz), 1.29 (d, 
3H, J = 6.3  Hz).  
• 19F NMR (282 MHz, CDCl3) δ -131.9 (m, 1F), -139.8 (m, 
1F), -144.0 (m, 1F), -147.7 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.5, 145.2 (dt, J = 261.1, 
14.4  Hz), 144.2 (dd, J = 257.6, 11.6 Hz), 142.1 (dt, J = 
260.7, 14.4 Hz), 141.4 (dd, J = 260.6, 11.7 Hz), 136.2, 129.9, 
129.5, 126.8, 122.5 (d, J = 15.2 Hz), 120.4 (d, J = 17.6 Hz), 
73.5, 70.5, 21.8.  
• IR (nujol) 3229, 1746, 1644, 1523, 1362, 1315, 1256, 1171, 
1033, 920 cm-1. 
• Anal. Calcd. for C17H13F4NO4S: C, 50.62; H, 3.25; N, 
3.47. Found: C, 50.60; H, 3.26; N, 3.45. 
F
F
F
F
8c, C17H13F4NO4S
MW: 403,35
NH
S
O O
CO2Pr
i
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tert-Butyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (8d).  
 
Compound PM mmol mg mL 
(R)-tert-Butyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido)-2-phenylacetate 
(S-3d). 
437,38 1 437,4  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
16 h, 379,8 mg, 91%; 
• white solid; mp 108-109°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.39 (m, 5H), 6.16 (s, 
1H), 1.52 (s, 9H).  
• 19F NMR (282 MHz, CDCl3) δ -132.0 (m, 1F), -140.1 (m, 
1F), -144.4 (m, 1F), -148.1 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 166.4, 146.5-139.1 (4 C-F 
Ar), 136.1, 129.5, 129.1, 125.9, 120.5, 119.5, 86.6, 70.5, 27.9.  
• IR (nujol) 3233, 1745, 1641, 1523, 1363, 1315, 1257, 1171, 
1040, 903 cm-1. 
• Anal. Calcd. for C18H15F4NO4S: C, 51.80; H, 3.62; N, 
3.36. Found: C, 51.81; H, 3.63; N, 3.39. 
F
F
F
F
8d, C18H15F4NO4S
MW: 417,37
NH
S
O O
CO2Bu
t
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Methyl 4,5,6,7-tetrafluoro-3-(3-fluorophenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11a).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(3-fluorophenyl)acetate 
(10a). 
413,29 1 413,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
5 h, 373 mg, 95%; 
• white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.38-7.33 (m, 1H), 7.19-
7.06 (m, 3H), 6.4 (br, 1H), 3.94 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -110.9 (s, 1F), -132.5 (m, 
1F), -139.7 (m, 1F), -143.5 (m, 1F), -147.3 (m, 1F).  
• 13C NMR (125 MHz, CDCl3) δ 168.4, 162.8 (d, J = 247.7 
Hz), 144.9 (dt, J = 262.8, 13.8  Hz), 143.7 (ddd, J = 260.4, 
11.3, 2.5 Hz), 141.9 (dt, J = 262.8, 13.8 Hz), 141.1 (dd, J = 
260.3, 11.3 Hz), 137.8, 130.9 (d, J = 7.5 Hz),  122.2, 121.3 
(dd, J = 14.3, 3.1 Hz), 119.7 (dd, J = 18, 2.5 Hz), 116.9 (d, J 
= 20.1 Hz), 114.0 (d, J = 23.9 Hz),  69.4, 54.8. 
• IR (nujol) 3275, 1752, 1631, 1508, 1376, 1324, 1263, 1175, 
1031, 840 cm-1.  
• Anal. Calcd. for C15H8F5NO4S: C, 45.81; H, 2.05; N, 3.56. 
Found: C, 45.84; H, 2.09; N, 3.52. 
F
F
F
F
11a, C15H8F5NO4S
MW: 393,29
NH
S
O O
CO2Me
F
Synthesis of polyfluorobenzo[d]sultams 
 
178 
 
Methyl 4,5,6,7-tetrafluoro-3-(4-fluorophenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11b).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(4-fluorophenyl)acetate 
(10b). 
413,29 1 413,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
5 h, 385 mg, 98%; 
• white solid; mp 83.5-84.5°C. 
•  1H NMR (300 MHz, CDCl3) δ 7.39-7.33 (m, 2H), 7.10-
7.04 (m, 2H), 6.32 (s, 1H), 3.93 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -111.2 (s, 1F), -132.8 (m, 
1F), -139.6 (m, 1F), -143.5 (m, 1F), -147.3 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.4, 163.7 (d, J = 
249.3Hz), 145.2 (dt, J = 261.1, 14.8  Hz), 144.0 (ddd, J = 
258.3, 12.9, 2.9 Hz), 142.3 (dt, J = 261.1, 14.1 Hz), 141.6 
(dd, J = 258.3, 12.4 Hz), 131.8, 129.0, 122.1 (d, J = 14.3 Hz), 
120.1 (d, J = 17.2 Hz), 116.6 (d, J = 22.3 Hz), 69.8, 55.1.  
• IR (nujol) 3272, 1750, 1635, 1508, 1376, 1321, 1261, 1175, 
1038, 914, 843 cm-1.  
• Anal. Calcd. for C15H8F5NO4S: C, 45.81; H, 2.05; N, 3.56. 
Found: C, 45.82; H, 2.09; N, 3.60. 
F
F
F
F
11b, C15H8F5NO4S
MW: 393,29
NH
S
O O
CO2Me
F
Synthesis of polyfluorobenzo[d]sultams 
 
179 
 
Methyl 4,5,6,7-tetrafluoro-3-(4-chlorophenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11c).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(4-chlorophenyl)acetate 
(10c). 
429,75 1 429,8  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
5 h, 365 mg, 91%; 
• white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.37-7.30 (m, 4H), 6.26 (s, 
1H), 3.94 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -132.7 (m, 1F), -139.5 (m, 
1F), -143.4 (m, 1F), -147.1 (m, 1F).  
• 13C NMR (125 MHz,  CDCl3) δ 167.8, 144.9 (dt, J = 264.1, 
15.1 Hz), 143.7 (ddd, J = 261.6, 12.6, 5.0 Hz), 141.9 (dt, J = 
264.1, 15.1 Hz), 141.2 (dd, J = 261.6, 12.6 Hz), 136.1, 134.0, 
129.4, 127.9, 121.4 (dd, J = 15.1, 3.8 Hz), 119.7 (dd, J = 
17.6, 3.8 Hz), 69.4, 54.8. 
• IR (nujol) 3284, 1739, 1648, 1507, 1379, 1325, 1270, 1185, 
1028, 911 cm-1.  
• Anal. Calcd. for C15H8ClF4NO4S: C, 43.97; H, 1.97; N, 
3.42. Found: C, 44.03; H, 2.00; N, 3.45. 
F
F
F
F
11c, C15H8ClF4NO4S
MW: 409,74
NH
S
O O
CO2Me
Cl
Synthesis of polyfluorobenzo[d]sultams 
 
180 
 
Methyl 4,5,6,7-tetrafluoro-3-(4-bromophenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11d).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(4-bromophenyl)acetate 
(10d). 
474,20 1 474,2  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
  
5 h, 422 mg, 93%; 
• white solid; mp 49-49.5 °C. 
•  1H NMR (300 MHz, CDCl3) δ 7.52-7.49 (m, 2H), 7.27-
7.24 (m, 2H), 5.93 (s, 1H), 3.93 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -132.7 (m, 1F), -139.6 (m, 
1F), -143.5 (m, 1F), -147.2 (m, 1F).  
• 13C NMR (125 MHz, CDCl3) δ 167.8, 144.9 (dt, J = 262.8, 
15.1 Hz), 143.7 (ddd, J = 261.6, 12.6, 3.8 Hz), 141.9 (dt, J = 
262.8, 14.8 Hz), 141.1 (dd, J = 261.6, 12.6 Hz), 134.6, 132.3, 
128.1, 124.1, 121.4 (dd, J = 14.6, 3.3 Hz), 119.7 (dd, J = 
18.2, 2.9 Hz), 69.5, 54.8. 
• IR (nujol) 3276, 1738, 1630, 1518, 1361, 1302, 1257, 1174, 
1044, 906 cm-1.  
• Anal. Calcd. for C15H8BrF4NO4S: C, 39.67; H, 1.78; N, 
3.08. Found: C, 39.61; H, 1.72; N, 3.13. 
F
F
F
F
11d, C15H8BrF4NO4S
MW: 454,19
NH
S
O O
CO2Me
Br
Synthesis of polyfluorobenzo[d]sultams 
 
181 
 
Methyl 4,5,6,7-tetrafluoro-3-(4-tolyl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (11e).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(4-tolyl)acetate (10e). 
409,33 1 409,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
6 h, 385 mg, 99%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.24-7.17 (m, 4H), 6.32 (s, 
1H), 3.93 (s, 3H), 2.34 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -132.4 (m, 1F), -140.1 (m, 
1F), -144.0 (m, 1F), -147.9 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.2, 144.6 (dt, J = 276.7, 
15.8 Hz), 143.7 (dd, J = 261.9, 12.1 Hz), 141.6 (dm, J = 
276.5 Hz), 141.1 (dd, J = 261.9, 12.8 Hz), 140.0, 132.5, 
129.8, 126.2, 122.1 (d, J = 11.2 Hz), 119.8 (d, J = 15.4 Hz), 
69.8, 54.4, 21.0.  
• IR (nujol) 3238, 1720, 1509, 1391, 1355, 1324, 1294, 1189, 
1169, 1061, 1039, 911 cm-1.  
• Anal. Calcd. for C16H11F4NO4S: C, 49.36; H, 2.85; N, 
3.60. Found: C, 49.32; H, 2.88; N, 3.62. 
F
F
F
F
11e, C16H11F4NO4S
MW: 389,32
NH
S
O O
CO2Me
Me
Synthesis of polyfluorobenzo[d]sultams 
 
182 
 
Methyl 4,5,6,7-tetrafluoro-3-(3-metoxyphenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11f).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(3-metoxyphenyl)acetate 
(10f). 
425,33 1 425,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
6 h, 397 mg, 98%; 
• white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.32-7.27 (m, 1H), 6.93-
6.90 (m, 3H), 6.32 (s, 1H), 3.93 (s, 3H), 3.76 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -132.0 (m, 1F), -140.1 (m, 
1F), -143.9 (m, 1F), -147.8 (m, 1F). 
• 13C NMR (75 MHz, CDCl3) δ 169.9, 160.0, 144.7 (dt, J = 
261.7, 14.3 Hz), 143.8 (dd, J = 262.5, 12.1 Hz), 141.7 (dt, J = 
261.6, 14.3 Hz), 141.1 (dd, J = 262.5, 12.0 Hz), 136.9, 130.2, 
121.7 (d, J = 11.3 Hz), 119.7 (d, J = 14.2 Hz), 118.4, 114.7, 
112.7, 69.8, 55.3, 54.5.  
• IR (nujol) 3261, 1748, 1603, 1455, 1436, 1358, 1326, 1261, 
1177, 1047, 909 cm-1.  
• Anal. Calcd. for C16H11F4NO5S: C, 47.41; H, 2.74; N, 
3.46. Found: C, 47.44; H, 2.77; N, 3.42. 
F
F
F
F
11f, C16H11F4NO5S
MW: 405,32
NH
S
O O
CO2Me
OMe
Synthesis of polyfluorobenzo[d]sultams 
 
183 
 
Methyl 4,5,6,7-tetrafluoro-3-(4-metoxyphenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11g).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(4-metoxyphenyl)acetate 
(10g). 
425,33 1 425,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
8 h, 385 mg, 95%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.26-7.23 (m, 2H), 6.88-
6.85 (m, 2H), 5.9 (s, 1H), 3.91 (s, 3H), 3.78 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -132.7 (m, 1F), -140.2 (m, 
1F), -144.1 (m, 1F), -148.1 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.2, 160.5, 144.7 (dt, J = 
264.2, 14.3 Hz), 143.7 (dd, J = 261.9, 12.1 Hz), 141.6 (dt, J = 
264.2, 14.4 Hz), 140.9 (dd, J = 261.9, 12.1 Hz), 127.7, 127.2, 
122.2 (J = 13.6 Hz), 119.8 (d, J = 17.4 Hz), 114.1,  69.7, 55.3, 
54.4.  
• IR (nujol) 3270, 1750, 1600, 1458, 1436, 1352, 1326, 1258, 
1170, 1050, 912 cm-1.  
• Anal. Calcd. for C16H11F4NO5S: C, 47.41; H, 2.74; N, 
3.46. Found: C, 47.44; H, 2.77; N, 3.42. 
F
F
F
F
11g, C16H11F4NO5S
MW: 405,32
NH
S
O O
CO2Me
MeO
Synthesis of polyfluorobenzo[d]sultams 
 
184 
 
Methyl 4,5,6,7-tetrafluoro-3-(4-benzyloxyphenyl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11h).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(4-benzyloxyphenyl) 
acetate (10h). 
501,42 1 501,4  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
12 h, 390 mg, 81%; 
• white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.33 (m, 5H), 7.31-
7.25 (m, 2H), 7.00-6.96 (m, 2H), 6.13 (s, 1H), 5.06 (s, 1H), 
3.93 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -132.5 (m, 1F), -140.0 (m, 
1F), -143.9 (m, 1F), -147.9 (m, 1F). 
• IR (nujol) 3284, 1739, 1645, 1508, 1371, 1304, 1255, 1170, 
1022, 906 cm-1.  
• Anal. Calcd. for C22H15F4NO5S: C, 54.89; H, 3.14; N, 
2.91. Found: C, 54.92; H, 3.06; N, 2.88. 
F
F
F
F
11h, C22H15F4NO5S
MW: 481,42
NH
S
O O
CO2Me
BnO
Synthesis of polyfluorobenzo[d]sultams 
 
185 
 
Methyl 4,5,6,7-tetrafluoro-3-(thiophen-3-yl)-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (11i).  
 
Compound PM mmol mg mL 
rac-Methyl 2-(2,3,4,5,6-pentafluorophenyl 
sulfonamido)-2-(thiophen-3-yl)acetate 
(10i). 
401,33 0,4 160  
DBU ( ρ = 1,018 g/mL) 152,24 1,6 243,6  
DME    2 
 
 
8 h, 134 mg, 88%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.45 (d, 1H, J = 3.5 Hz), 
7.34 (dd, 1H, J = 5.2, 3.5 Hz), 7.12 (d, 1H, J = 5.2 Hz), 5.3 
(s, 1H), 3.92 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -133.2 (m, 1F), -139.7 (m, 
1F), -143.8 (m, 1F), -147.8 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.8, 146. (dt, J = 264.8, 
13.9 Hz), 143.6 (dd, J = 261.5, 11.5 Hz), 141.7 (dt, J = 264.7, 
13.9 Hz), 141.0 (dd, J = 261.4, 11.6 Hz), 135.8, 127.5, 125.8, 
124.9, 122.1, 119.3, 66.9, 54.7.  
• IR (nujol) 3280, 1753, 1639, 1499, 1378, 1318, 1248, 1172, 
1032, 912, 840 cm-1.  
• Anal. Calcd. for C13H7F4NO4S2: C, 40.95; H, 1.85; N, 
3.67. Found: C, 40.99; H, 1.88; N, 3.70. 
F
F
F
F
11i, C13H7F4NO4S2
MW: 381,32
NH
S
O O
CO2Me
S
Synthesis of polyfluorobenzo[d]sultams 
 
186 
 
Methyl 7-bromo-4,5,6-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (31a).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2-Bromo-3,4,5,6-tetrafluoro 
phenylsulfonamido)-2-phenylacetate 
(30a). 
456,94 1 456,9  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
24 h, 383,9 mg, 88%; 
• pale yellow solid; mp 62.5-63.5°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.40-7.34 (m, 5H), 6.24 (s, 
1H), 3.93 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -120.2 (m, 1F), -128.3 (m, 
1F), -146.2 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.6, 151.0 (dt, J = 256.6, 
13.1  Hz), 147.4 (dm, J = 262.0 Hz), 144.1 (dt, J = 262.2, 
16.3 Hz), 136.1, 131.1, 130.2, 129.6, 126.8, 124.5 (d, J = 14.4 
Hz), 99.9 (d, J = 19.3 Hz), 69.0, 55.0.  
• IR (nujol) 3237, 1743, 1644, 1522, 1367, 1310, 1251, 1170, 
1037, 925 cm-1. 
• Anal. Calcd. for C15H9BrF3NO4S: C, 41.30; H, 2.08; N, 
3.21. Found: C, 41.32; H, 2.08; N, 3.22. 
Br
F
F
F
31a, C15H9BrF3NO4S
MW: 436,20
NH
S
O O
CO2Me
Synthesis of polyfluorobenzo[d]sultams 
 
187 
 
Methyl 5-bromo-4,6,7-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (31b).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(4-Bromo-2,3,5,6-tetrafluoro 
phenylsulfonamido)-2-phenylacetate 
(30b). 
456,94 1 456,9  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
24 h, 401,3 mg, 92%; 
• pale yellow solid; mp 116-118°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.39-7.36 (m, 5H), 6.55 
(br, 1H), 3.91 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -103.8 (m, 1F), -119.6 (m, 
1F), -141.5 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.1, 151.2 (d, J = 258.2  
Hz), 149.3 (dd, J = 256.9, 13.5 Hz), 140.4 (dd, J = 256.5, 
12.5 Hz), 135.4, 129.6, 129.0, 126.3, 124.4, 121.3 (d, J = 19.2 
Hz), 107.0 (t, J = 23.9 Hz), 69.8, 54.3.  
• IR (nujol) 3232, 1744, 1643, 1529, 1365, 1312, 1251, 1175, 
1033, 926 cm-1. 
• Anal. Calcd. for C15H9BrF3NO4S: C, 41.30; H, 2.08; N, 
3.21. Found: C, 41.32; H, 2.09; N, 3.22. 
F
Br
F
F
31b, C15H9BrF3NO4S
MW: 436,20
NH
S
O O
CO2Me
Synthesis of polyfluorobenzo[d]sultams 
 
188 
 
Methyl 4,5,7-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (31c).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,6-tetrafluoro 
phenylsulfonamido)-2-phenylacetate 
(30c). 
377,31 1 377,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
160 h, 107,2 mg, 30%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.46 (dt, J = 6.4, 1.9 Hz), 
7.41-7.34 (m, 5H), 5.94 (s, 1H), 3.95 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -125.1 (m, 1F), -127.2 (m, 
1F), -149.3 (m, 1F).  
• IR (nujol) 3245, 1741, 1634, 1523, 1377, 1321, 1256, 1168, 
1043, 911 cm-1.. 
• Anal. Calcd. for C15H10F3NO4S: C, 50.42; H, 2.82; N, 
3.92. Found: C, 50.44; H, 2.86; N, 3.94. 
F
F
31c, C15H10F3NO4S
MW: 357,30
NH
S
O O
CO2Me
F
Synthesis of polyfluorobenzo[d]sultams 
 
189 
 
Methyl 4,5,7-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (31d).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,3,4,6-tetrafluoro 
phenylsulfonamido)-2-phenylacetate 
(30d). 
377,31 1 377,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
20 h, 328,7 mg, 92%; 
• white solid; mp 207.5-209.5°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.39 (m, 5H), 7.21-
7.14 (m, 1H), 5.95 (s, 1H), 3.95 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -115.8 (m, 1F), -122.6 (m, 
1F), -137.6 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.3, 154.6 (dm, J = 247.5 
Hz), 151.3 (dm, J = 247.5 Hz), 142.1 (dd, J = 262.5, 15.0 
Hz), 135.8, 129.7, 129.2, 127.2, 126.4, 119,5, 108.9 (t, J = 
30.0 Hz), 70.2, 54.5. 
• IR (nujol) 3241, 1746, 1631, 1521, 1380, 1318, 1254, 1171, 
1038, 909 cm-1.. 
• Anal. Calcd. for C15H10F3NO4S: C, 50.42; H, 2.82; N, 
3.92. Found: C, 50.39; H, 2.82; N, 3.93. 
F
F
F
31d, C15H10F3NO4S
MW: 357,30
NH
S
O O
CO2Me
Synthesis of polyfluorobenzo[d]sultams 
 
190 
 
Methyl 7-Bromo-4,5-difluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (31e).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2-Bromo-4,5,6-trifluoro 
phenylsulfonamido)-2-phenylacetate 
(30e). 
438,21 1 438,2  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
24 h, 384,7 mg, 92%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.58 (dd, J = 8.7, 2.9 Hz), 
7.38-7.35 (m, 5H), 6.16 (s, 1H), 3.93 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -126.4 (m, 1F), -133.9 (m, 
1F).  
• 13C NMR (75 MHz, CDCl3) δ 168.2, 153.5 (dd, J = 259.4, 
12.7 Hz), 146.2 (dd, J = 261.4, 14.2 Hz), 135.8, 132.0, 129.2, 
129.0, 126.4, 125.8, 124.6 (d, J = 21.9 Hz), 110.1 (t, J = 4.1 
Hz), 68.5, 54.4. 
• Anal. Calcd. for C15H10BrF2NO4S: C, 43.08; H, 2.41; N, 
3.35. Found: C, 43.09; H, 2.38; N, 3.36. 
Synthesis of polyfluorobenzo[d]sultams 
 
191 
 
Methyl 5,7-difluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (31f).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2,4,6-trifluoro 
phenylsulfonamido)-2-phenylacetate 
(30f). 
359,32 1 359,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
30 h, 244,4 mg, 72%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.37 (m, 5H), 7.24 
(dd, 1H, J = 8.3, 1.9  Hz), 7.00 (dt, 1H, J = 8.3, 2.0 Hz), 6.18 
(s, 1H), 3.93 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -98.6 (m, 1F), -110.1 (m, 
1F).  
• IR (nujol) 3246, 1741, 1639, 1518, 1380, 1315, 1261, 1169, 
1034, 905 cm-1. 
• Anal. Calcd. for C15H11F2NO4S: C, 53.10; H, 3.27; N, 
4.13. Found: C, 53.08; H, 3.25; N, 4.13. 
F
F
31f, C15H11F2NO4S
MW: 339,31
NH
S
O O
CO2Me
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Methyl 7-bromo-5-fluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (31g).  
 
Compound PM mmol mg mL 
(S)-Methyl 2-(2-Bromo-4,6-
difluorophenyl sulfonamido)-2-
phenylacetate (30g). 
420,23 1 420,2  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
24 h, 256,1 mg, 64%; 
• white solid; mp 119-120°C. 
• 1H NMR (300 MHz, CDCl3) δ 7.45 (dd, 1H, J = 7.9, 2.1 
Hz), 7.38-7.36 (m, 6H), 6.14 (s, 1H), 3.93 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -102.2 (m, 1F).  
• Anal. Calcd. for C15H11BrFNO4S: C, 45.02; H, 2.77; N, 
3.50. Found: C, 45.03; H, 2.80; N, 3.52. 
Br
F
31g, C15H11BrFNO4S
MW: 400,22
NH
S
O O
CO2Me
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tert-Butyl 7-bromo-5-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (52).  
 
Compound PM mmol mg mL 
(R)-tert-butyl 2-(2-Bromo-4,6-
difluorophenyl phenylsulfonamido)-2-
phenylacetate (50). 
462,31 1 462,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
24 h, 265,4 mg, 60%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.45 (dd, 1H, J = 7.8, 
2.2Hz), 7.40-7.34 (m, 6H), 6.25 (s, 1H), 1.50 (s, 9H). 
• 19F NMR (282 MHz, CDCl3) δ -102.6 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.4, 165.0 (d, J = 257.3  
Hz), 143.5 (d, J = 9.5 Hz), 138.7, 132.3, 129.6, 129.5, 126.6, 
122.8 (d, J = 26.0 Hz), 117.3 (d, J = 10.3 Hz), 114.0 (d, J = 
25.1 Hz), 86.9, 69.9, 28.4.  
• Anal. Calcd. for C18H17BrFNO4S: C, 48.88; H, 3.87; N, 
3.17. Found: C, 48.85; H, 3.85; N, 3.16. 
Br
F
Number, C18H17BrFNO4S
MW: 442,30
NH
S
O O
CO2Bu
t
Synthesis of polyfluorobenzo[d]sultams 
 
194 
 
Diethyl 4,5,6,7-tetrafluoro-2,3-dihydrobenzo[d]isothiazole-3,3-dicarboxylate 1,1-
dioxide (25).  
 
 
 
Compound PM mmol mg mL 
Diethyl 2-(2,3,4,5,6-pentafluoro 
phenylsulfonamido) malonate (23). 
405,29 1 405,3  
DBU ( ρ = 1,018 g/mL) 152,24 4 609  
DME    5 
 
 
20 h, 258,1 mg, 67%; 
• white solid; mp 87-89°C. 
• 1H NMR (200 MHz, CDCl3) δ 6.23 (s, 1H), 4.38 (dq, 4H, J = 7.2, 1.9 Hz), 1.33 (t, 
6H, J = 7.1 Hz). 
• 19F NMR (282 MHz, CDCl3) δ -131.6 (m, 1F), -139.4 (m, 1F), -143.5 (m, 1F), -146.2 
(m, 1F).  
• 13C NMR (50 MHz, CDCl3) δ 164.2, 144.9 (dt, J = 260.7, 14.7 Hz), 144.0 (dd, J = 
264.2, 9.6 Hz), 142.2 (dt, J = 261.5, 14.1 Hz), 141.1 (dd, J = 258.6, 12.3 Hz), 120.0 (d, J 
= 17.9 Hz), 117.3 (d, J = 14.3 Hz), 67.8, 64.7, 15.0.  
• IR (nujol) 3255, 1751, 1635, 1493, 1375, 1323, 1251, 1176, 1036, 918, 838 cm-1.  
• Anal. Calcd. for C13H11F4NO6S2: C, 40.53; H, 2.88; N, 3.64. Found: C, 40.54; H, 
2.87; N, 3.65. 
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Ring Closing Reactions of N-Alkylsulfonamides 7a,b under 
Homogeneous Conditions: General Procedure. 
 
 
To a solution of N-alkyl-sulfonamide (0.2 mmol) in dry Acetonitrile (0,8 mL) at 25 °C, 
DBU (1 mmol) in Acetonitrile (0,2 mL) was added and the mixture was stirred at 25 
°C until completion (TLC control). The solution was then diluted with AcOEt (10 
mL), washed with aqueous 5% citric acid (3×10 mL), saturated NaHCO3 solution 
(2×10 mL), and brine (10 mL). The organic phase was dried over MgSO4, filtered, and 
concentrated under reduced pressure (RV) Starting sulfonamides, reaction time, 
product, yield are as follows. 
 
 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4a). 
 
Starting sulfonamide 7a, 82 mg; 
sultam 4a, 47,4 mg, 61%,  
MPLC (AcOEt : hexane – 1 : 12). 
 
 
 
 
 
 
F
F
F
F
N
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CO2Me
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Methyl 4,5,6,7-tetrafluoro-2-benzyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4b). 
 
 
Starting sulfonamide 7b, 97 mg;  
sultam 4b, 42 mg, 45%, 
MPLC (AcOEt : esano – 1 : 12). 
 
F
F
F
F
N
S
O O
CO2Me
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N-Alkylation of Benzo[d]sultams 8a; 31a,b,d-g and 25: General 
Procedure.  
 
X1
X3
X4
CH3CN, 25°C
X2
1) K2CO3, TEBA
2) R'X
N
S
O O
Aryl CO2R
X1
X3
X4
X2
NH
S
O O
Aryl CO2R
R'
 
 
To a solution of sultam (0,25 mmol) and TEBA (5,7 mg, 0,025 mmol) in dry 
acetonitrile (1 mL) at 25 °C, anhydrous potassium carbonate (51,8 mg, 0,375 mmol) 
was added. The resulting heterogeneous mixture was stirred for 10 min, then the 
alkylating agent R’X (0,375 mmol) was added and the reaction was monitored by 
TLC until completion. The mixture was filtered through a celite pad and, after 
evaporation of the solvent (RV), the crude was purified by FCC. Starting sulfonamide 
and alkylating agent (RX), reaction time, product, yield and eluant are as follows. 
 
 
 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carbossilate 1,1-dioxide (4a). 
 
Starting sultam 8a, 93,8 mg; MeI, 53,2 mg; 
sultam 4a, 142 mg, 91%,  
MPLC (AcOEt : hexane – 1 : 12). 
 
 
  
F
F
F
F
N
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Synthesis of polyfluorobenzo[d]sultams 
 
198 
 
Methyl 4,5,6,7-tetrafluoro-2-ethyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4d). 
 
Starting sultam 8a, 93,8 mg; EtI, 58,5 mg; 
sultam 4d, 87,2 mg, 95%, 
MPLC (AcOEt : esano – 1 : 12). 
 
 
Methyl 4,5,6,7-tetrafluoro-2-n-propyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4e). 
 
Starting sultam 8a, 93,8 mg; n-PrI, 63,7 mg; 
sultam 4e, 83,9 mg, 88%, 
MPLC (AcOEt : esano – 1 : 12). 
 
 
Methyl 4,5,6,7-tetrafluoro-2-n-butyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4f). 
 
Starting sultam 8a, 93,8 mg; n-BuI, 69,2 mg; 
sultam 4f, 88,4 mg, 82%, 
MPLC (AcOEt : esano – 1 : 12). 
 
  
F
F
F
F
N
S
O O
CO2Me
Et
4d
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F
F
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Methyl 4,5,6,7-tetrafluoro-2-allyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4c). 
 
Starting sultam 8a, 93,8  mg,; AllBr, 45,4 mg; 
sultam 4c, 85,1 mg, 82%, 
MPLC (AcOEt : esano – 1 : 9). 
 
 
Methyl 4,5,6,7-tetrafluoro-2-benzyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4b). 
 
Starting sultam 8a, 93,8 mg; BnBr, 64,1 mg; 
sultam 4b, 116,3 mg, 80%, 
MPLC (AcOEt : esano – 1 : 9). 
 
 
Methyl 7-bromo-4,5,6-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-
3-carbossilate 1,1-dioxide (35a). 
 
Starting sultam 31a, 109 mg; MeI, 53,2 mg; 
sultam 35a, 106,2 mg, 94%, 
MPLC (AcOEt : hexane – 1 : 9). 
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Methyl 5-bromo-4,6,7-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-
3-carbossilate 1,1-dioxide (36). 
 
Starting sultam 31b, 109 mg; MeI, 53,2 mg; 
sultam 36, 101,3 mg, 90%,  
MPLC (AcOEt : hexane – 1 : 9). 
 
 
Methyl 4,5,7-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carbossilate 1,1-dioxide (32). 
 
Starting sultam 31d, 89,3 mg; MeI, 53,2 mg; 
sultam 32, 85,4 mg, 92%,  
MPLC (AcOEt : hexane – 1 : 9). 
 
 
Methyl 5,7-difluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carbossilate 1,1-dioxide (33). 
 
Starting sultam 31f, 93,3 mg; MeI, 53,2 mg; 
sultam 33, 65,4 mg, 74%,  
MPLC (AcOEt : hexane – 1 : 12). 
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Methyl 7-bromo-5-fluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carbossilate 1,1-dioxide (34). 
 
Starting sultam 31g, 84,8 mg; MeI, 53,2 mg; 
sultam 34, 72,4 mg, 82%,  
MPLC (AcOEt : hexane – 1 : 12). 
 
 
Diethyl 4,5,6,7-tetrafluoro-2-methyl-2,3-dihydrobenzo[d]isothiazole-3,3-
dicarboxylate 1,1-dioxide (24a).  
 
Starting sultam 25, 96,3 mg; MeI, 53,2 mg; 
sultam 24a, 82,8 mg, 86%,  
• FCC - AcOEt/hexane (1 : 9).  
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Diethyl 4,5,6,7-tetrafluoro-2-allyl-2,3-dihydrobenzo[d]isothiazole-3,3-dicarboxylate 
1,1-dioxide (24b). 
 
Starting sultam 25, 96,3 mg  
• 24 h, 101 mg, 95%;  
• FCC - AcOEt/hexane (1 : 9), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 5.92-5.81 (m, 1H), 5.32 
(dd,1H, J = 16.9, 1.1 Hz), 5.21 (dd,1H, J = 10.3, 1.1 Hz), 
4.31-4.23 (m, 6H), 1.29 (t, 6H, J = 7.1). 
• 19F NMR (282 MHz, CDCl3) δ -133.1 (m, 1F), -139.8 (m, 
1F), - 144.8 (m, 1F), -147.4 (m, 1F).   
• Anal. Calcd. for C16H15F4NO6S: C, 45.18; H, 3.55; N, 
3.29. Found: C, 45.19; H, 3.55; N, 3.27. 
 
Diethyl 4,5,6,7-tetrafluoro-2-benzyl-2,3-dihydrobenzo[d]isothiazole-3,3-
dicarboxylate 1,1-dioxide (24c). 
 
Starting sultam 25, 96,3 mg  
• 20 h, 83,2 mg, 70%;  
• FCC - AcOEt/hexane (1 : 9), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.39-7.38 (m, 2H), 7.36-
7.27 (m, 3H), 4.87 (s, 2H), 4.04-3.91 (m, 4H), 1.45 (t, 6H, J 
= 7.1).  
• 19F NMR (282 MHz, CDCl3) δ -133.0 (m, 1F), -139.9 (m, 
1F), - 144.9 (m, 1F), -147.6 (m, 1F).   
• Anal. Calcd. for C16H13BrFNO4S: C, 50.53; H, 3.60; N, 
2.95. Found: C, 50.51; H, 3.59; N, 2.94. 
F
F
F
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24b, C16H15F4NO6S
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SL-PTC ‘One-Pot’ Synthesis of N-Alkyl-benzo[d]sultams 48a-c: General 
Procedure. 
 
 
 
To a solution of sulfonamide and TEBA in dry DMSO at 25 °C, anhydrous potassium 
carbonate was added. The resulting heterogeneous mixture was stirred for 10 min, 
then the alkylating agent RX was added and the reaction was monitored by TLC 
(AcOEt : hexane – 1 : 6) until completion. The mixture was diluted with water and 
extracted with DCM and concentrated; the residue was diluted with AcOEt (10 mL) 
and washed with brine (5×10 mL), dried over MgSO4 and filtered. After evaporation 
of the solvent (RV), the crude was purified by FCC. 
Starting alkylating agent (RX), reaction time, product, yield, eluant, physical and 
analytical data are as follows. 
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Methyl 4,5,6,7-tetrafluoro-2-methyl-3-oxo-1-phenylisoindoline-1-carboxylate (48a).  
 
Compound PM mmol mg mL 
(S)-methyl 2-(perfluorobenzamido)-2-
phenylacetate (47). 
359,27 1 359,3  
Potassium carbonate 138,21 2,5 345,8  
Triethylbenzyl ammonium chloride 227,81 0,2 45,6  
Methyl Iodide 141,94 1,5 291,6  
DMSO    4 
 
 
• 26 h, 279 mg, 79%;  
• FCC - AcOEt/hexane (1 : 12), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.39-7.37 (m, 3H), 7.12-
7.09 (m, 2H), 3.87 (s, 3H), 2.95 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -138.6 (m, 1F), -143.3 (m, 
1F), - 147.9 (m, 1F), -152.1 (m, 1F).   
• 13C NMR (75 MHz, CDCl3) δ 167.2, 162.5, 143.4 (dt, J = 
257.6, 14.6 Hz), 143.1 (dd, J = 262.4, 13.1 Hz), 142.5 (dd, J 
= 256.4, 9.1 Hz), 141.4 (dt, J = 255.2, 13.9 Hz), 132.7, 129.3, 
129.1, 128.9, 127.3 (d, J = 12.2 Hz), 126.5, 114.2 (t, J = 11.2 
Hz), 73.3, 53.3, 26.7. 
• IR (nujol) 1742, 1703, 1514, 1429, 1400, 1252, 1094, 1026, 
5 746, 693 cm-1.  
• Anal. Calcd. for C16H13BrFNO4S: C, 46.39; H, 3.16; N, 
3.38. Found: C, 46.38; H, 3.17; N, 3.37. 
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Methyl 4,5,6,7-tetrafluoro-2-allyl-3-oxo-1-phenylisoindoline-1-carboxylate (48b).  
 
Compound PM mmol mg mL 
(S)-methyl 2-(perfluorobenzamido)-2-
phenylacetate (47). 
420,23 0,25 89,8  
Potassium carbonate 138,21 0,5 76,2  
Triethylbenzyl ammonium chloride 227,81 0,05 11,4  
Allyl Bromide 104,03 0,375 40  
DMSO    1 
 
 
• 20 h, 53 mg, 56%; 
• FCC - AcOEt/hexane (1 : 8), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.44-7.42 (m, 3H), 7.24-
7.21 (m, 2H), 5.75-5.65 (m, 1H), 5.08 (s, 1H), 5.03 (d, J = 
7.5 Hz), 4.28 (dd, J = 15.3, 4.5 Hz), 3.92 (dd, J = 15.8, 6.3 
Hz), 3.86 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -138.4 (m, 1F), -142.9 (m, 
1F), - 147.7 (m, 1F), -152.0 (m, 1F).   
• IR (nujol) 1747, 1718, 1500, 1435, 1392, 1249, 1095, 1024, 
993, 746, 698 cm-1.  
 
F
F
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F
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48b, C19H13F4NO3
MW: 379,31
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Methyl 4,5,6,7-tetrafluoro-2-allyl-3-oxo-1-phenylisoindoline-1-carboxylate (48c).  
 
Compound PM mmol mg mL 
(S)-methyl 2-(perfluorobenzamido)-2-
phenylacetate (47). 
420,23 0,25 89,8  
Potassium carbonate 138,21 0,5 76,2  
Triethylbenzyl ammonium chloride 227,81 0,05 11,4  
Benyl Bromide  0,375 64,2  
DMSO     
 
 
• 20 h, 43,3 mg, 40%;  
• FCC - AcOEt/hexane (1 : 9), white wax.  
• 1H NMR (300 MHz, CDCl3) δ 7.46-7.42 (m, 3H), 7.25-
7.22 (m, 5H), 7.15-7.12 (m, 2H), 5.12 (d, J = 15.6 Hz), 4.40 
(d, J = 15.6 Hz), 3.40 (s, 3H).  
• 19F NMR (282 MHz, CDCl3) δ -138.4 (m, 1F), -143.1 (m, 
1F), - 147.6 (m, 1F), -151.9 (m, 1F).   
• IR (nujol) 1753, 1724, 1513, 1429, 1247, 1022, 993, 727, 
697 cm-1.  
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Methyl 5-(2,2,2-trifluoroacetamido)-4,6,7-trifluoro-2-methyl-3-phenyl-2,3-
dihydrobenzo [d] isothiazole-3-carboxylate 1,1-dioxide (37). 
 
 
Compound PM mmol mg mL 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-
phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4a). 
389,33 0,3 117  
CF3CONH2 113,04 0,3 34  
K2CO3 138,21 0,6 83  
Triethyl benzylammonium chloride 227,81 0,03 7  
Acetonitrile    0,3 
 
To a solution of N-methyl-sultam in dry acetonitrile the base, TEBA and the trifluoro 
acetamide were added and the resulting suspension was heated under magnetical 
stirring monitoring by TLC (AcOEt : hexane – 1 : 5) until completion, then quenched 
with few drop of a saturate NH4Cl solution. The solvent was removed under vacuum 
(RV) and the crude was purified by flash column chromatography. 
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43 h, 130 mg, 90%; 
• FCC - AcOEt/hexane (1 : 7), white solid, mp 191-193 °C  
• 1H NMR (300 MHz, CDCl3) δ 7.41-7.37 (m, 3H), 7.34-7.24 (m, 2H), 3.90 (s, 3H), 
2.82 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -75.5 (s, 3F), -117.4 (m, 1F), -131.3 (m, 1F), -141.9 (m, 
1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.3, 155.7 (t, J = 38.6 Hz), 149.3 (d, J = 260.0 Hz), 
147.2 (dd, J = 260.3, 13.1 Hz), 140.9 (dd, J = 256.4, 14.1 Hz), 133.3, 130.1, 129.5, 127.9, 
122.4 (d, J = 17.3 Hz), 121.7 (d, J = 11.7 Hz), 119.8 (t, J = 16.7 Hz), 115.9 (q, J = 285.4 
Hz), 72.2, 54.1, 25.7. 
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Methyl 5-metoxy-4,6,7-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo 
[d]isothiazole-3-carboxylate 1,1-dioxide (38). 
 
 
Compound PM mmol mg mL 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-
phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4a). 
389,33 0,2 77,8  
MeONa 54,03 0,2 11,1  
DME    0,3 
MeOH    0,5 
 
To a solution of N-methyl-sultam in dry DME at -78 °C, a solution of MeONa in 
MeOH was added under magnetical stirring. This mixture was monitored by TLC 
(AcOEt : hexane – 1 : 7) until completion, then warmed to room temperature and 
quenched with few drop of a saturate NH4Cl solution. The solvent was removed 
under vacuum (RV) to give the crude product without any further purification. 
 
4 h, 60 mg, 75%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.40-7.25 (m, 5H), 4.04 (t, 3H, J = 17.5 Hz), 3.89 (s, 
3H), 2.81 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -131.1 (m, 1F), -142.4 (m, 1F), -146.2 (m, 1F).  
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Methyl 5,7-dialkoxy-4,6-difluoro-2-methyl-3-phenyl-2,3-dihydrobenzo 
[d]isothiazole-3-carboxylate 1,1-dioxide (39a,b). 
Methyl 5,7-dimetoxy-4,6-difluoro-2-methyl-3-phenyl-2,3-dihydrobenzo 
[d]isothiazole-3-carboxylate 1,1-dioxide (39a). 
 
 
Compound PM mmol mg mL 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-
phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4a). 
389,33 0,2 77,8  
MeONa 54,03 0,4 22,2  
DME    0,5 
 
To a solution of N-methyl-sultam in dry DME MeONa was added and the resulting 
mixture was stirred monitoring by TLC (AcOEt : hexane – 1 : 5) until completion, 
then quenched with few drop of a saturate NH4Cl solution. The solvent was removed 
under vacuum (RV) to give the crude product without any further purification. 
 
20 h, 67,8 mg, 82%; 
• white wax. 
• 1H NMR (300 MHz, CDCl3) δ 7.37-7.25 (m, 5H), 4.16 (s, 3H), 3.98 (s, 3H), 3.87 (s, 
3H), 2.80 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -139.0 (m, 1F), -147.5 (m, 1F).  
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Methyl 5,7-phenoxy-4,6-difluoro-2-methyl-3-phenyl-2,3-dihydrobenzo [d]isothiazole-
3-carboxylate 1,1-dioxide (39b) 
 
24 h, 98,9 mg, 92%; 
• white wax  
• 1H NMR (300 MHz, CDCl3) δ 7.40-6.83 (m, 15H), 3.92 
(s, 3H), 2.86 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -111.2 (m, 1F), -117.1 (m, 
1F).  
 
OPh
PhO
F
39b, C28H21F2NO6S
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Methyl 5-(oct-1-inyl)-4,6,7-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo 
[d]isothiazole-3-carboxylate 1,1-dioxide (40b). 
 
 
Compound PM mmol mg mL 
Methyl 5-Bromo-4,6,7-trifluoro-2-methyl-
3-phenyl-2,3-dihydrobenzo[d]isothiazole-
3-carboxylate 1,1-dioxide (36). 
450,23 0,2 90,1  
1-Octine 110,20 0,3 33,1  
PdCl2(PPh4)2 701,90 0,01 7  
CuI 190,45 0,01 2  
Diisopropyl amine    1 
THF    1 
 
To a degased solution of the sultam and the amine in dry THF was added the alkyne 
and the catalyst, was heated under magnetical stirring monitoring by TLC (AcOEt : 
hexane – 1 : 4) until completion. The mixture is then cooled and filtered through a celite 
pad then, anidrifyed over MgSO4 and the solvent was removed under vacuum (RV); the 
crude was purified by flash column chromatography to give the desired compound. 
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7 h, 39,3 mg, 41%; 
• FCC - AcOEt/hexane (1 : 8), yellow wax  
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.38 (m, 3H), 7.28-7.25 (m, 2H), 3.89 (s, 3H), 
2.82 (s, 3H), 2.44 (t, 2H, J = 7.1 Hz), 1.62-1.53 (m, 2H), 1.45-1.41 (m, 2H), 1.39-1.24 
(m, 4H), 0.88-0.84 (m, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -110.4 (m, 1F), -126.5 (m, 1F), -144.5 (m, 1F).  
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Methyl 7-Phenyl-4,5,6-trifluoro-2-methyl-3-phenyl-2,3-dihydrobenzo 
[d]isothiazole-3-carboxylate 1,1-dioxide (43). 
 
 
Compound PM mmol mg mL 
Methyl 7-Bromo-4,5,6-trifluoro-2-methyl-
3-phenyl-2,3-dihydrobenzo[d]isothiazole-
3-carboxylate 1,1-dioxide (35a). 
436,13 0,2 87,3  
Phenylboronic acid 121,03 0,325 39,3  
Pd(PPh3)4 1155 0,033 37,5  
CsF 151,9 0,433 65,8  
DME    1,2 
 
A solution of the sultam, the boronic acid and cesium fluoride in dry DME, was 
degased with Argon and, after adding the catalyst, was heated under magnetical 
stirring monitoring by TLC (AcOEt : hexane – 1 : 9) until completion. The mixture is 
then cooled and filtered through a celite pad then, anidrifyed over MgSO4 and the 
solvent was removed under vacuum (RV); the crude was purified by flash column 
chromatography to give the desired compound. 
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6,5 h, 58,8 mg, 68%; 
• FCC - AcOEt/hexane (1 : 9), pale yellow wax  
• 1H NMR (300 MHz, CDCl3) δ 7.63-7.61 (m, 2H), 7.54-7.51 (m, 3H),7.43-7.40 (m, 
3H), 7.32-7.29 (m, 2H), 3.93 (s, 3H), 2.80 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -130.9 (m, 1F), -131.7 (m, 1F), -150.3 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 167.5, 149.7 (dd, J = 254.5, 10.8 Hz), 146.1 (dd, J = 
260.6, 12.2 Hz), 143.1 (dt, J = 258.3, 16.1 Hz), 133.5, 130.1, 129.9, 129.5, 129.0, 128.6, 
127.5, 127.1, 123.2 (t, J = 16.1 Hz), 70.8, 53.6, 25.4. 
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4,5,6,7-Tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole 
1,1-dioxide (44). 
 
Compound PM mmol mg mL 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-
phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4a). 
389,32 0,3 116,8  
NaOH 40 0,6 24  
H2O    0,5 
DMF    4 
 
A solution of the sultam in aqueous sodium hydroxide-DMF was heated under 
magnetical stirring monitoring by TLC (AcOEt : hexane – 1 : 9) until completion. The 
mixture is then cooled and the solvent was removed under vacuum (RV); the crude was 
purified by flash column chromatography to give the desired compound. 
 
48 h, 50,6 mg, 51%; 
• FCC - AcOEt/hexane (1 : 9), white wax  
• 1H NMR (300 MHz, CDCl3) δ 7.42-7.39 (m, 3H), 7.37-7.33 (m, 2H), 5.36 (s, 1H), 
2.84 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -139.9 (m, 2F), -145.7 (m, 1F), -150.0 (m, 1F).  
• IR (nujol) 1635, 1492, 1293, 1249, 1228, 1173, 1076, 977, 914, 881, 690, 630 cm-1.  
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Methyl 6-(hydroxy(4-nitrophenyl)methyl)-4,5,7-trifluoro-2-methyl-3-
phenyl -2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (45). 
 
Compound PM mmol mg mL 
Methyl 4,5,7-trifluoro-2-methyl-3-phenyl-
2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (32). 
371,34 0,3 112  
Buthyllitium 1M  0,31  0,31 
p-nitro benzaldehyde 151,15 0,36 54,7  
THF    3,5 
 
To a solution of the sultam in dry THF, a solution of Buthyllitium in THF was added 
dropwise under Argon atmosphere at -78°C; the solution, which turns deeply red in 
color, is stirred for 30’ than quenched with the aldheide and let react monitoring the 
reaction by TLC (AcOEt : hexane – 1 : 3) until completion, than interrupted with 
NH4Clacq and warmed to room temperature; Extraction with Ethyl acetate, 
anidrification over MgSO4 and remotion of the solvent under vacuum (RV) furnishes 
the crude, which was purified by flash column chromatography to give the desired 
compound. 
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4 h, 72,9 mg, 47%; 
• FCC - AcOEt/hexane (1 : 3), white wax  
• 1H NMR (300 MHz, CDCl3) δ 8.22-8.18 (m, 2H), 7.64-7.61 (m, 2H), 7.41-7.38 (m, 
3H), 7.25-7.21 (m, 2H), 6.38 (s 1H), 3.89 (s, 3H), 3.64 (br 1H), 2.81 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -121.4 (m, 1F), -126.3 (m, 1F), -137.7 (m, 1F).  
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Decarboxylation of 4,5,6,7-Tetrafluoro-2-alkyl-2,3-dihydrobenzo[d]iso 
thiazole-3,3-dicarboxylate 1,1-dioxide (25 and 24a-c): General Procedure. 
 
F
AcOH, 110°C
FH2O, H2SO4 cat
N
S
O O
CO2HF
F
F
N
S
O O
CO2Et
CO2Et
F
RR
F
F
 
 
The sultam (0,2 mmol) si dissolved in a mixture of AcOH-H2O (0,9 mL, 2 : 1) then 
H2SO4 was added and the solution was heated until completion, monitoring the 
reaction by TLC (AcOEt : hexane – 1 : 3), The mixture is then cooled, to pH4 by 
addition of solid NaHCO3 then extracted with ethyl acetate; anidrification over 
MgSO4 and remotion of the solvent under vacuum (RV) furnishes the pure product, 
without any further purification. Starting sulfonamide, reaction time, product and 
yield are as follows. 
 
 
4,5,6,7-tetrafluoro-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide (26a) 
 
3 h, 54,2 mg, 95%; 
•white wax  
• 1H NMR (300 MHz, (CD3)2CO) δ 7.25 (br, 2H), 5.61 (s, 
1H). 
• 19F NMR (282 MHz, (CD3)2CO) δ -137.6 (m, 1F), -143.3 
(m, 1F), -147.8 (m, 1F), -151.3 (m, 1F).  
• IR (nujol) 3206, 1739, 1617, 1511, 1457, 1292, 1243, 1177, 
1125, 1066, 1037, 911, 841 cm-1.  
F
F
NH
S
O O
CO2HF
F
26a, C8H3F4NO4S
MW: 285,17
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4,5,6,7-tetrafluoro-2-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide 
(26b) 
 
18 h, 47,3 mg, 79%; 
• white wax  
• 1H NMR (300 MHz, CDCl3) δ 6.50 (br, 1H), 5.03 (s, 1H), 
3.05 (s, 3H). 
• 19F NMR (282 MHz, CDCl3) δ -138.1 (m, 1F), -139.0 (m, 
1F), -144.7 (m, 1F), -147.8 (m, 1F).  
• IR (nujol) 3151, 1741, 1615, 1514, 1456, 1295, 1244, 1176, 
1129, 1059, 1028, 911, 844 cm-1.  
 
 
 
4,5,6,7-tetrafluoro-2-allyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide 
(26c) 
 
50 h, 55,3 mg, 85%; 
• white wax  
• 1H NMR (300 MHz, CDCl3) δ 7.88 (br, 1H), 5.90-5.77 
(m, 1H), 5.42 (d, 1H, J = 11.7 Hz), 5.38 (d, 1H, J = 4.7 Hz), 
5.16 (s, 1H), 4.20.(dd, 1H, J = 15.1, 5.1 Hz), 3.91.(dd, 1H, J 
= 15.1, 8.3 Hz). 
• 19F NMR (282 MHz, CDCl3) δ -137.7 (m, 1F), -138.9 (m, 
1F), -144.7 (m, 1F), -147.8 (m, 1F).  
• IR (nujol) 3148, 1744, 1613, 1514, 1457, 1291, 1246, 1174, 
1126, 1061, 1032, 914, 846 cm-1.  
F
F
N
S
O O
CO2HF
F
Me
26b, C9H5F4NO4S
MW: 299,20
F
F
N
S
O O
CO2HF
F
26c, C11H7F4NO4S
MW: 325,24
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4,5,6,7-tetrafluoro-2-benzyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide 
(26d) 
 
72 h, Propionic acid used instead of acetic acid 62,3 mg, 
83%; 
• white wax  
• 1H NMR (300 MHz, CDCl3) δ 7.88 (br, 1H), 5.90-5.77 
(m, 1H), 5.42 (d, 1H, J = 11.7 Hz), 5.38 (d, 1H, J = 4.7 Hz), 
5.16 (s, 1H), 4.20.(dd, 1H, J = 15.1, 5.1 Hz), 3.91.(dd, 1H, J 
= 15.1, 8.3 Hz). 
• 19F NMR (282 MHz, CDCl3) δ -137.7 (m, 1F), -138.9 (m, 
1F), -144.7 (m, 1F), -147.8 (m, 1F).  
F
F
N
S
O O
CO2HF
F
26d, C15H9F4NO4S
MW: 375,29
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Esterification of 4,5,6,7-Tetrafluoro-2-alkyl-2,3-dihydrobenzo 
[d]isothiazole-3-carboxylate 1,1-dioxide (26a-d): General Procedure. 
 
F
MeOH, 70°C
FH2SO4 cat
N
S
O O
CO2MeF
R
F
F
F
N
S
O O
CO2HF
R
F
 
 
The sultam (0,2 mmol) si dissolved in a mixture of AcOH-H2O (0,9 mL, 2 : 1) then 
H2SO4 was added and the solution was heated until completion, monitoring the 
reaction by TLC (AcOEt : hexane – 1 : 3), The mixture is then cooled, to pH4 by 
addition of solid NaHCO3 then extracted with ethyl acetate; anidrification over 
MgSO4 and remotion of the solvent under vacuum (RV) furnishes the pure product, 
without any further purification. Starting sulfonamide, reaction time, product and 
yield are as follows. 
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Methyl 4,5,6,7-tetrafluoro-2-methyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (27b). 
 
20 h, 58,3 mg, 93%; 
• FCC - AcOEt/hexane (1 : 7), white wax  
• 1H NMR (300 MHz, (CD3)2CO) δ 5.03 (s, 1H), 3.85 (s, 
3H), 3.02 (s, 3H). 
• 19F NMR (282 MHz, (CD3)2CO) δ -138.9 (m, 1F), -139.5 
(m, 1F), -145.3 (m, 1F), -148.4 (m, 1F).  
• 13C NMR (75 MHz, CDCl3) δ 166.0, 144.6 (dt, J = 261.3, 
14.4 Hz), 143.3 (dd, J = 258.2, 11.9 Hz), 142.3 (dm, J = 
261.2 Hz), 142.0 (dd, J = 260.1, 12.8 Hz), 119.7 (d, J = 19.3 
Hz), 116.4 (d, J = 17.0 Hz), 61.2, 54.3, 30.0. 
• Anal. Calcd. for C10H7F4NO4S: C, 38.35; H, 2.25; N, 4.47. 
Found: C, 38.37; H, 2.28; N, 4.48. 
F
F
N
S
O O
CO2MeF
F
27b, C10H7F4NO4S
MW: 313,23
Me
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Methyl 4,5,6,7-tetrafluoro-2-benzyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (27c). 
 
44 h, 58,4 mg, 75%; 
• FCC - AcOEt/hexane (1 : 4), white wax  
• 1H NMR (300 MHz, CDCl3) δ 7.37-7.33 (m, 5H), 4.91 (s, 
1H), 4.74 (d, J = 14.8 Hz), 4.42 (d, J = 14.8 Hz), 3.70 (s, 
3H). 
• 19F NMR (282 MHz, (CD3)2CO) δ -138.7 (m, 1F), -139.0 
(m, 1F), -145.2 (m, 1F), -148.3 (m, 1F).  
• 13C NMR (50 MHz, CDCl3) δ 165.8, 144.1 (dt, J = 262.2, 
16.1 Hz), 142.9 (dd, J = 258.6, 13.9 Hz), 142.0 (dm, J = 
261.0 Hz), 141.6 (dm, J = 259.9 Hz), 133.1, 119.4, 116.2, 
57.4, 53.6, 46.6. 
• Anal. Calcd. for C16H11F4NO4S: C, 49.36; H, 2.85; N, 
3.60. Found: C, 49.32; H, 2.83; N, 3.57. 
F
F
N
S
O O
CO2MeF
F
27c, C16H11F4NO4S
MW: 389,32
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Deprotection of 4,5,6,7-Tetrafluoro-2-allyl-3-phenyl-2,3-dihydrobenzo 
[d]isothiazole 1,1-dioxide ((-)-4c). 
 
Compound PM mmol mg mL 
Methyl 4,5,6,7-tetrafluoro-2-allyl-3-
phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide ((-)-4a). 
415,36 0,2 83,1  
Pd(PPh3)4 1155 0,01 11,6  
Dimedone 140,18 0,24 33,6  
THF    1 
 
A solution of the sultam, triphenylphosphine and dimedone in dry THF, was 
degased with Argon and, after adding the catalyst, was magnetical stirred 
monitoring by TLC (AcOEt : hexane – 1 : 4) until completion. The mixture is then 
cooled and the solvent was removed under vacuum (RV); the crude was purified by 
flash column chromatography to give the desired compound. 
 
5 h, 73,6 mg, 98%; 
• FCC - AcOEt/hexane (1 : 5) 
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Enantiomeric excess HPLC determination: Analytical Methods. 
 
 
Methyl 4,5,6,7-tetrafluoro-2-methyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carbossilate 1,1-dioxide (4a). 
 
4a, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2,  
Flow rate 1 mL/min, P= 15 bar, t1 = 5.4 min, t2 = 6.7 min. 
 
 
Methyl 4,5,6,7-tetrafluoro-2-ethyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4d). 
 
4d, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2,  
Flow rate 1 mL/min, P= 15 bar, t1 = 4.9 min, t2 = 6.3 min. 
 
 
Methyl 4,5,6,7-tetrafluoro-2-n-propyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4e). 
 
4e, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1,  
Flow rate 0.6 mL/min, P= 7 bar, t1 = 8.7 min, t2 = 10.6 min. 
 
 
Methyl 4,5,6,7-tetrafluoro-2-allyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4c). 
 
4e, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1,  
Flow rate 0.7 mL/min, P= 8 bar, t1 = 8.3 min, t2 = 9.5 min. 
 
 
F
F
F
F
N
S
O O
CO2Me
F
F
F
F
N
S
O O
CO2Me
Et
F
F
F
F
N
S
O O
CO2Me
n-Pr
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Methyl 7-bromo-4,5,6-trifluoro-2-allyl-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (4c). 
 
4e, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1,  
Flow rate 0.7 mL/min, P= 8 bar, t1 = 10.2 min, t2 = 13.2 
min. 
 
 
Methyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (8a). 
 
8a, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2  
+ 0,2% TFA,  
Flow rate 0.7 mL/min, P= 10 bar, t1 = 9.9 min, t2 = 10.7 
min. 
 
Ethyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (8b). 
 
8b, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 13 bar, t1 = 8.9 min, t2 = 10.0 min. 
 
iso-Propyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (8c). 
 
8c, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 13 bar, t1 = 7.1 min, t2 = 9.5 min. 
 
F
F
F
F
NH
S
O O
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F
F
F
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O O
CO2Et
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tert-Butyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (8d). 
 
8d, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 13 bar, t1 = 6.2 min, t2 = 7.0 min. 
 
Benzyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (8e). 
 
8e, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2 
+ 0,2% TFA,  
Flow rate 0.6 mL/min, P= 8 bar, t1 = 14.5 min, t2 = 15.4 
min. 
 
Methoxyethyl 4,5,6,7-tetrafluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (8f). 
 
8f, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2 
+ 0,2% TFA,  
Flow rate 0.8 mL/min, P= 11 bar, t1 = 9.4 min, t2 = 10.9 
min. 
 
Methyl 7-Bromo-4,5,6-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (31a). 
 
31a, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 14 bar, t1 = 8.2 min, t2 = .10.6 min 
F
F
F
F
NH
S
O O
CO2Bn
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Methyl 5-bromo-4, 6,7-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-
carboxylate 1,1-dioxide (31b). 
 
31b, CHIRALCEL OD ®, Hexane – Isopropanol 12 : 1 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 12 bar, t1 = 13.0 min, t2 = 14.0 
min. 
 
Methyl 5,4,7-trifluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-
dioxide (31d). 
 
31d, CHIRALCEL OD ®, Hexane – Isopropanol 9 : 1 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 8 bar, t1 = 14.0 min, t2 = 15.5 min. 
 
Methyl 7-bromo-4,5-difluoro-3-phenyl-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 
1,1-dioxide (31e). 
 
31e, CHIRALCEL OD ®, Hexane – Isopropanol 8 : 2 
+ 0,2% TFA,  
Flow rate 1 mL/min, P= 13 bar, t1 = 10.0 min, t2 = 11.8 
min. 
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